# Patent

## Title
Method of treating inflammation with glutaminyl cyclase inhibitors

## Abstract

Provided herein are methods for the treatment and/or prevention of an inflammatory disease or disorder through administration of an inhibitor of a glutaminyl peptide cyclotransferase. Inflammatory diseases or disorders treated or prevented by methods disclosed herein include mild cognitive impairment (MCI), rheumatoid arthritis, atherosclerosis, restenosis and pancreatitis.

## Background
RELATED APPLICATIONS AND INCORPORATION BY REFERENCE
The present application is a continuation in part of U.S. patent application Ser. No. 11/685,881, filed Mar. 14, 2007 (claiming priority to U.S. Provisional Application Ser. No. 60/892,265, filed Mar. 1, 2007), issued as U.S. Pat. No. 7,732,162 on Jun. 8, 2010, which is a continuation in part of U.S. patent application Ser. No. 10/839,017, filed May 5, 2004 (claiming priority to U.S. Provisional Application Ser. No. 60/512,038, filed Oct. 15, 2003; U.S. Provisional Application Ser. No. 60/468,014, filed May 5, 2003; and U.S. Provisional Application Ser. No. 60/468,043, filed May 5, 2003), issued as U.S. Pat. No. 7,381,537 on Jun. 3, 2008, which are fully incorporated herein by reference to the extent permitted by law.
The present application also is a continuation in part of U.S. patent application Ser. No. 11/685,881, filed Mar. 14, 2007, fully incorporated herein by reference to the extent permitted by law. U.S. patent application Ser. No. 11/685,881 is a continuation in part of U.S. patent application Ser. No. 10/839,017.
This application also claims priority to United State Provisional Application 60/892,265, filed Mar. 1, 2007.


SEQUENCE LISTING
The accompanying sequence listing is fully incorporated herein by reference for all purposes.
BACKGROUND OF THE INVENTION
The present invention relates in general to an inhibitor of a glutaminyl peptide cyclotransferase, and the use thereof for the treatment and/or prevention of a disease or disorder selected from the group consisting of rheumatoid arthritis, atherosclerosis, restenosis, lung fibrosis, liver fibrosis, renal fibrosis, pancreatitis, mild cognitive impairment, Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, Familial Danish Dementia, neuropathic pain, graft rejection/graft failure/graft vasculopathy, hypertension, HIV infections/AIDS, gestosis, cancer/hemangioendothelioma proliferation, tuberous sclerosis, and gastric carcinomas.
Further, the present invention pertains to diagnostic kits and methods based on the use of a glutaminyl cyclase inhibitor.
Glutaminyl cyclase (QC, EC 2.3.2.5) catalyzes the intramolecular cyclization of N-terminal glutaminyl residues into pyroglutamic acid (5-oxo-proline, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamyl residues into pyroglutamic acid under liberation of water.
A QC was first isolated by Messer from the Latex of the tropical plant Carica papaya in 1963 (Messer, M. 1963 Nature 4874, 1299). 24 years later, a corresponding enzymatic activity was discovered in animal pituitary (Busby, W. H. J. et al. 1987 J Biol Chem 262, 8532-8536; Fischer, W. H. and Spiess, J. 1987 Proc Natl Acad Sci USA 84, 3628-3632). For the mammalian QCs, the conversion of Gln into pGlu by QC could be shown for the precursors of TRH and GnRH (Busby, W. H. J. et al. 1987 J Biol Chem 262, 8532-8536; Fischer, W. H. and Spiess, J. 1987 Proc Natl Acad Sci USA 84, 3628-3632). In addition, initial localization experiments of QC revealed a co-localization with its putative products of catalysis in the bovine tractus hypothalamo-hypophysal is further improving the suggested function in peptide hormone maturation (Bockers, T. M. et al. 1995 J Neuroendocrinol 7, 445-453). In contrast, the physiological function of the plant QC is less clear. In case of the enzyme from C. papaya, a role in the plant defense against pathogenic microorganisms was suggested (El Moussaoui, A. et al. 2001 Cell Mol Life Sci 58, 556-570). Putative QCs from other plants were identified by sequence comparisons recently (Dahl, S. W. et al. 2000 Protein Expr Purif 20, 27-36). The physiological function of these enzymes, however, is still ambiguous.
The QCs known from plants and animals show a strict specificity for L-Glutamine in the N-terminal position of the substrates and their kinetic behaviour was found to obey the Michaelis-Menten equation (Pohl, T. et al. 1991 Proc Natl Acad Sci USA 88, 10059-10063; Consalvo, A. P. et al. 1988 Anal Biochem 175, 131-138; Gololobov, M. Y. et al. 1996 Biol Chem Hoppe Seyler 377, 395-398). A comparison of the primary structures of the QCs from C. papaya and that of the highly conserved QC from mammals, however, did not reveal any sequence homology (Dahl, S. W. et al. (2000) Protein Expr Purif 20, 27-36). Whereas the plant QCs appear to belong to a new enzyme family (Dahl, S. W. et al. (2000) Protein Expr Purif 20, 27-36), the mammalian QCs were found to have a pronounced sequence homology to bacterial aminopeptidases (Bateman, R. C. et al. 2001 Biochemistry 40, 11246-11250), leading to the conclusion that the QCs from plants and animals have different evolutionary origins.
EP 02 011 349.4 discloses polynucleotides encoding insect glutaminyl cyclase, as well as polypeptides encoded thereby. This application further provides host cells comprising expression vectors comprising polynucleotides of the invention. Isolated polypeptides and host cells comprising insect QC are useful in methods of screening for agents that reduce glutaminyl cyclase activity. Such agents are described as useful as pesticides.
Chemotactic cytokines (chemokines) are proteins that attract and activate leukocytes and are thought to play a fundamental role in inflammation. Chemokines are divided into four groups categorized by the appearance of N-terminal cysteine residues (“C”-; “CC”-; “CXC”- and “CX3C”-chemokines). “CXC”-chemokines preferentially act on neutrophils. In contrast, “CC”-chemokines attract preferentially monocytes to sites of inflammation. Monocyte infiltration is considered to be a key event in a number of disease conditions (Gerard, C. and Rollins, B. J. (2001) Nat. Immunol 2, 108-115; Bhatia, M., et al., (2005) Pancreatology. 5, 132-144; Kitamoto, S., Egashira, K., and Takeshita, A. (2003) J Pharmacol Sci. 91, 192-196). The MCP family, as one family of chemokines, consists of four members (MCP-1-4), displaying a preference for attracting monocytes but showing differences in their potential (Luini, W., et al., (1994) Cytokine 6, 28-31; Uguccioni, M., et al., (1995) Eur J Immunol 25, 64-68). In the following both cDNA as well as amino acid sequences of MCP-1-4 are indicated:








Human MCP-1 (CCL2) (GeneBank Accession: M24545)



cDNA (300 bp)








SEQ ID NO: 2









  1 atgaaagtct ctgccgccct tctgtgcctg ctgctcatag cagccacctt cattccccaa



 


 61 gggctcgctc agccagatgc aatcaatgcc ccagtcacct gctgttataa cttcaccaat


 


121 aggaagatct cagtgcagag gctcgcgagc tatagaagaa tcaccagcag caagtgtccc


 


181 aaagaagctg tgatcttcaa gaccattgtg gccaaggaga tctgtgctga ccccaagcag


 


241 aagtgggttc aggattccat ggaccacctg gacaagcaaa cccaaactcc gaagacttga


 


Protein (Signal Sequence in bold: 23 aa; Mature MCP-1: 76 aa)








SEQ ID NO: 1









MKVSAALLCLLLIAATFIPQGLAQPDAINAPVTCCYNFTNRKISVQRLASYRRITSSKCPKEAVIFKTI



 


VAKEICADPKQKWVQDSMDHLDKQTQTPKT


 


Human MCP-2 (CCL8) (GeneBank Accession: Y10802)


cDNA (300 bp)








SEQ ID NO: 12









  1 atgaaggttt ctgcagcgct tctgtgcctg ctgctcatgg cagccacttt cagccctcag



 


 61 ggacttgctc agccagattc agtttccatt ccaatcacct gctgctttaa cgtgatcaat


 


121 aggaaaattc ctatccagag gctggagagc tacacaagaa tcaccaacat ccaatgtccc


 


181 aaggaagctg tgatcttcaa gacccaacgg ggcaaggagg tctgtgctga ccccaaggag


 


241 agatgggtca gggattccat gaagcatctg gaccaaatat ttcaaaatct gaagccatga


 


Protein (Signal Sequence in bold: 23 aa; Mature MCP-2: 76 aa)








SEQ ID NO: 11









MKVSAALLCLLLMAATFSPQGLAQPDSVSIPITCCFNVINRKIPIQRLESYTRITNIQCPKEAVIFKTQ



 


RGKEVCADPKERWVRDSMKHLDQIFQNLKP


 


Human MCP-3 (CCL7) (GeneBank Accession: X71087)


cDNA (300 bp)








SEQ ID NO: 14









  1 atgaaagcct ctgcagcact tctgtgtctg ctgctcacag cagctgcttt cagcccccag



 


 61 gggcttgctc agccagttgg gattaatact tcaactacct gctgctacag atttatcaat


 


121 aagaaaatcc ctaagcagag gctggagagc tacagaagga ccaccagtag ccactgtccc


 


181 cgggaagctg taatcttcaa gaccaaactg gacaaggaga tctgtgctga ccccacacag


 


241 aagtgggtcc aggactttat gaagcacctg gacaagaaaa cccaaactcc aaagctttga


 


Protein (Signal Sequence in bold: 23 aa; Mature MCP-3: 76 aa)








SEQ ID NO: 13









MKASAALLCLLLTAAAFSPQGLAQPVGINTSTTCCYRFINKKIPKQRLESYRRTTSSHCPREAVIFKTK



 


LDKEICADPTQKWVQDFMKHLDKKTQTPKL


 


Human MCP-4 (CCL13) (GeneBank Accession: U46767)


cDNA (297 bp)








SEQ ID NO: 16









  1 atgaaagtct ctgcagtgct tctgtgcctg ctgctcatga cagcagcttt caacccccag



 


 61 ggacttgctc agccagatgc actcaacgtc ccatctactt gctgcttcac atttagcagt


 


121 aagaagatct ccttgcagag gctgaagagc tatgtgatca ccaccagcag gtgtccccag


 


181 aaggctgtca tcttcagaac caaactgggc aaggagatct gtgctgaccc aaaggagaag


 


241 tgggtccaga attatatgaa acacctgggc cggaaagctc acaccctgaa gacttga


 


Protein (Signal Sequence in bold: 23 aa; Mature MCP-4: 75 aa)








SEQ ID NO: 15









MKVSAVLLCLLLMTAAFNPQGLAQPDALNVPSTCCFTFSSKKISLQRLKSYVITTSRCPQKAVIFRTKL



 


GKEICADPKEKWVQNYMKHLGRKAHTLKT






A number of studies have underlined in particular the crucial role of MCP-1 for the development of atherosclerosis (Gu, L., et al., (1998) Mol. Cell 2, 275-281; Gosling, J., et al., (1999) J. Clin. Invest 103, 773-778); rheumatoid arthritis (Gong, J. H., et al., (1997) J. Exp. Med 186, 131-137; Ogata, H., et al., (1997) J Pathol. 182, 106-114); pancreatitis (Bhatia, M., et al., (2005) Am. J Physiol Gastrointest. Liver Physiol 288, G1259-G1265); Alzheimer's disease (Yamamoto, M., et al., (2005) Am. J Pathol. 166, 1475-1485); lung fibrosis (Inoshima, I., et al., (2004) Am. J Physiol Lung Cell Mol. Physiol 286, L1038-L1044); renal fibrosis (Wada, T., et al., (2004) J. Am. Soc. Nephrol. 15, 940-948), and graft rejection (Saiura, A., et al., (2004) Arterioscler. Thromb. Vasc. Biol. 24, 1886-1890). Furthermore, MCP-1 might also play a role in gestosis (Katabuchi, H., et al., (2003) Med Electron Microsc. 36, 253-262), as a paracrine factor in tumor development (Ohta, M., et al., (2003) Int. J Oncol. 22, 773-778; Li, S., et al., (2005) J. Exp. Med 202, 617-624), neuropathic pain (White, F. A., et al., (2005) Proc. Natl. Acad. Sci. U.S.A) and AIDS (Park, I. W., Wang, J. F., and Groopman, J. E. (2001) Blood 97, 352-358; Coll, B., et al., (2006) Cytokine 34, 51-55).
The mature form of human and rodent MCP-1 is posttranslationally modified by Glutaminyl Cyclase (QC) to possess an N-terminal pyroglutamyl (pGlu) residue. The N-terminal pGlu modification makes the protein resistant against N-terminal degradation by aminopeptidases, which is of importance, since chemotactic potency of MCP-1 is mediated by its N-terminus (Van Damme, J., et al., (1999) Chem Immunol 72, 42-56). Artificial elongation or degradation leads to a loss of function although MCP-1 still binds to its receptor (CCR2) (Proost, P., et al., (1998), J Immunol 160, 4034-4041; Zhang, Y. J., et al., 1994, J. Biol. Chem. 269, 15918-15924; Masure, S., et al., 1995, J Interferon Cytokine Res. 15, 955-963; Hemmerich, S., et al., (1999) Biochemistry 38, 13013-13025).
Due to the major role of MCP-1 in a number of disease conditions, an anti-MCP-1 strategy is required. Therefore, small orally available compounds inhibiting the action of MCP-1 are promising candidates for a drug development. Inhibitors of Glutaminyl Cyclase are small orally available compounds, which target the important step of pGlu-formation at the N-terminus of MCP-1 (Cynis, H., et al., (2006) Biochim. Biophys. Acta 1764, 1618-1625; Buchholz, M., et al., (2006) J Med Chem 49, 664-677). In consequence, caused by QC-inhibition, the N-terminus of MCP-1 is not protected by a pGlu-residue. Instead, the N-terminus possesses a glutamine-proline motif, which is prone to cleavage by dipeptidylpeptidases, e.g. dipeptidylpeptidase 4 and fibroblast activating protein (FAP, Seprase), which are abundant on the endothelium and within the blood circulation. This cleavage results in the formation of N-terminal truncated MCP-1. These molecules unfold, in turn, an antagonistic action at the CCR2 receptor and therefore, monocyte-related disease conditions are inhibited efficiently.
Atherosclerotic lesions, which limit or obstruct coronary blood flow, are the major cause of ischemic heart disease related mortality, resulting in 500,000-600,000 deaths annually. Percutaneous transluminal coronary angioplasty (PTCA) to open the obstructed artery was performed in over 550,000 patients in the U.S. and 945,000+ patients worldwide in 1996 (Lemaitre et al., 1996). A major limitation of this technique is the problem of post-PTCA closure of the vessel, both immediately after PTCA (acute occlusion) and in the long term (restenosis): 30% of patients with subtotal lesions and 50% of patients with chronic total lesions will progress to restenosis after angioplasty. Additionally, restenosis is a significant problem in patients undergoing saphenous vein bypass graft. The mechanism of acute occlusion appears to involve several factors and may result from vascular recoil with resultant closure of the artery and/or deposition of blood platelets along the damaged length of the newly opened blood vessel followed by formation of a fibrin/red blood cell thrombus.
Restenosis after angioplasty is a more gradual process and involves initial formation of a subcritical thrombosis with release from adherent platelets of cell derived growth factors with subsequent proliferation of intimal smooth muscle cells and local infiltration of inflammatory cells contributing to vascular hyperplasia. It is important to note that multiple processes, among those thrombosis, cell proliferation, cell migration and inflammation each seem to contribute to the restenotic process.
In the U.S., a 30-50% restenosis rate translates to 120,000-200,000 U.S. patients at risk from restenosis. If only 80% of such patients elect repeated angioplasty (with the remaining 20% electing coronary artery bypass graft) and this is added to the costs of coronary artery bypass graft for the remaining 20%, the total costs for restenosis treatment easily amounts to billions of dollars in the U.S. Thus, successful prevention of restenosis could result not only in significant therapeutic benefit but also in significant health care savings.
Monocyte chemoattractant protein 1 (MCP-1, CCL2) belongs to a family of potent chemotactic cytokines (CC chemokines), that regulate the trafficking of leukocytes, especially monocytes, macrophages and T-cells, to sites of inflammation (Charo, I. F. and Taubman, M. B. (2004) Circ. Res. 95, 858-866). Besides its role in, e.g. vascular disease, compelling evidence points to a role of MCP-1 in Alzheimer's disease (AD) (Xia, M. Q. and Hyman, B. T. (1999) J Neurovirol. 5, 32-41). The presence of MCP-1 in senile plaques and in reactive microglia, the residential macrophages of the CNS have been observed in brains of patients suffering from AD (Ishizuka, K., et al., (1997) Psychiatry Clin. Neurosci. 51, 135-138). Stimulation of monocytes and microglia with Amyloid-β protein (Aβ) induces chemokine secretion in vitro (Meda, L., et al., (1996) J Immunol 157, 1213-1218; Szczepanik, A. M., et al., (2001) J Neuroimmunol. 113, 49-62) and intracerebroventricular infusion of Aβ(1-42) into murine hippocampus significantly increases MCP-1 in vivo. Moreover, Aβ deposits attract and activate microglial cells and force them to produce inflammatory mediators such as MCP-1, which in turn leads to a feed back to induce further chemotaxis, activation and tissue damage. At the site of Aβ deposition, activated microglia also phagocytose Aβ peptides leading to an amplified activation (Rogers, J. and Lue, L. F. (2001) Neurochem. Int. 39, 333-340).
Examination of chemokine expression in a 3×Tg mouse model for AD revealed that neuronal inflammation precedes plaque formation and MCP-1 is upregulated by a factor of 11. Furthermore, the upregulation of MCP-1 seems to correlate with the occurrence of first intracellular Aβ deposits (Janelsins, M. C., et al., (2005) J Neuroinflammation. 2, 23). Cross-breeding of the Tg2575 mouse model for AD with a MCP-1 overexpressing mouse model has shown an increased microglia accumulation around Aβ deposits and that this accumulation was accompanied by increased amount of diffuse plaques compared to single-transgenic Tg2576 littermates (Yamamoto, M., et al. (2005) Am. J Pathol. 166, 1475-1485). MCP-1 levels are increased in CSF of AD patients and patients showing mild cognitive impairment (MCI) (Galimberti, D., et al., (2006) Arch. Neurol. 63, 538-543). Furthermore, MCP-1 shows an increased level in serum of patients with MCI and early AD (Clerici, F., et al., (2006) Neurobiol. Aging 27, 1763-1768).
SUMMARY OF THE INVENTION
The present application discloses inhibitors of a glutaminyl peptide cyclotransferase and the use thereof for the treatment and/or prevention of a disease or disorder selected from the group consisting of inflammatory diseases selected from

    
    
        a. neurodegenerative diseases, e.g. mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, Familial Danish Dementia, multiple sclerosis,
        b. chronic and acute inflammations, e.g. rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis,
        c. fibrosis, e.g. lung fibrosis, liver fibrosis, renal fibrosis,
        d. cancer, e.g. cancer/hemangioendothelioma proliferation, gastric carcinomas,
        e. metabolic diseases, e.g. hypertension,
        f. and other inflammatory diseases, e.g. neuropathic pain, graft rejection/graft failure/graft vasculopathy, HIV infections/AIDS, gestosis, tuberous sclerosis.
    
    





BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows the incubation of MCP-1(1-76) bearing an N-terminal glutaminyl (A) or Pyroglutamyl (5-oxo-L-Prolyl) residue (B) with recombinant human DP4 for 24 h. For cyclization of N-terminal glutamine into pyroglutamate MCP-1 was incubated with recombinant human QC 3 h prior to assay start. The DP4 cleavage products were analyzed after 0 min, 15 min, 30 min, 1 h, 4 h and 24 h using Maldi-TOF mass spectrometry.
FIG. 2 shows the incubation of MCP-1(1-76) bearing an N-terminal glutaminyl (A) or Pyroglutamyl (5-oxo-L-Prolyl) residue with human synovial fibroblast MMP-1 for 24 h. For cyclization of N-terminal glutamine into pyroglutamate MCP-1 was incubated with recombinant human QC 3 h prior to assay start. The MMP-1 cleavage products were analyzed after 0 min, 15 min, 30 min, 1 h, 2 h, 4 h and 24 h using Maldi-TOF mass spectrometry.
FIG. 3 shows the incubation of MCP-1(1-76) carrying an N-terminal glutaminyl (A) or Pyroglutamyl (5-oxo-L-Prolyl) with human synovial fibroblast MMP-1 and recombinant human DP4 for 24 h. For cyclization of N-terminal glutamine into pyroglutamate, MCP-1 was incubated with recombinant human QC 3 h prior to assay start. Resulting MMP-1 cleavage products were analyzed after 0 min, 15 min, 30 min, 1 h, 2 h, 4 h and 24 h using Maldi-TOF mass spectrometry
FIG. 4 shows the isolation of human MCP-1 from human neuroblastoma cell line SH-SY5Y. (M:DNA standard in bp; 1: full length human MCP-1 isolated from SH-SY5Y)
FIG. 5 shows the nucleotide (A) and amino acid (B) alignment of human MCP-1 isolated from SH-SY5Y (upper lane) and human MCP-1 genebank accession M24545 (lower lane). Single nucleotide polymorphism is depicted in bold. C: shows the concentration of human MCP-1(1-76) (WT) and mutant human MCP-1 lacking the N-terminal pGlu residue (ΔQ1) in the supernatant of transfected HEK293 cells in comparison to vector transfected control (pcDNA). (n.s.: not significant, Student's t-test; n=6) D: Migration of THP-1 monocytes towards the generated supernatant of transfected HEK293 cells in dilutions 1:1, 1:3, 1:10 and 1:30. (*, P<0.05; **, P<0.01; ***, P<0.001; Student's t-test, n=3).
FIG. 6 A: shows the concentration of human MCP-1(1-76) (WT) and mutant human MCP-1 lacking the two N-terminal amino acids (ΔQ1P2) in the supernatant of transfected HEK293 cells in comparison to vector transfected control (pcDNA). (**, P<0.01; Student's t-test; n=6) B: Migration of THP-1 monocytes towards the generated supernatant of transfected HEK293 cells in dilutions 1:1, 1:3, 1:10 and 1:30. (*, P<0.05; **, P<0.01; ***, P<0.001; Student's t-test, n=3).
FIG. 7 A: shows the concentration of human MCP-1(1-76) (WT) in the supernatant of transfected HEK293 cells in absence and presence of 10 μM 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride in comparison to vector transfected control (pcDNA). (n.s.: not significant; Student's t-test; n=6) B: Migration of THP-1 monocytes towards the generated supernatant of transfected HEK293 cells in absence or presence of 10 μM1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride in dilutions of 1:1, 1:3, 1:10 and 1:30. (**, P<0.01; Student's t-test, n=3).
FIG. 8 shows the quantification of the vascular remodeling of the cuffed vessel wall segments of untreated ApoE3 Leiden mice (black bars) and mice, which were treated (open bars) with 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride. Mice were sacrificed 14 days after cuff placement. Expressed is the vascular circumference (A) i.e. the total area within the outer diameter of the vessel segment and the remaining lumen (B) in 1 μm2.
FIG. 9 shows the quantification of the vascular remodeling of the cuffed vessel wall segments of untreated ApoE3 Leiden mice (black bars) or mice treated with (open bars) 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride. Mice were sacrificed 14 days after cuff placement. Expressed is the lumen stenosis A in % and the area of neointima B in 1 μm2. (*, P<0.05, Student's t-test).
FIG. 10 shows the quantification of the vascular remodeling of the cuffed vessel wall segments of untreated ApoE3 Leiden mice (black bars) or mice, which were treated with (open bars) of 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride. Mice were sacrificed 14 days after cuff placement. Expressed is the area of the media A in 1 μm2 and the intima/media ratio B. (*, P<0.05, Student's t-test).
FIG. 11 shows adhering and infiltrating cells per cross section in absence (black bars) or presence (open bars) of 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride treatment. Total number of adhering cells per cross section was counted in the cross section of the cuffed femoral arteries harvested two days after cuff placement. Within the total population of adhering cells a specific staining for monocytes/macrophages was used to identify the adhering and infiltrating monocytes. (*, P<0.05, Student's t-test).
FIG. 12 shows examples of MCP-1 staining by immunohistochemistry of lesions at the early time point (2 days) and the late time point (14 days) in untreated mice (control) and mice, which were treated with 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride.
FIG. 13 shows the quantification of MCP-1 staining in cross sections of mice sacrificed after 2 days (early time point) A or after 14 days (late time point) B within the media and neointima in absence (black bars) and presence (open bars) of 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride treatment. (*, P<0.05; Student's t-test).
FIG. 14 shows the relative amount of MCP-1 staining (%) in cross sections of mice sacrificed after 2 days (early time point) (A) or after 14 days (late time point) (B) within the media and neointima in absence (black bars) and presence (open bars) of 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride treatment. (*, P<0.05; Student's t-test).
FIG. 15 shows the quantification of the accelerated atherosclerosis in the vessel wall based on the quantification of monocyte/macrophage staining using marker AIA31240. Presented are cross sections of mice sacrificed at the late time point (14 days) treated in absence (black bars) and presence (open bars) of 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride. Foam cell accumulation is illustrated as (A) foam cell positive area/cross section in % and (B) foam cell positive area/cross section in μm2.
FIG. 16 illustrates cleavage of human MCP-1(1-76) bearing an N-terminal glutaminyl (A) or pyroglutamyl (5-oxo-L-Prolyl) residue (B) by recombinant human Aminopeptidase P for 24 h. The pyroglutamate formation at the N-Terminus was accomplished by incubation of MCP-1 with recombinant human QC for 3 h prior to the assay. The DP4 cleavage products were analyzed after 0 min, 15 min, 30 min, 1 h, 2 h, 4 h and 24 h using Maldi-TOF mass spectrometry.
FIG. 17 illustrates the cleavage of human MCP-1(1-76) bearing an N-terminal glutaminyl (A) or pyroglutamyl (5-oxo-L-Prolyl) residue (B) by recombinant human DP4 for 4 h. The pyroglutamate formation at the N-Terminus was accomplished by incubation of MCP-1 with recombinant human QC for 3 h prior to assay. In addition, the incubation of Gln1-MCP-1 with recombinant human QC was carried out in presence of 10 μM QC-specific inhibitor 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride. The DP4 cleavage products were analyzed using Maldi-TOF mass spectrometry after 0 min, 15 min, 30 min, 1 h, 2 h and 4 h.
FIG. 18 shows the degradation of human MCP-1(1-76) carrying an N-terminal glutaminyl residue (A) or pyroglutamyl (5-oxo-L-Prolyl) residue (B) in human serum for 7 and 24 h, respectively. For cyclization of the N-terminal glutamine residue into pyroglutamate, MCP-1 was incubated with recombinant human QC for 3 h prior to assay start. In addition, Gln1-MCP-1 was incubated in human serum in the presence of 9.6 μM DP4 Inhibitor Isoleucyl-Thiazolidine (P32/98) for 24 h (C). The cleavage products were analyzed after 0 min, 10 min, 30 min, 1 h, 2 h, 3 h 5 h and 7 h for Gln1-MCP-1, 0 min, 30 min, 1 h, 2 h, 3 h 5 h, 7 h and 24 h for pGlu1-MCP-1 and 0 min, 1 h, 2 h, 3 h, 5 h, 7 h and 24 h for Gln1-MCP-1 in combination with Isoleucyl-Thiazolidine using Maldi-TOF mass spectrometry.
FIG. 19 shows the degradation of human MCP-2(1-76) bearing an N-terminal glutaminyl (A) or pyroglutamyl (5-oxo-L-Prolyl) residue (B) by recombinant human DP4 for 24 h. For cyclization of N-terminal glutamine into pyroglutamate, MCP-2 was incubated with recombinant human QC for 3 h prior to assay start. The DP4 cleavage products were analyzed using Maldi-TOF mass spectrometry after 0 min, 15 min, 30 min, 1 h, 2 h, 4 h and 24 h.
FIG. 20 shows the degradation of human MCP-3(1-76) carrying an N-terminal glutaminyl (A) or pyroglutamyl (5-oxo-L-Prolyl) residue (B) by recombinant human DP4 for 24 h. For cyclization of N-terminal glutamine into pyroglutamate, MCP-3 was incubated with recombinant human QC for 3 h prior to assay start. The DP4 cleavage products were analyzed using Maldi-TOF mass spectrometry after 0 min, 15 min, 30 min, 1 h, 2 h, 4 h and 24 h.
FIG. 21 illustrates the cleavage of human MCP-4(1-75) bearing an N-terminal glutaminyl (A) or pyroglutamyl (5-oxo-L-Prolyl) residue (B) by recombinant human DP4 for 4 hours. For cyclization of N-terminal glutamine into pyroglutamate, MCP-4 was incubated with recombinant human QC for 3 h prior to assay start. The DP4 cleavage products were analyzed using Maldi-TOF mass spectrometry after 0 min, 15 min, 30 min, 1 h, 2 h, and 4 h.
FIG. 22 shows the chemotactic potency of human N-terminal MCP-1 variants starting with N-terminal glutamine (Gln1-MCP-1), pyroglutamic acid (pGlu1-MCP-1) (5-oxo-L-Proline), starting with proline 2 (Pro2-MCP-1, the aminopeptidase P cleavage product), starting with aspartic acid 3 (Asp3-MCP-1, the DP4 cleavage product) and starting with isoleucine 5 (Ile5-MCP-1, the MMP-1 cleavage product) towards human THP-1 monocytes.
FIG. 23 shows the analysis of chemotactic potency of human MCP-1, which was incubated with human recombinant DP4 in presence (Gln1-MCP-1+QC+DP4) and absence (Gln1-MCP-1+DP4) of QC-mediated pGlu formation. In addition, the influence of the QC-inhibitor 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride (QCI) (10 μM) on the formation of the N-terminal pGlu-residue, followed by subsequent DP4 cleavage (Gln1-MCP-1+QC+QCI+DP4) is shown.
FIG. 24 shows the chemotactic potency of human MCP-1 (A), MCP-2 (B), MCP-3 (C) and MCP-4 (D) in absence or presence of the N-terminal pyroglutamyl residue.
FIG. 25 shows the chemotactic potency of full-length human MCP-1 (A), MCP-3 (B), MCP-2 (C) and MCP-4 (D) starting with an N-terminal glutamine in comparison to their respective DP4 cleavage products.
FIG. 26 shows the significant reduction of TNFα-levels after application of QC-inhibitor 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride in a model of LPS-induced sepsis in rats (ANOVA, P<0.05).
FIG. 27 shows the dose-dependent reduction of infiltrating monocytes to the peritoneum in a model of thioglycollate-induced peritonitis in mice, caused by a QC-inhibitor. Thioglycollate and QCI (1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride) in three different concentrations of 25 mg/kg, 50 mg/kg and 100 mg/kg were injected. Cells infiltrating the peritoneum, were classified using FACS analysis 4 h after inducing the peritonits. (*, P<0.05, Student's t-test).
FIG. 28 shows the reduction of Moma2-positive cells in the peritoneal lavage fluid of mice, which received a thioglycollate challenge in combination with the QC-specific inhibitor QCI (1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea), compared to animals receiving no QCI (*, P<0.05, Student's t-test).



DETAILED DESCRIPTION OF THE PRESENTLY PREFERRED EMBODIMENTS
In particular the present invention pertains to the following items:

    1. A QC inhibitor for the treatment and/or prevention of an inflammatory disease or condition, selected from
    
        a. neurodegenerative diseases, comprising mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, Familial Danish Dementia, and multiple sclerosis,
        b. chronic and acute inflammations, comprising rheumatoid arthritis, atherosclerosis, restenosis, and pancreatitis,
        c. fibrosis, comprising lung fibrosis, liver fibrosis, and renal fibrosis,
        d. cancer, comprising cancer/hemangioendothelioma proliferation, and gastric carcinomas,
        e. metabolic diseases, comprising hypertension,
        f. and other inflammatory diseases, comprising neuropathic pain, graft rejection/graft failure/graft vasculopathy, HIV infections/AIDS, gestosis, tuberous sclerosis.
    
    
    2. The QC inhibitor according to item 1, wherein the neurodegenerative disease is selected from mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, Familial Danish Dementia, multiple sclerosis.
    3. The QC inhibitor according to item 1 or 2, wherein the disease is mild cognitive impairment.
    4. The QC inhibitor according to any of items 1 to 3, wherein the QC inhibitor is administered in combination with a further agent, selected from the group consisting of nootropic agents, neuroprotectants, antiparkinsonian drugs, amyloid protein deposition inhibitors, beta amyloid synthesis inhibitors, antidepressants, anxiolytic drugs, antipsychotic drugs and anti-multiple sclerosis drugs.
    5. The QC inhibitor according to item 1, wherein the disease is a chronic or acute inflammation, selected from rheumatoid arthritis, atherosclerosis, restenosis and pancreatitis.
    6. The QC inhibitor according to item 1 or 5, wherein the disease is selected from restenosis and pancreatitis.
    7. The QC inhibitor according to item 1, 5 or 6, wherein the QC inhibitor is administered in combination with a further agent, selected from the group consisting of inhibitors of the angiotensin converting enzyme (ACE); angiotensin II receptor blockers; diuretics; calcium channel blockers (CCB); beta-blockers; platelet aggregation inhibitors; cholesterol absorption modulators; HMG-Co-A reductase inhibitors; high density lipoprotein (HDL) increasing compounds; renin inhibitors; IL-6 inhibitors; antiinflammatory corticosteroids; antiproliferative agents; nitric oxide donors; inhibitors of extracellular matrix synthesis; growth factor or cytokine signal transduction inhibitors; MCP-1 antagonists and tyrosine kinase inhibitors.
    8. Use of a QC inhibitor for the treatment and/or prevention of an inflammatory disease or condition selected from
    
        a. neurodegenerative diseases, comprising mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, Familial Danish Dementia, multiple sclerosis,
        b. chronic and acute inflammations, comprising rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis,
        c. fibrosis, comprising lung fibrosis, liver fibrosis, renal fibrosis,
        d. cancer, comprising cancer/hemangioendothelioma proliferation, gastric carcinomas,
        e. metabolic diseases, comprising hypertension,
        f. and other inflammatory diseases, comprising neuropathic pain, graft rejection/graft failure/graft vasculopathy, HIV infections/AIDS, gestosis, tuberous sclerosis.
    
    
    9. The use according to item 8, wherein the disease is a neurodegenerative disease, selected from mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, Familial Danish Dementia, multiple sclerosis.
    10. The use according to item 8 or 9, wherein the disease is mild cognitive impairment (MCI).
    11. The use according to any of items 8 to 10, wherein the QC inhibitor is administered in combination with a further agent, selected from the group consisting of nootropic agents, neuroprotectants, antiparkinsonian drugs, amyloid protein deposition inhibitors, beta amyloid synthesis inhibitors, antidepressants, anxiolytic drugs, antipsychotic drugs and anti-multiple sclerosis drugs.
    12. The use according to item 8, wherein the disease is a chronic or acute inflammation, selected from rheumatoid arthritis, atherosclerosis, restenosis and pancreatitis.
    13. The use according to item 8 or 12, wherein the disease is selected from restenosis and pancreatitis.
    14. The use according to item 8, 12 or 13, wherein the QC inhibitor is administered in combination with a further agent, selected from the group consisting of inhibitors of the angiotensin converting enzyme (ACE); angiotensin II receptor blockers; diuretics; calcium channel blockers (CCB); beta-blockers; platelet aggregation inhibitors; cholesterol absorption modulators; HMG-Co-A reductase inhibitors; high density lipoprotein (HDL) increasing compounds; renin inhibitors; IL-6 inhibitors; antiinflammatory corticosteroids; antiproliferative agents; nitric oxide donors; inhibitors of extracellular matrix synthesis; growth factor or cytokine signal transduction inhibitors; MCP-1 antagonists and tyrosine kinase inhibitors.
    15. Use of a QC inhibitor for the preparation of a medicament for treating and/or preventing an inflammatory disease or condition selected from
    
        a. neurodegenerative diseases, comprising mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, Familial Danish Dementia, multiple sclerosis,
        b. chronic and acute inflammations, comprising rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis,
        c. fibrosis, comprising lung fibrosis, liver fibrosis, renal fibrosis,
        d. cancer, comprising cancer/hemangioendothelioma proliferation, gastric carcinomas,
        e. metabolic diseases, comprising hypertension,
        f. and other inflammatory diseases, comprising neuropathic pain, graft rejection/graft failure/graft vasculopathy, HIV infections/AIDS, gestosis, tuberous sclerosis.
    
    
    16. The use according to item 15, wherein the disease is a neurodegenerative disease, selected from mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, Familial Danish Dementia, multiple sclerosis.
    17. The use according to item 15 or 16, wherein the disease is mild cognitive impairment (MCI).
    18. The use according to any of items 15 to 17, wherein the QC inhibitor is administered in combination with a further agent, selected from the group consisting of nootropic agents, neuroprotectants, antiparkinsonian drugs, amyloid protein deposition inhibitors, beta amyloid synthesis inhibitors, antidepressants, anxiolytic drugs, antipsychotic drugs and anti-multiple sclerosis drugs.
    19. The use according to item 15, wherein the disease is a chronic or acute inflammation, selected from rheumatoid arthritis, atherosclerosis, restenosis and pancreatitis.
    20. The use according to item 15 or 19, wherein the disease is selected from restenosis and pancreatitis.
    21. The use according to any of items 15, 19 or 20, wherein the QC inhibitor is administered in combination with a further agent, selected from the group consisting of inhibitors of the angiotensin converting enzyme (ACE); angiotensin II receptor blockers; diuretics; calcium channel blockers (CCB); beta-blockers; platelet aggregation inhibitors; cholesterol absorption modulators; HMG-Co-A reductase inhibitors; high density lipoprotein (HDL) increasing compounds; renin inhibitors; IL-6 inhibitors; antiinflammatory corticosteroids; antiproliferative agents; nitric oxide donors; inhibitors of extracellular matrix synthesis; growth factor or cytokine signal transduction inhibitors; MCP-1 antagonists and tyrosine kinase inhibitors.
    22. A Method of treatment and/or prevention of an inflammatory disease or condition, selected from
    
        a. neurodegenerative diseases, comprising mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, Familial Danish Dementia, multiple sclerosis,
        b. chronic and acute inflammations, comprising rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis,
        c. fibrosis, comprising lung fibrosis, liver fibrosis, renal fibrosis,
        d. cancer, comprising cancer/hemangioendothelioma proliferation, gastric carcinomas,
        e. metabolic diseases, comprising hypertension,
        f. and other inflammatory diseases, comprising neuropathic pain, graft rejection/graft failure/graft vasculopathy, HIV infections/AIDS, gestosis, tuberous sclerosis,
        wherein an effective amount of a QC inhibitor is administered to a subject in need thereof.
    
    
    23. The method of treatment and/or prevention according to item 22, wherein the disease is a neurodegenerative disease, selected from mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, Familial Danish Dementia, multiple sclerosis.
    24. The method of treatment and/or prevention according to item 23 or 24, wherein the disease is mild cognitive impairment (MCI).
    25. The method of treatment and/or prevention according to any of items 23 to 25, wherein the QC inhibitor is administered in combination with a further agent, selected from the group consisting of nootropic agents, neuroprotectants, antiparkinsonian drugs, amyloid protein deposition inhibitors, beta amyloid synthesis inhibitors, antidepressants, anxiolytic drugs, antipsychotic drugs and anti-multiple sclerosis drugs.
    26. The method of treatment and/or prevention according to item 23, wherein the disease is a chronic or acute inflammation, selected from rheumatoid arthritis, atherosclerosis, restenosis and pancreatitis.
    27. The method of treatment and/or prevention according to item 23 or 26, wherein the disease is selected from restenosis and pancreatitis.
    28. The method of treatment and/or prevention according to item 23, 26 or 27 wherein the QC inhibitor is administered in combination with a further agent, selected from the group consisting of inhibitors of the angiotensin converting enzyme (ACE); angiotensin II receptor blockers; diuretics; calcium channel blockers (CCB); beta-blockers; platelet aggregation inhibitors; cholesterol absorption modulators; HMG-Co-A reductase inhibitors; high density lipoprotein (HDL) increasing compounds; renin inhibitors; IL-6 inhibitors; antiinflammatory corticosteroids; antiproliferative agents; nitric oxide donors; inhibitors of extracellular matrix synthesis; growth factor or cytokine signal transduction inhibitors; MCP-1 antagonists and tyrosine kinase inhibitors.
    29. The use according to any of items 7 to 21, wherein the disease and/or condition afflict a human being.
    30. The method of any of items 22 to 28, wherein the disease and/or condition afflicts a human being.
    31. The use or method according to any one of the preceding items, wherein said QC inhibitor is an inhibitor selected from formulae 1, 1*, 1a, 1b, 1c, 1d, 1e, 1f, 1g, 1h, and 1i.
    32. The use or method according to any one of items 1 to 31, wherein said QC inhibitor is an inhibitor selected from examples 1 to 141.
    33. The use or method according to any one of items 1 to 32, wherein said QC inhibitor is 1-(3-(1H-imidazole-1-yl)propyl)-3-(3,4-dimethoxy-phenyl)thiourea hydrochloride.
    34. Diagnostic assay, comprising a QC inhibitor.
    35. Diagnostic assay according to item 34, wherein said QC inhibitor is an inhibitor selected from formulae 1, 1*, 1a, 1b, 1c, 1d, 1e, 1f, 1g, 1h, and 1i.
    36. Diagnostic assay according to item 34 or 35, wherein said QC inhibitor is an inhibitor selected from examples 1 to 141.
    37. Diagnostic assay according to any of items 34 to 36, wherein said QC inhibitor is 1-(3-(1H-imidazole-1-yl)propyl)-3-(3,4-dimethoxy-phenyl)thiourea hydrochloride.
    38. A method of diagnosing any one of the diseases and/or conditions as defined in item 1, comprising the steps of
    
        collecting a sample from a subject who is suspected to be afflicted with said disease and/or condition,
        contacting said sample with a QC inhibitor, and
        determining whether or not said subject is afflicted by said disease and/or condition.
    
    
    39. The method according to item 38, wherein said subject is a human being.
    40. The method according to item 38 or 39, wherein said QC inhibitor is an inhibitor selected from formulae 1, 1*, 1a, 1b, 1c, 1d, 1e, 1f, 1g, 1h, and 1i.
    41. The method according to any of items 38 to 40, wherein said QC inhibitor is an inhibitor selected from examples 1 to 141.
    42. The method according to any of items 38 to 41, wherein said QC inhibitor is 1-(3-(1H-imidazole-1-yl)propyl)-3-(3,4-dimethoxy-phenyl)thiourea hydrochloride.
    43. The method of any of items 38 to 42, wherein said sample is a blood sample, a serum sample, a sample of cerebrospinal liquor or a urine sample.
    44. Diagnostic kit for carrying out the method of items 38 to 42 comprising as detection means the diagnostic assay of any of items 34 or 37 and a determination means.
    45. Pharmaceutical composition, comprising the QC inhibitor according to any of items 1 to 7 or 31 to 33.


In an especially preferred embodiment, the invention relates to the use of a QC inhibitor in methods of treating a chronic or acute inflammation, selected from rheumatoid arthritis, atherosclerosis, restenosis and pancreatitis, particularly restenosis and pancreatitis, most preferably restenosis.
The effect of a QC inhibitor for treating a chronic or acute inflammation, selected from rheumatoid arthritis, atherosclerosis, restenosis and pancreatitis, can be tested using the in vivo assays described in examples 3, 7 and 8 of the present invention.
Even preferred according to the present invention is the use of a QC inhibitor in methods of treating mild cognitive impairment (MCI).
Accordingly, the present invention pertains more preferably to the following items:

    1. A QC inhibitor for the treatment and/or prevention of an inflammatory disease or condition, selected from mild cognitive impairment (MCI), restenosis, and pancreatitis.
    2. Use of a QC inhibitor for the treatment and/or prevention of an inflammatory disease or condition selected from mild cognitive impairment (MCI), restenosis, and pancreatitis.
    3. Use of a QC inhibitor for the preparation of a medicament for treating and/or preventing an inflammatory disease or condition selected from mild cognitive impairment (MCI), restenosis, and pancreatitis.
    4. The QC inhibitor or use according to any of items 1 to 3, wherein the disease is mild cognitive impairment (MCI).
    5. The QC inhibitor or use according to any of items 1 to 4, wherein the QC inhibitor is administered in combination with a further agent, selected from the group consisting of nootropic agents, neuroprotectants, antiparkinsonian drugs, amyloid protein deposition inhibitors, beta amyloid synthesis inhibitors, antidepressants, anxiolytic drugs, antipsychotic drugs and anti-multiple sclerosis drugs.
    6. The QC inhibitor or use according to any of items 1 to 3, wherein the disease is selected from restenosis and pancreatitis.
    7. The QC inhibitor or use according to any of items 1 to 3 or 6, wherein the disease is restenosis.
    8. The QC-inhibitor or use according to any of items 1 to 3, 6 or 7, wherein the QC inhibitor is administered in combination with a further agent, selected from the group consisting of inhibitors of the angiotensin converting enzyme (ACE); angiotensin II receptor blockers; diuretics; calcium channel blockers (CCB); beta-blockers; platelet aggregation inhibitors; cholesterol absorption modulators; HMG-Co-A reductase inhibitors; high density lipoprotein (HDL) increasing compounds; renin inhibitors; IL-6 inhibitors; antiinflammatory corticosteroids; antiproliferative agents; nitric oxide donors; inhibitors of extracellular matrix synthesis; growth factor or cytokine signal transduction inhibitors; MCP-1 antagonists and tyrosine kinase inhibitors.
    9. A Method of treatment and/or prevention of an inflammatory disease or condition, selected from mild cognitive impairment (MCI), restenosis and pancreatitis, wherein an effective amount of a QC inhibitor is administered to a subject in need thereof.
    10. The method of treatment and/or prevention according to item 9, wherein the disease is mild cognitive impairment (MCI).
    11. The method of treatment and/or prevention according to item 9 or 10, wherein the QC inhibitor is administered in combination with a further agent, selected from the group consisting of nootropic agents, neuroprotectants, antiparkinsonian drugs, amyloid protein deposition inhibitors, beta amyloid synthesis inhibitors, antidepressants, anxiolytic drugs, antipsychotic drugs and anti-multiple sclerosis drugs.
    12. The method of treatment and/or prevention according to item 9, wherein the disease is a chronic or acute inflammation, selected from rheumatoid arthritis, atherosclerosis, restenosis and pancreatitis.
    13. The method of treatment and/or prevention according to item 9 or 12, wherein the disease is selected from restenosis and pancreatitis.
    14. The method of treatment and/or prevention according to any of item 9, 12 or 13, wherein the disease is restenosis.
    15. The method of treatment and/or prevention according to any of items 9, or 12 to 14, wherein the QC inhibitor is administered in combination with a further agent, selected from the group consisting of inhibitors of the angiotensin converting enzyme (ACE); angiotensin II receptor blockers; diuretics; calcium channel blockers (CCB); beta-blockers; platelet aggregation inhibitors; cholesterol absorption modulators; HMG-Co-A reductase inhibitors; high density lipoprotein (HDL) increasing compounds; renin inhibitors; IL-6 inhibitors; antiinflammatory corticosteroids; antiproliferative agents; nitric oxide donors; inhibitors of extracellular matrix synthesis; growth factor or cytokine signal transduction inhibitors; MCP-1 antagonists and tyrosine kinase inhibitors.
    16. The use according to any of items 2 to 8, wherein the disease and/or condition afflict a human being.
    17. The method of any of items 9 to 15, wherein the disease and/or condition afflicts a human being.
    18. The QC-inhibitor, use or method according to any one of items 1 to 17, wherein said QC inhibitor is an inhibitor selected from formulae 1, 1*, 1a, 1b, 1c, 1d, 1e, 1f, 1g, 1h, and 1i.
    19. The QC-inhibitor, use or method according to any one of items 1 to 18, wherein said QC inhibitor is an inhibitor selected from examples 1 to 141.
    20. The QC-inhibitor, use or method according to any one of items 1 to 19, wherein said QC inhibitor is 1-(3-(1H-imidazole-1-yl)propyl)-3-(3,4-dimethoxy-phenyl)thiourea hydrochloride.
    21. Diagnostic assay, comprising a QC inhibitor.
    22. Diagnostic assay according to item 21, wherein said QC inhibitor is an inhibitor selected from formulae 1, 1*, 1a, 1b, 1c, 1d, 1e, 1f, 1g, 1h, and 1i.
    23. Diagnostic assay according to item 21 or 22, wherein said QC inhibitor is an inhibitor selected from examples 1 to 141.
    24. Diagnostic assay according to any of items 21 to 23, wherein said QC inhibitor is 1-(3-(1H-imidazole-1-yl)propyl)-3-(3,4-dimethoxy-phenyl)thiourea hydrochloride.
    25. A method of diagnosing any one of the diseases and/or conditions as defined in item 1, comprising the steps of
    
        collecting a sample from a subject who is suspected to be afflicted with said disease and/or condition,
        contacting said sample with an inhibitor of a glutaminyl peptide cyclotransferase, and
        determining whether or not said subject is afflicted by said disease and/or condition.
    
    
    26. The method according to item 26, wherein said subject is a human being.
    27. The method according to item 26 or 27, wherein said QC inhibitor is an inhibitor selected from formulae 1, 1*, 1a, 1b, 1c, 1d, 1e, 1f, 1g, 1h, and 1i.
    28. The method according to any of items 25 to 27, wherein said QC inhibitor is an inhibitor selected from examples 1 to 141.
    29. The method according to any of items 25 to 28, wherein said QC inhibitor is 1-(3-(1H-imidazole-1-yl)propyl)-3-(3,4-dimethoxy-phenyl)thiourea hydrochloride.
    30. The method of any of items 25 to 29, wherein said sample is a blood sample, a serum sample, a sample of cerebrospinal liquor or a urine sample.
    31. Diagnostic kit for carrying out the method of items 25 to 30 comprising as detection means the diagnostic assay of any of items 21 to 24 and a determination means.
    32. Pharmaceutical composition, comprising the QC inhibitor according to any of items 1, 4 to 6 or 18 to 20.


DEFINITIONS
Enzyme Inhibitors, in Particular Inhibitors of QC
Reversible enzyme inhibitors: comprise competitive inhibitors, non-competitive reversible inhibitors, slow-binding or tight-binding inhibitors, transition state analogues and multisubstrate analogues.
Competitive Inhibitors Show
i) non-covalent interactions with the enzyme,
ii) compete with substrate for the enzyme active site.
The principal mechanism of action of a reversible enzyme inhibitor and the definition of the dissociation constant can be visualized as follows:








  
    K
    D
  
  =
  
    
      K
      i
    
    =
    
      
        k
        off
      
      
        k
        on
      
    
  




The formation of the enzyme-inhibitor [E-I] complex prevents binding of substrates, therefore the reaction cannot proceed to the normal physiological product, P. A larger inhibitor concentration [I] leads to larger [E-I], leaving less free enzyme to which the substrate can bind.
Non-Competitive Reversible Inhibitors
i) bind at a site other than active site (allosteric binding site)
ii) cause a conformational change in the enzyme which decreases or stops catalytic activity.
Slow-Binding or Tight-Binding Inhibitors
i) are competitive inhibitors where the equilibrium between inhibitor and enzyme is reached slowly,
ii) (kon is slow), possibly due to conformational changes that must occur in the enzyme or inhibitor
a) are often transition state analogues
b) are effective at concentrations similar to the enzyme concentration (subnanomolar KD values)
c) due to koff values being so low these types of inhibitors are “almost” irreversible.
Transition State Analogues
Are competitive inhibitors which mimic the transition state of an enzyme catalyzed reaction. Enzyme catalysis occurs due to a lowering of the energy of the transition state, therefore, transition state binding is favored over substrate binding.
Multisubstrate Analogues
For a reaction involving two or more substrates, a competitive inhibitor or transition state analogue can be designed which contains structural characteristics resembling two or more of the substrates.
Irreversible enzyme inhibitors: drive the equilibrium between the unbound enzyme and inhibitor and enzyme inhibitor complex (E+I< - - - >E-I) all the way to the E-1-side with a covalent bond ( ̃100 kcal/mole), making the inhibition irreversible.
Affinity Labeling Agents
Active-site directed irreversible inhibitors (competitive irreversible inhibitor) are recognized by the enzyme (reversible, specific binding) followed by covalent bond formation, and
i) are structurally similar to substrate, transition state or product allowing for specific interaction between drug and target enzyme,
ii) contain reactive functional group (e.g. a nucleophile, —COCH2Br) allowing for covalent bond formation.
The reaction scheme below describes an active-site directed reagent with its target enzyme where KD is the dissociation constant and kinactivation is the rate of covalent bond formation.




Mechanism-based enzyme inactivators (also called suicide inhibitors) are active-site directed reagents (unreactive) which bind to the enzyme active site where they are transformed to a reactive form (activated) by the enzyme's catalytic capabilities. Once activated, a covalent bond between the inhibitor and the enzyme is formed.
The reaction scheme below shows the mechanism of action of a mechanism based enzyme inactivator, where KD is the dissociation complex, k2 is the rate of activation of the inhibitor once bound to the enzyme, k3 is the rate of dissociation of the activated inhibitor, P, from the enzyme (product can still be reactive) from the enzyme and k4 is the rate of covalent bond formation between the activated inhibitor and the enzyme.




Inactivation (covalent bond formation, k4) must occur prior to dissociation (k3) otherwise the now reactive inhibitor is released into the environment. The partition ratio, k3/k4: ratio of released product to inactivation should be minimized for efficient inactivation of the system and minimal undesirable side reactions.
A large partition ratio (favors dissociation) leads to nonspecific reactions.
Uncompetitive enzyme inhibitors: As a definition of uncompetitive inhibitor (an inhibitor which binds only to ES complexes) the following equilibria equation can be assumed:




The ES complex dissociates the substrate with a dissociation constant equal to Ks, whereas the ESI complex does not dissociate it (i.e has a Ks value equal to zero). The Km's of Michaelis-Menten type enzymes are expected to be reduced. Increasing substrate concentration leads to increasing ESI concentration (a complex incapable of progressing to reaction products) therefore the inhibition cannot be removed.
Preferred according to the present invention are competitive enzyme inhibitors.
Most preferred are competitive reversible enzyme inhibitors.
The terms “Ki” or “KI” and “KD” are binding constants, which describe the binding of an inhibitor to and the subsequent release from an enzyme. Another measure is the “IC50” value, which reflects the inhibitor concentration, which at a given substrate concentration results in 50% enzyme activity.
QC
The term “QC” as used herein comprises glutaminyl cyclase (QC) and QC-like enzymes. QC and QC-like enzymes have identical or similar enzymatic activity, further defined as QC activity. In this regard, QC-like enzymes can fundamentally differ in their molecular structure from QC.
The term “QC activity” as used herein is defined as intramolecular cyclization of N-terminal glutaminyl residues into pyroglutamic acid (pGlu*) or of N-terminal L-homoglutaminyl or L-beta-homoglutaminyl to a cyclic pyro-homoglutamine derivative under liberation of ammonia. See schemes 1 and 2 in this regard.








The term “EC” as used herein comprises the side activity of QC and QC-like enzymes as glutamate cyclase (EC), further defined as EC activity.
The term “EC activity” as used herein is defined as intramolecular cyclization of N-terminal glutamyl residues into pyroglutamic acid (pGlu*) by QC. See scheme 3 in this regard.




The term “QC-inhibitor” “glutaminyl cyclase inhibitor” is generally known to a person skilled in the art and means enzyme inhibitors as generally defined above, which inhibit the catalytic activity of glutaminyl cyclase (QC) or its glutamyl cyclase (EC) activity.
Potency of QC Inhibition
In light of the correlation with QC inhibition, in preferred embodiments, the subject method and medical use utilize an agent with a Ki for QC inhibition of 10 μM or less, more preferably of 1 μM or less, even more preferably of 0.1 μM or less or 0.01 μM or less, or most preferably 0.001 μM or less. Indeed, inhibitors with Ki values in the lower micromolar, preferably the nanomolar and even more preferably the picomolar range are contemplated. Thus, while the active agents are described herein, for convenience, as “QC inhibitors”, it will be understood that such nomenclature is not intended to limit the subject matter of the invention in any way.
Molecular Weight of QC Inhibitors
In general, the QC inhibitors of the subject method or medical use will be small molecules, e.g., with molecular weights of 1000 g/mole or less, 500 g/mole or less, preferably of 400 g/mole or less, and even more preferably of 350 g/mole or less and even of 300 g/mole or less.
The term “subject” as used herein, refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment and/or is suspected of being afflicted with a disease and/or condition as defined in the items.
The term “therapeutically effective amount” as used herein, means that amount of an active compound or a pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.
As used herein, the term “pharmaceutically acceptable” embraces both human and veterinary use: for example the term “pharmaceutically acceptable” embraces a veterinary acceptable compound or a compound acceptable in human medicine and health care.
Pharmaceutically Acceptable Salts:
In view of the close relationship between the free compounds and the compounds in the form of their salts or solvates, whenever a compound or inhibitor, respectively, is referred to in this context, a corresponding salt or solvate is also intended, provided such is possible or appropriate under the circumstances.
Salts and solvates of the inhibitors of the present invention and physiologically functional derivatives thereof which are suitable for use in medicine are those wherein the counter-ion or associated solvent is pharmaceutically acceptable. However, salts and solvates having non-pharmaceutically acceptable counter-ions or associated solvents are within the scope of the present invention, for example, for use as intermediates in the preparation of other compounds and their pharmaceutically acceptable salts and solvates.
Suitable salts according to the invention include those formed with both organic and inorganic acids or bases. Pharmaceutically acceptable acid addition salts include those formed from hydrochloric, hydrobromic, sulphuric, nitric, citric, tartaric, phosphoric, lactic, pyruvic, acetic, trifluoroacetic, triphenylacetic, sulphamic, sulphanilic, succinic, oxalic, fumaric, maleic, malic, mandelic, glutamic, aspartic, oxalacetic, methanesulphonic, ethanesulphonic, arylsulphonic (for example p-toluenesulphonic, benzenesulphonic, naphthalenesulphonic or naphthalene-disulphonic), salicylic, glutaric, gluconic, tricarballylic, cinnamic, substituted cinnamic (for example, phenyl, methyl, methoxy or halo substituted cinnamic, including 4-methyl and 4-methoxycinnamic acid), ascorbic, oleic, naphthoic, hydroxynaphthoic (for example 1- or 3-hydroxy-2-naphthoic), naphthaleneacrylic (for example naphthalene-2-acrylic), benzoic, 4 methoxybenzoic, 2- or 4-hydroxybenzoic, 4-chlorobenzoic, 4-phenylbenzoic, benzeneacrylic (for example 1,4-benzenediacrylic), isethionic acids, perchloric, propionic, glycolic, hydroxyethanesulfonic, pamoic, cyclohexanesulfamic, salicylic, saccharinic and trifluoroacetic acid. Pharmaceutically acceptable base salts include ammonium salts, alkali metal salts such as those of sodium and potassium, alkaline earth metal salts such as those of calcium and magnesium and salts with organic bases such as dicyclohexylamine and N-methyl-D-glutamine.
All pharmaceutically acceptable acid addition salt forms of the inhibitors of the present invention are intended to be embraced by the scope of this invention.
Examples of solvates include hydrates.
Polymorph Crystal Forms:
Furthermore, some of the crystalline forms of the inhibitors may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e. hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention. The inhibitors, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.
Prodrugs:
The present invention further includes within its scope prodrugs of the inhibitors of this invention. In general, such prodrugs will be functional derivatives of the inhibitors, which are readily convertible in vivo into the desired therapeutically active inhibitors. Thus, in these cases, the methods of treatment of the present invention, the term “administering” shall encompass the treatment of the various disorders described with prodrug versions of one or more of the itemed inhibitors, but which converts to the above specified inhibitors in vivo after administration to the subject. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985 and the patent applications DE 198 28 113, DE 198 28 114, WO 99/67228 and WO 99/67279 which are fully incorporated herein by reference.
Protective Groups:
During any of the processes for preparation of the inhibitors of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J. F. W. McOmie, Plenum Press, 1973; and T. W. Greene & P. G. M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991, fully incorporated herein by reference. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.
As used herein, the term “composition” is intended to encompass a product comprising the itemed compounds in the therapeutically effective amounts, as well as any product, which results, directly or indirectly, from combinations of the itemed compounds.
Carriers and Additives for Galenic Formulations:
For liquid oral preparations, such as for example, suspensions, elixirs and solutions, suitable carriers and additives may advantageously include water, glycols, oils, alcohols, flavouring agents, preservatives, colouring agents and the like; for solid oral preparations such as, for example, powders, capsules, gelcaps and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like.
Carriers, which can be added to the mixture, include necessary and inert pharmaceutical excipients, including, but not limited to, suitable binders, suspending agents, lubricants, flavorants, sweeteners, preservatives, coatings, disintegrating agents, dyes and colouring agents.
Soluble polymers as targetable drug carriers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxidepolyllysine substituted with palmitoyl residue(s). Furthermore, the inhibitors of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled/sustained release of a drug, for example, poly acetic acid, poly-epsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
Suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
Disintegrating agents include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like.
Examples of QC-Inhibitors
QC-inhibitors, which are suitable for uses and methods according to the present invention are disclosed in WO 2005/075436, which is incorporated herein in its entirety with regard to the structure, synthesis and methods of use of the QC-inhibitors.
The present invention provides novel inhibitors of QC (EC) of the formula 1,




wherein:

A is either:

an alkyl chain, alkenyl chain or alkynyl chain;
or A is a group selected from:




wherein:

    
    
        R6, R7, R8, R9 and R10 are independently H or an alkyl chain, alkenyl chain, alkynyl chain, cycloalkyl, a carbocycle, aryl, heteroaryl, or a heterocycle;
        n and n1 are independently 1-5;
        m is 1-5;
        o is 0-4;

and B is a group selected from (VI)-(XIV):

    
    









wherein:

    
    
        D and E independently represent an alkyl chain, alkenyl chain, alkynyl chain, a cycloalkyl, carbocycle, aryl, -alkylaryl, heteroaryl, -alkylheteroaryl, acyl or a heterocycle.
        X represents CR20R21, O, S, NR19, with the proviso for formulas (VIII) and (IX) that, if Z=CH, X is O or S;
        R19 is selected from the group consisting of H, alkyl, cycloalkyl, aryl, heteroaryl, -oxyalkyl, -oxyaryl, carbonyl, amido, hydroxy, NO2, NH2, CN;
        R20 and R21 are independently selected from H, alkyl, cycloalkyl, heterocycle, aryl, heteroaryl, -oxyalkyl, -oxyaryl, carbonyl, amido, NO2, NH2, CN, CF3;
        X1, X2 and X3 are independently O or S provided that X2 and X3 are not both O;
        Y is O or S, with the proviso that Y may not be O, when the carbocycle formed by R17 and R18 has 3 members in the ring;
        Z is CH or N;
        R11, R12, R13 and R14 can be independently selected from H, an alkyl chain, an alkenyl chain, an alkynyl chain, cycloalkyl, carbocycle, aryl, heteroaryl, a heterocycle, halogen, alkoxy-, -thioalkyl, carboxyl, carboxylic acid ester, carbonyl, carbamide, carbimide, thiocarbamide or thiocarbonyl, NH2, NO2;
        R15 and R16 are independently of each other H or a branched or unbranched alkyl chain, or a branched or unbranched alkenyl chain;
        R17 and R18 are independently selected from H or an alkyl chain, alkenyl chain, a alkynyl chain, a carbocycle, aryl, heteroaryl, heteroalkyl or can be connected to form a carbocycle with up to 6 ring atoms;
        n is 0 or 1;
    
    


In one proviso, the following compounds:




are excluded from formula 1.

When A is selected from an alkyl chain, alkenyl chain or alkynyl chain, preferably A is a C1-C7 alkyl chain, C1-C7 alkenyl chain or a C1-C7 alkynyl chain. In one embodiment of the invention A is an unbranched C2-5 alkyl chain, in particular an unbranched C3-4 alkyl chain, especially an unbranched C3 alkyl chain. In a second embodiment of the invention A represents a C3 alkyl chain which is substituted at the 2 position by one (i.e. in S or R configuration) or two methyl groups.
When A is selected from the formulae (I) to (V), preferably A is selected from groups (I) to (IV). In one embodiment of the invention A represents a group of formula (IV), wherein n1 are each equal to 1 and m=1-4, especially m=1. In a second embodiment of the invention A represents a group of formula (I), (II) or (III), wherein n and n1 are each equal to 1 and R6, R7, R8, R9 and R10 represent H.
Preferably R6, R7, R8, R9 and R10 represent H or methyl.
In one embodiment of the invention the group B is chosen from (VI), (VIa), (VIb), (VII), (X), (XI), (XII), (XIII) and (XIV). In a second embodiment of the invention group B represents formula (VI). In a third embodiment of the invention group B represents formula (VIa). In a fourth embodiment of the invention group B represents formula (VIb). In a fifth embodiment of the invention group B represents formula (VII). In a sixth embodiment of the invention group B represents formula (X). In a seventh embodiment of the invention group B represents formula (XI). In an eighth embodiment of the invention group B represents formula (XII). In another embodiment of the invention group B represents formula (XIII). In a further embodiment of the invention group B represents formula (XIV). In a preferred embodiment of the invention B represents a group of formula (VI) or (VII).
When B represents a group (IX) suitably A does not represent alkynyl.
Preferably D and E independently represent benzyl, aryl, heteroaryl or a heterocycle.
In one embodiment of the invention D and E represent aryl, in particular phenyl or napthyl, especially substituted phenyl. Preferred substituent groups when D represents phenyl include alkoxy-, -thioalkyl, halogen, or a carboxylic acid alkyl or aryl ester. Also preferred are fluoro, chloro, bromo, iodo, trifluoromethyl, trifluoromethoxy, methoxy, ethoxy, benzyloxy, cyano, acetyl, dimethyl amino, methylsulphanyl, nitro, oxazolyl, pyrazolyl, isopropyl, ethyl and methoxycarbonyl. Where a phenyl group is mono-substituted it is preferred that substitution is in the 4-position. Other suitable aryl groups, which D and E may represent include dihydrobenzodioxine, benzodioxole, benzodithiole dihydrobenzodithiine, benzooxathiole and dihydrobenzooxathiine. A particularly preferred group, which D or E may represent is 3,4-(dimethoxy)-phenyl,
Preferably R20 and R21 represent NO2, CN, CF3 or, if R20 is H, R21 is NO2, CN, CF3, or, if R21 is H, R20 is NO2, CN, CF3.
In one embodiment, X or Y is S, O or NR1. Preferably X or Y is S.
Preferably Z represents N.
In a preferred embodiment, R11 and R14 are H.
In a further preferred embodiment, R12 and R13 are independently selected from oxyalkyl or thioalkyl, halogen, or carboxylic acid alkyl ester or phenyl.
In a preferred embodiment, at least one of R15 and R16 is H, more preferably, R15 and R16 are both H.
In a preferred embodiment, one of R17 and R18 is H and the other is Me. Also preferred are compounds wherein one of R17 and R18 is H and the other is phenyl. Additionally preferred are compounds where R17 and R18 form a carbocycle with up to 6 members in the ring atoms.
Preferred compounds include those defined by Examples 13, 119 and 125 below.
The present invention provides compounds of formula 1 for use as a pharmaceutical. In one embodiment regarding the use of the compounds of formula 1 as a pharmaceutical, the compounds:




are excluded from formula 1.

The compound (a) of the proviso above is disclosed as compound 7 in Ganellin et al (1995) J Med Chem 38(17) 3342-3350. This paper discloses said compound as a weak inhibitor of the histamine H3 receptor.
The compound of proviso (b) is disclosed as compound 7 in Venkatachalam et al (2001) Bioorganic Med Chem Lett 11, 523-528. This discloses said compound as an HIV1 reverse transcriptase inhibitor.
The compound of proviso (c) is disclosed as compound 19b in Moon et al (1991) J Med Chem 34, 2314-2327. This paper discloses said compound as a cholinergic agonist with potential use in the treatment of Alzheimer's disease.
The compounds of proviso (d) are disclosed as compounds 99, 100 and 102-103 in Wright et al (1986) J Med Chem 29, 523-530. This paper discloses said compounds as thromoxane synthetase inhibitors.
Certain compounds which would be embraced by formula 1 if it were not for the proviso “provided that X2 and X3 are not both O” are disclosed in Wright et al (1987) J Med Chem 30, 2277-2283 as thromboxane synthetase inhibitors.
Certain compounds which would be embraced by formula 1 if it were not for the proviso “that Y may not be O, when the carbocycle formed by R17 and R18 has 3 members in the ring” are disclosed in EP 0 117 462 A2 as thromboxane synthetase inhibitors.
In particular:
A suitable compound, that of formula 1* shown below, is a inhibitor of QC:




In a further embodiment, the inhibitors of QC (EC) are those of formula 1a,




wherein R is defined in examples 1 to 53.
















Ex-

ESI-MS
Res. Act.
IC50
Ki


ample
R
(M + H)
(%)
(μM)
(μM)




















1
Methyl
199.3
4.3

13


2
tert-Butyl
241.4
60.7

14.7


3
Benzyl
275.4
60.9

5.67


4
Phenyl
261.4
42.3

4.4


5
4-(fluoro)-phenyl
279.35
42.0

4.73


6
4-(chloro)-phenyl
295.80


1.2


7
4-(ethyl)-phenyl
289.41
28.7

2.78


8
4-(trifluoromethyl)-
329.4
38.5

3.93



phenyl


9
4-(methoxy-
319.4


1.19



carbonyl)-



Phenyl


10
4-(acetyl)-phenyl
303.4
17.0

1.70


11
4-(methoxy)-phenyl
291.4
9.7

0.70


12
bicyclo[2.2.1]hept-
277.5
16.0



5-en-2-yl


13
3,4-(dimethoxy)-
321.5
0.7
0.22
0.06



phenyl


14
2,4-(dimethoxy)-
321.5
2.2

0.57



phenyl


15
3,5-(dimethoxy)-
321.5
2.86

0.75



phenyl


16
2-(methoxy-
319.4



carbonyl)-



Phenyl


17
4-(oxazol-5-y)-
328.5
3.64

0.86



phenyl


18
4-(pyrazol-1-yl)-
327.4



phenyl


19
4-(isopropyl)-phenyl
303.5
8.7


20
4-(piperidine-1-
408.6
8.5

2.27



sulfonyl)-



Phenyl


21
4-(morpholin-4-yl)-
346.5
9.0



phenyl


22
4-(cyano)-phenyl
286.4
9.0

2.89


23
2,3-dihydro-
319.4
4.17

1.12



benzo[1,4]



dioxin-6-yl


24
benzo[1,3]dioxol-5-
305.4
16.7

5.66



yl


25
3,4,5(trimethoxy)-
351.5
1.7

0.34



phenyl


26
3-(methoxy)-phenyl
291.4
6.8

1.86


27
4-(ethoxy)-phenyl
305.5
7.2

0.89


28
4-(benzyloxy)-phenyl
367.5


0.98


29
4-(methoxy)-benzyl
305.5


3.93


30
3,4-(dimethoxy)-
335.5


1.55



benzyl


31
2-(methoxy-
325.5



carbonyl)-



thiophene-3-yl


32
3-(ethoxy-carbonyl)-
392.6



4,5,6,7-



tetrahydrobenzo[b]thio-



phene2-yl


33
2-(methoxy-
339.5



carbonyl)-4-



(methyl)-thiophene-



3-yl


34
Benzo[c][1,2,5]thiazol-
319.5



4-yl


35
Benzo[c][1,2,5]thiazol-
319.5
4.4

1.37



5-yl


36
5-(methyl)-3-
342.5



(phenyl)-



isooxazol-4-yl


37
3,5-(dimethyl)-
280.4



isooxazol-



4-yl


38
4-(iodo)-phenyl
387.3
23.5

2.12


39
4-(bromo)-phenyl
340.3


2.52


40
4-(methyl)-phenyl
275.4
31.3

2.14


41
Naphthalen-1-yl
311.5
26.7

2.79


42
4-(nitro)-phenyl
306.4
31.1

2.68


43
Butyl
241.4
53.8
14.0


44
Cyclooctyl
295.5
33.1
9.1


45
Furan-2-ylmethyl
265.4
61.4
10.0


46
Tetrahydrofuran-2-
269.4
46.0
12.8



ylmethyl


47
Benzo[1,3]dioxol-5-
319.4
42.7

6.1



ylmethyl


48
2-(morpholin-4-yl)-
298.5
55.0
13.3



ethyl


49
4-(methylsulfanyl)-
307.5
19.1

1.66



phenyl


50
4-(dimethylamino)-
304.5


2.03



phenyl


51
4-
345.4
14.2



(trifluoromethoxy)-



phenyl


52
Benzoyl
288.3


53
Pyridin-4-yl
261.1









Further suitable inhibitors of QC (EC) are those of formula 1b,




wherein R1 and R2 are defined in examples 54 to 95.



















ESI-MS
Res. Act.



Example
R1
R2
(M + H)
(%)
Ki (μM)




















54
Cyano
Methyl
207.3

1.5


55
Cyano
3,4-(dimethoxy)-
329.4

1.36




phenyl


56
Cyano
2,4-(dimethoxy)-
329.4




phenyl


57
Cyano
3,5-(dimethoxy)-
329.4

0.91




phenyl


58
Cyano
2,3-
327.4

0.64




dihydrobenzo[b][1,4]dioxin-




7-yl


59
Cyano
Benzo[d][1,3]dioxol-
313.4

0.73




6-yl


60
Cyano
3,4,5-(trimethoxy)-
359.4

0.88




phenyl


61
Cyano
3-(methoxy)-phenyl
299.4


62
Cyano
4-(ethoxy)-phenyl
313.4


63
Cyano
4-(benzyloxy)-phenyl
375.5


64
Cyano
Phenyl
269.4

1.02


65
Cyano
4-(methoxy)-phenyl
299.4

0.70


66
Cyano
4-(acetyl)-phenyl
311.4


67
Cyano
4-(nitro)-phenyl
314.4


68
Cyano
Benzyl
283.4
22.5
8.17


69
Cyano
Naphthalen-1-yl
319.4


70
Cyano
4-(fluoro)-phenyl
387.3


71
Cyano
4-(iodo)-phenyl
395.3


72
Cyano
4-(bromo)-phenyl
348.3


73
Cyano
Cyclooctyl
289.4


74
Cyano
tert-butyl
249.3


75
Cyano
4-(methyl)-phenyl
283.3

1.34


76
Cyano
4-(methylthio)-phenyl
315.5


77
Cyano
4-(ethyl)-phenyl
297.4


78
Cyano
4-(dimethylamino)-
312.4




phenyl


79
Cyano
Butyl
249.4


80
Cyano
Trityl
435.6


81
Cyano
(Benzo[d][1,3]dioxol-
327.4

1.53




6yl)methyl


82
Cyano
(tetrahydrofuran-
277.4




2yl)methyl


83
Cyano
4-(trifluoromethyl)-
334.4




phenyl


84
Cyano
(furan-2-yl)methyl
273.4


85
Cyano
2-(morpholin-4-yl)-
306.4




ethyl


86
Cyano
4-(oxazol-5yl)-phenyl
336.4


87
Cyano
Pyridin-3-yl
270.4


88
Cyano
4-(cyano)-phenyl
294.4


89
Cyano
4-(trifluoromethoxy)-
353.4




phenyl


90
Cyano
4-
416.6




(piperidinosulfonyl)-




phenyl


91
Cyano
4-(1H-pyrazol-1-
335.4




yl)phenyl


92
H
3,4-(dimethoxy)-
304.4

204.5




phenyl


93
Methyl
3,4-(dimethoxy)-
318.4

3.62




phenyl


94
Cyano
2,3,4-(trimethoxy)-
358.1




phenyl


95
Cyano
Cycloheptyl
288.2









Further suitable inhibitors of QC (EC) are those of formula 1c,




wherein R3 is defined in examples 96 to 102.


















ESI-MS
Res. Act.
IC50
Ki


Example
R3
(M + H)
(%)
(μM)
(μM)




















96
Ethyl
197.3


19.2


97
6-fluoro-4H-benzo[d]
321.4
19.0
12.0



[1,3]dioxin-8-yl


98
3-(cylopentyloxy)-4-
359.4
2.87

0.62



(methoxy)-phenyl


99
4-(heptyloxy)-phenyl
359.5
5.6
9.9


100
3,4-dihydro-2H-
317.4



benzo[b]



[1,4]dioxepin-7-yl


101
4-(butoxy)-phenyl
317.4


102
3,4-(dimethoxy)-
305.4


0.46



phenyl









Further suitable inhibitors of QC (EC) are those of formula 1d,




wherein the position on the ring is defined in examples 103 to 105.
















Position of the






Benzyl-
ESI-MS
Res. Act.
Ki


Example
substitution
(M + H)
(%)
(μM)







103
2
383.5
16.27
4.84


104
3
383.5

3.52


105
4
383.5

1.86









Further suitable inhibitors of QC (EC) are those of formula 1e,




wherein R4 and R5 are defined in examples 106 to 109.




















ESI-MS
Res. Act.
IC50
Ki


Example
R4
R5
(M + H)
(%)
(μM)
(μM)







106 (S)
H
Methyl
335.5


0.76


107 (R)
Methyl
H
335.5


0.35


108
Methyl
Methyl
349.5












109
—CH2—CH2—
347.5


7.85









Further suitable inhibitors of QC (EC) are those of formula 1f,




wherein R6 is defined in examples 110 to 112.


















ESI-MS
Res. Act.
IC50
Ki


Example
R6
(M + H)
(%)
(μM)
(μM)







110
H
259.4


3.00


111
Chloro
293.8


3.35


112
Methoxy
289.4


1.57









Further suitable inhibitors of QC (EC) are those of formula 1g,




wherein R7, R8 and R9 are defined in examples 113 to 132.





















ESI-MS
Res. Act.
Ki


Example
R7
R8
R9
(M + H)
(%)
(μM)





















113
Phenyl
H
H
260.4

4.62


114
Thiophen-2-yl
H
H
266.5

3.29


115 (R)
Phenyl
Methyl
H
274.5
21.2
7.34


116 (S)
Phenyl
H
Methyl
274.5
8.1
3.51


117
Phenyl
H
Ethyl
288.5

3.57


118
Phenyl
H
Phenyl
336.5
13.5
4.48


119
3,4-
H
H
320.5

0.39



(dimethoxy)-



Phenyl


120
3,4-
Methyl
Methyl
347.2



(dimethoxy)-



Phenyl












121
4-(chloro)-
—CH2—CH2—CH2—
334.9

4.88



phenyl


122
4-(chloro)-
—CH2—C2H4—CH2—
349.0

7.3



phenyl


123
4-(methoxy)-
—CH2—C3H6—CH2—
358.6

2.78



phenyl


124
4-(methoxy)-
—CH2—CH2—
316.5

0.39



phenyl


125
3,4-
—CH2—CH2—
346.5

0.09



(dimethoxy)-



Phenyl


126
3,4,5-
—CH2—CH2—
376.6



(trimethoxy)-



Phenyl


127
2,3,4-
—CH2—CH2—
376.6



(trimethoxy)-



Phenyl


128
2-(methoxy)-
—CH2—CH2—
316.5



phenyl


129
3-(methoxy)-
—CH2—CH2—
316.5



phenyl


130
2,3-
—CH2—CH2—
346.5



(dimethoxy)-



Phenyl


131
3,5-
—CH2—CH2—
346.5



(dimethoxy)-



Phenyl


132
2,5-
—CH2—CH2—
346.5



(dimethoxy)-



Phenyl









Further suitable inhibitors of QC (EC) are those of formula 1h,




wherein n is defined in examples 133 to 135.



















ESI-MS
Ki



Example
N
(M + H)
(μM)









133
3
306.4




134
4
320.5
0.99



135
5
334.5










Further suitable inhibitors of QC (EC) are those of formula 1i,




wherein m is defined in examples 136 and 137.

















ESI-MS
Res. Act.
Ki


Example
m
(M + H)
(%)
(μM)



















136
2
307.4

17.6


137
4
335.5
2.19
0.55









Further suitable inhibitors of QC (EC) are those of formula 138 to 141.

















ESI-MS
Res. Act.
IC50
Ki


Example
Structure
(M + H)
(%)
(μM)
(μM)




















138




347.5


 


139




347.2


 


140




226.3
13.8

20.5


 


141




370.4









A preferred inhibitor of glutaminyl peptide cyclotransferase is 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride (further named as QCI)




In a preferred embodiment, the present invention provides a composition, preferably a pharmaceutical composition, comprising at least one QC inhibitor optionally in combination with at least one other agent selected from the group consisting of nootropic agents, neuroprotectants, antiparkinsonian drugs, amyloid protein deposition inhibitors, beta amyloid synthesis inhibitors, antidepressants, anxiolytic drugs, antipsychotic drugs and anti-multiple sclerosis drugs.
More specifically, the aforementioned other agent is selected from the group consisting of beta-amyloid antibodies, cysteine protease inhibitors, PEP-inhibitors, LiCl, acetylcholinesterase (AChE) inhibitors, PIMT enhancers, inhibitors of beta secretases, inhibitors of gamma secretases, inhibitors of neutral endopeptidase, inhibitors of Phosphodiesterase-4 (PDE-4), TNFalpha inhibitors, muscarinic M1 receptor antagonists, NMDA receptor antagonists, sigma-1 receptor inhibitors, histamine H3 antagonists, immunomodulatory agents, immunosuppressive agents, MCP-1 antagonists or an agent selected from the group consisting of antegren (natalizumab), Neurelan (fampridine-SR), campath (alemtuzumab), IR 208, NBI 5788/MSP 771 (tiplimotide), paclitaxel, Anergix.MS (AG 284), SH636, Differin (CD 271, adapalene), BAY 361677 (interleukin-4), matrix-metalloproteinase-inhibitors (e.g. BB 76163), interferon-tau (trophoblastin) and SAIK-MS.
Furthermore, the other agent may be, for example, an anti-anxiety drug or antidepressant selected from the group consisting of

    
    
        (a) Benzodiazepines, e.g. alprazolam, chlordiazepoxide, clobazam, clonazepam, clorazepate, diazepam, fludiazepam, loflazepate, lorazepam, methaqualone, oxazepam, prazepam, tranxene,
        (b) Selective serotonin re-uptake inhibitors (SSRI's), e.g. citalopram, fluoxetine, fluvoxamine, escitalopram, sertraline, paroxetine,
        (c) Tricyclic antidepressants, e.g. amitryptiline, clomipramine, desipramine, doxepin, imipramine
        (d) Monoamine oxidase (MAO) inhibitors,
        (e) Azapirones, e.g. buspirone, tandopsirone,
        (f) Serotonin-norepinephrine reuptake inhibitors (SNRI's), e.g. venlafaxine, duloxetine,
        (g) Mirtazapine,
        (h) Norepinephrine reuptake inhibitors (NRI's), e.g. reboxetine,
        (i) Bupropione,
        (j) Nefazodone,
        (k) beta-blockers,
        (l) NPY-receptor ligands: NPY agonists or antagonists.
    
    


In a further embodiment, the other agent may be, for example, an anti-multiple sclerosis drug selected from the group consisting of

    
    
        a) dihydroorotate dehydrogenase inhibitors, e.g. SC-12267, teriflunomide, MNA-715, HMR-1279 (syn. to HMR-1715, MNA-279),
        b) autoimmune suppressant, e.g. laquinimod,
        c) paclitaxel,
        d) antibodies, e.g. AGT-1, anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody, Nogo receptor modulators, ABT-874, alemtuzumab (CAMPATH), anti-OX40 antibody, CNTO-1275, DN-1921, natalizumab (syn. to AN-100226, Antegren, VLA-4 Mab), daclizumab (syn. to Zenepax, Ro-34-7375, SMART anti-Tac), J-695, priliximab (syn. to Centara, CEN-000029, cM-T412), MRA, Dantes, anti-IL-12-antibody,
        e) peptide nucleic acid (PNA) preparations, e.g. reticulose,
        f) interferon alpha, e.g. Alfaferone, human alpha interferon (syn. to Omniferon, Alpha Leukoferon),
        g) interferon beta, e.g. Frone, interferon beta-1a like Avonex, Betron (Rebif), interferon beta analogs, interferon beta-transferrin fusion protein, recombinant interferon beta-1b like Betaseron,
        h) interferon tau,
        i) peptides, e.g. AT-008, AnergiX.MS, Immunokine (alpha-Immunokine-NNSO3), cyclic peptides like ZD-7349,
        j) therapeutic enzymes, e.g. soluble CD8 (sCD8),
        k) multiple sclerosis-specific autoantigen-encoding plasmid and cytokine-encoding plasm1d, e.g. BHT-3009;
        l) inhibitor of TNF-alpha, e.g. BLX-1002, thalidomide, SH-636,
        m) TNF antagonists, e.g. solimastat, lenercept (syn. to RO-45-2081, Tenefuse), onercept (sTNFR1), CC-1069,
        n) TNF alpha, e.g. etanercept (syn. to Enbrel, TNR-001)
        o) CD28 antagonists, e.g. abatacept,
        p) Lck tyrosine kinase inhibitors,
        q) cathepsin K inhibitors,
        r) analogs of the neuron-targeting membrane transporter protein taurine and the plant-derived calpain inhibitor leupeptin, e.g. Neurodur,
        s) chemokine receptor-1 (CCR1) antagonist, e.g. BX-471,
        t) CCR2 antagonists,
        u) AMPA receptor antagonists, e.g. ER-167288-01 and ER-099487, E-2007, talampanel,
        v) potassium channel blockers, e.g. fampridine,
        w) tosyl-proline-phenylalanine small-molecule antagonists of the VLA-4/VCAM interaction, e.g. TBC-3342,
        x) cell adhesion molecule inhibitors, e.g. TBC-772,
        y) antisense oligonucleotides, e.g. EN-101,
        z) antagonists of free immunoglobulin light chain (IgLC) binding to mast cell receptors, e.g. F-991,
        aa) apoptosis inducing antigens, e.g. Apogen MS,
        bb) alpha-2 adrenoceptor agonist, e.g. tizanidine (syn. to Zanaflex, Ternelin, Sirdalvo, Sirdalud, Mionidine),
        cc) copolymer of L-tyrosine, L-lysine, L-glutamic acid and L-alanine, e.g. glatiramer acetate (syn. to Copaxone, COP-1, copolymer-1),
        dd) topoisomerase II modulators, e.g. mitoxantrone hydrochloride,
        ee) adenosine deaminase inhibitor, e.g. cladribine (syn. to Leustatin, Mylinax, RWJ-26251),
        ff) interleukin-10, e.g. ilodecakin (syn. to Tenovil, Sch-52000, CSIF),
        gg) interleukin-12 antagonists, e.g. lisofylline (syn. to CT-1501R, LSF, lysofylline),
        hh) Ethanaminum, e.g. SRI-62-834 (syn. to CRC-8605, NSC-614383),
        ii) immunomodulators, e.g. SAIK-MS, PNU-156804, alpha-fetoprotein peptide (AFP), IPDS,
        jj) retinoid receptor agonists, e.g. adapalene (syn. to Differin, CD-271),
        kk) TGF-beta, e.g. GDF-1 (growth and differentiation factor 1),
        ll) TGF-beta-2, e.g. BetaKine,
        mm) MMP inhibitors, e.g. glycomed,
        nn) phosphodiesterase 4 (PDE4) inhibitors, e.g. RPR-122818,
        oo) purine nucleoside phosphorylase inhibitors, e.g. 9-(3-pyridylmethyl)-9-deazaguanine, peldesine (syn. to BCX-34, TO-200),
        pp) alpha-4/beta-1 integrin antagonists, e.g. ISIS-104278,
        qq) antisense alpha4 integrin (CD49d), e.g. ISIS-17044, ISIS-27104,
        rr) cytokine-inducing agents, e.g. nucleosides, ICN-17261,
        ss) cytokine inhibitors,
        tt) heat shock protein vaccines, e.g. HSPPC-96,
        uu) neuregulin growth factors, e.g. GGF-2 (syn. to neuregulin, glial growth factor 2),
        vv) cathepsin S-inhibitors,
        ww) bropirimine analogs, e.g. PNU-56169, PNU-63693,
        xx) Monocyte chemoattractant protein-1 inhibitors, e.g. benzimidazoles like MCP-1 inhibitors, LKS-1456, PD-064036, PD-064126, PD-084486, PD-172084, PD-172386.
    
    


Further, the present invention provides pharmaceutical compositions e.g. for parenteral, enteral or oral administration, comprising at least one QC inhibitor, optionally in combination with at least one of the other aforementioned agents.
These combinations provide a particularly beneficial effect. Such combinations are therefore shown to be effective and useful for the treatment of the aforementioned diseases. Accordingly, the invention provides a method for the treatment of these conditions.
The method comprises either co-administration of at least one QC inhibitor and at least one of the other agents or the sequential administration thereof.
Co-administration includes administration of a formulation, which comprises at least one QC inhibitor and at least one of the other agents or the essentially simultaneous administration of separate formulations of each agent.
Beta-amyloid antibodies and compositions containing the same are described, e.g. in WO 2006/137354, WO 2006/118959, WO 2006/103116, WO 2006/095041, WO 2006/081171, WO 2006/066233, WO 2006/066171, WO 2006/066089, WO 2006/066049, WO 2006/055178, WO 2006/046644, WO 2006/039470, WO 2006/036291, WO 2006/026408, WO 2006/016644, WO 2006/014638, WO 2006/014478, WO 2006/008661, WO 2005/123775, WO 2005/120571, WO 2005/105998, WO 2005/081872, WO 2005/080435, WO 2005/028511, WO 2005/025616, WO 2005/025516, WO 2005/023858, WO 2005/018424, WO 2005/011599, WO 2005/000193, WO 2004/108895, WO 2004/098631, WO 2004/080419, WO 2004/071408, WO 2004/069182, WO 2004/067561, WO 2004/044204, WO 2004/032868, WO 2004/031400, WO 2004/029630, WO 2004/029629, WO 2004/024770, WO 2004/024090, WO 2003/104437, WO 2003/089460, WO 2003/086310, WO 2003/077858, WO 2003/074081, WO 2003/070760, WO 2003/063760, WO 2003/055514, WO 2003/051374, WO 2003/048204, WO 2003/045128, WO 2003/040183, WO 2003/039467, WO 2003/016466, WO 2003/015691, WO 2003/014162, WO 2003/012141, WO 2002/088307, WO 2002/088306, WO 2002/074240, WO 2002/046237, WO 2002/046222, WO 2002/041842, WO 2001/062801, WO 2001/012598, WO 2000/077178, WO 2000/072880, WO 2000/063250, WO 1999/060024, WO 1999/027944, WO 1998/044955, WO 1996/025435, WO 1994/017197, WO 1990/014840, WO 1990/012871, WO 1990/012870, WO 1989/006242.
The beta-amyloid antibodies may be selected from, for example, polyclonal, monoclonal, chimenic or humanited antibodies. Furthermore, said antibodies may be useful to develop active and passive immune therapies, i.e. vaccines and monoclonal antibodies.
Suitable examples of beta-amyloid antibodies are ACU-5A5, huC091 (Acumen/Merck); PF-4360365, RI-1014, RI-1219, RI-409, RN-1219 (Rinat Neuroscience Corp (Pfizer Inc)); the nanobody therapeutics of Ablynx/Boehringer Ingelheim; beta-amyloid-specific humanized monoclonal antibodies of Intellect Neurosciences/IBL; m266, m266.2 (Eli Lilly & Co.); AAB-02 (Elan); bapineuzumab (Elan); BAN-2401 (Bioarctic Neuroscience AB); ABP-102 (Abiogen Pharma SpA); BA-27, BC-05 (Takeda); R-1450 (Roche); ESBA-212 (ESBATech AG); AZD-3102 (AstraZeneca) and beta-amyloid antibodies of Mindset BioPharmaceuticals Inc.
Especially preferred are antibodies, which recognize the N-terminus of the Aβ peptide. A suitable antibody, which recognize the Aβ-N-Terminus is, for example Acl-24 (AC immune CA). A monoclonal antibody against beta-amyloid peptide is disclosed in WO 2007/068412. Respective chimenic and humanized antibodies are disclosed in WO 2008/011348. A method for producing a vaccine composition for treating an amyloid-associated disease is disclosed in WO 2007/068411.
Suitable cysteine protease inhibitors are for example inhibitors of cathepsin B. Inhibitors of cathepsin B and compositions containing such inhibitors are described, e.g. in WO 2006/060473, WO 2006/042103, WO 2006/039807, WO 2006/021413, WO 2006/021409, WO 2005/097103, WO 2005/007199, WO2004/084830, WO 2004/078908, WO 2004/026851, WO 2002/094881, WO 2002/027418, WO 2002/021509, WO 1998/046559, WO 1996/021655.
Examples of suitable PIMT enhancers are 10-aminoaliphatyl-dibenz[b,f] oxepines described in WO 98/15647 and WO 03/057204, respectively. Further useful according to the present invention are modulators of PIMT activity described in WO 2004/039773.
Inhibitors of beta secretase and compositions containing such inhibitors are described, e.g. in WO 03/059346, WO 2006/099352, WO 2006/078576, WO 2006/060109, WO 2006/057983, WO 2006/057945, WO 2006/055434, WO 2006/044497, WO 2006/034296, WO 2006/034277, WO 2006/029850, WO 2006/026204, WO 2006/014944, WO 2006/014762, WO 2006/002004, U.S. Pat. No. 7,109,217, WO 2005/113484, WO 2005/103043, WO 2005/103020, WO 2005/065195, WO 2005/051914, WO 2005/044830, WO 2005/032471, WO 2005/018545, WO 2005/004803, WO 2005/004802, WO 2004/062625, WO 2004/043916, WO 2004/013098, WO 03/099202, WO 03/043987, WO 03/039454, U.S. Pat. No. 6,562,783, WO 02/098849 and WO 02/096897.
Suitable examples of beta secretase inhibitors for the purpose of the present invention are WY-25105 (Wyeth); Posiphen, (+)-phenserine (TorreyPines/NIH); LSN-2434074, LY-2070275, LY-2070273, LY-2070102 (Eli Lilly & Co.); PNU-159775A, PNU-178025A, PNU-17820A, PNU-33312, PNU-38773, PNU-90530 (Elan/Pfizer); KMI-370, KMI-358, kmi-008 (Kyoto University); OM-99-2, OM-003 (Athenagen Inc.); AZ-12304146 (AstraZeneca/Astex); GW-840736X (GlaxoSmithKline plc.) and DNP-004089 (De Novo Pharmaceuticals Ltd.).
Inhibitors of gamma secretase and compositions containing such inhibitors are described, e.g. in WO 2005/008250, WO 2006/004880, U.S. Pat. No. 7,122,675, U.S. Pat. No. 7,030,239, U.S. Pat. No. 6,992,081, U.S. Pat. No. 6,982,264, WO 2005/097768, WO2005/028440, WO 2004/101562, U.S. Pat. No. 6,756,511, U.S. Pat. No. 6,683,091, WO 03/066592, WO 03/014075, WO 03/013527, WO 02/36555, WO 01/53255, U.S. Pat. No. 7,109,217, U.S. Pat. No. 7,101,895, U.S. Pat. No. 7,049,296, U.S. Pat. No. 7,034,182, U.S. Pat. No. 6,984,626, WO 2005/040126, WO 2005/030731, WO 2005/014553, U.S. Pat. No. 6,890,956, EP 1334085, EP 1263774, WO 2004/101538, WO 2004/00958, WO 2004/089911, WO 2004/073630, WO 2004/069826, WO 2004/039370, WO 2004/031139, WO 2004/031137, U.S. Pat. No. 6,713,276, U.S. Pat. No. 6,686,449, WO 03/091278, U.S. Pat. No. 6,649,196, U.S. Pat. No. 6,448,229, WO 01/77144 and WO 01/66564.
Suitable gamma secretase inhibitors for the purpose of the present invention are GSI-953, WAY-GSI-A, WAY-GSI-B (Wyeth); MK-0752, MRK-560, L-852505, L-685-458, L-852631, L-852646 (Merck & Co. Inc.); LY-450139, LY-411575, AN-37124 (Eli Lilly & Co.); BMS-299897, BMS-433796 (Bristol-Myers Squibb Co.); E-2012 (Eisai Co. Ltd.); EHT-0206, EHT-206 (ExonHit Therapeutics SA); and NGX-555 (TorreyPines Therapeutics Inc.).
Suitable beta amyloid synthesis inhibitors for the purpose of the present invention are for example Bisnorcymserine (Axonyx Inc.); (R)-flurbiprofen (MCP-7869; Flurizan) (Myriad Genetics); nitroflurbiprofen (NicOx); BGC-20-0406 (Sankyo Co. Ltd.) and BGC-20-0466 (BTG plc.).
Suitable amyloid protein deposition inhibitors for the purpose of the present invention are for example SP-233 (Samaritan Pharmaceuticals); AZD-103 (Ellipsis Neurotherapeutics Inc.); AAB-001 (Bapineuzumab), AAB-002, ACC-001 (Elan Corp plc.); Colostrinin (ReGen Therapeutics plc.); Tramiprosate (Neurochem); AdPEDI-(amyloid-beta1-6)11) (Vaxin Inc.); MPI-127585, MPI-423948 (Mayo Foundation); SP-08 (Georgetown University); ACU-5A5 (Acumen/Merck); Transthyretin (State University of New York); PTI-777, DP-74, DP 68, Exebryl (ProteoTech Inc.); m266 (Eli Lilly & Co.); EGb-761 (Dr. Willmar Schwabe GmbH); SPI-014 (Satori Pharmaceuticals Inc.); ALS-633, ALS-499 (Advanced Life Sciences Inc.); AGT-160 (ArmaGen Technologies Inc.); TAK-070 (Takeda Pharmaceutical Co. Ltd.); CHF-5022, CHF-5074, CHF-5096 and CHF-5105 (Chiesi Farmaceutici SpA.).
Suitable PDE-4 inhibitors for the purpose of the present invention are for example Doxofylline (Instituto Biologico Chemioterapica ABC SpA.); idudilast eye drops, tipelukast, ibudilast (Kyorin Pharmaceutical Co. Ltd.); theophylline (Elan Corp.); cilomilast (GlaxoSmithKline plc.); Atopik (Barrier Therapeutics Inc.); tofimilast, CI-1044, PD-189659, CP-220629, PDE 4d inhibitor BHN (Pfizer Inc.); arofylline, LAS-37779 (Almirall Prodesfarma SA.); roflumilast, hydroxypumafentrine (Altana AG), tetomilast (Otska Pharmaceutical Co. Ltd.); tipelukast, ibudilast (Kyorin Pharmaceutical), CC-10004 (Celgene Corp.); HT-0712, IPL-4088 (Inflazyme Pharmaceuticals Ltd.); MEM-1414, MEM-1917 (Memory Pharmaceuticals Corp.); oglemilast, GRC-4039 (Glenmark Pharmaceuticals Ltd.); AWD-12-281, ELB-353, ELB-526 (Elbion AG); EHT-0202 (ExonHit Therapeutics SA.); ND-1251 (Neuro3d SA.); 4AZA-PDE4 (4 AZA Bioscience NV.); AVE-8112 (Sanofi-Aventis); CR-3465 (Rottapharm SpA.); GP-0203, NCS-613 (Centre National de la Recherche Scientifique); KF-19514 (Kyowa Hakko Kogyo Co. Ltd.); ONO-6126 (Ono Pharmaceutical Co. Ltd.); OS-0217 (Dainippon Pharmaceutical Co. Ltd.); IBFB-130011, IBFB-150007, IBFB-130020, IBFB-140301 (IBFB Pharma GmbH); IC-485 (ICOS Corp.); RBx-14016 and RBx-11082 (Ranbaxy Laboratories Ltd.). A preferred PDE-4-inhibitor is Rolipram.
MAO inhibitors and compositions containing such inhibitors are described, e.g. in WO 2006/091988, WO 2005/007614, WO 2004/089351, WO 01/26656, WO 01/12176, WO 99/57120, WO 99/57119, WO 99/13878, WO 98/40102, WO 98/01157, WO 96/20946, WO 94/07890 and WO 92/21333.
Suitable MAO-inhibitors for the purpose of the present invention are for example Linezolid (Pharmacia Corp.); RWJ-416-457 (RW Johnson Pharmaceutical Research Institute); budipine (Altana AG); GPX-325 (BioResearch Ireland); isocarboxazid; phenelzine; tranylcypromine; indantadol (Chiesi Farmaceutici SpA.); moclobemide (Roche Holding AG); SL-25.1131 (Sanofi-Synthelabo); CX-1370 (Burroughs Wellcome Co.); CX-157 (Krenitsky Pharmaceuticals Inc.); desoxypeganine (HF Arzneimittelforschung GmbH & Co. KG); bifemelane (Mitsubishi-Tokyo Pharmaceuticals Inc.); RS-1636 (Sankyo Co. Ltd.); esuprone (BASF AG); rasagiline (Teva Pharmaceutical Industries Ltd.); ladostigil (Hebrew University of Jerusalem); safinamide (Pfizer) and NW-1048 (Newron Pharmaceuticals SpA.).
Suitable histamine H3 antagonists for the purpose of the present invention are, e.g. ABT-239, ABT-834 (Abbott Laboratories); 3874-H1 (Aventis Pharma); UCL-2173 (Berlin Free University), UCL-1470 (BioProjet, Societe Civile de Recherche); DWP-302 (Daewoong Pharmaceutical Co Ltd); GSK-189254A, GSK-207040A (GlaxoSmithKline Inc.); cipralisant, GT-2203 (Gliatech Inc.); Ciproxifan (INSERM), 1S,2S)-2-(2-Aminoethyl)-1-(1H-imidazol-4-yl)cyclopropane (Hokkaido University); JNJ-17216498, JNJ-5207852 (Johnson & Johnson); NNC-0038-0000-1049 (Novo Nordisk A/S); and Sch-79687 (Schering-Plough).
PEP inhibitors and compositions containing such inhibitors are described, e.g. in JP 01042465, JP 03031298, JP 04208299, WO 00/71144, U.S. Pat. No. 5,847,155; JP 09040693, JP 10077300, JP 05331072, JP 05015314, WO 95/15310, WO 93/00361, EP 0556482, JP 06234693, JP 01068396, EP 0709373, U.S. Pat. No. 5,965,556, U.S. Pat. No. 5,756,763, U.S. Pat. No. 6,121,311, JP 63264454, JP 64000069, JP 63162672, EP 0268190, EP 0277588, EP 0275482, U.S. Pat. No. 4,977,180, U.S. Pat. No. 5,091,406, U.S. Pat. No. 4,983,624, U.S. Pat. No. 5,112,847, U.S. Pat. No. 5,100,904, U.S. Pat. No. 5,254,550, U.S. Pat. No. 5,262,431, U.S. Pat. No. 5,340,832, U.S. Pat. No. 4,956,380, EP 0303434, JP 03056486, JP 01143897, JP 1226880, EP 0280956, U.S. Pat. No. 4,857,537, EP 0461677, EP 0345428, JP 02275858, U.S. Pat. No. 5,506,256, JP 06192298, EP 0618193, JP 03255080, EP 0468469, U.S. Pat. No. 5,118,811, JP 05025125, WO 93/3065, JP 05201970, WO 9412474, EP 0670309, EP 0451547, JP 06339390, U.S. Pat. No. 5,073,549, U.S. Pat. No. 4,999,349, EP 0268281, U.S. Pat. No. 4,743,616, EP 0232849, EP 0224272, JP 62114978, JP 62114957, U.S. Pat. No. 4,757,083, U.S. Pat. No. 4,810,721, U.S. Pat. No. 5,198,458, U.S. Pat. No. 4,826,870, EP 0201742, EP 0201741, U.S. Pat. No. 4,873,342, EP 0172458, JP 61037764, EP 0201743, U.S. Pat. No. 4,772,587, EP 0372484, U.S. Pat. No. 5,028,604, WO 91/18877, JP 04009367, JP 04235162, U.S. Pat. No. 5,407,950, WO 95/01352, JP 01250370, JP 02207070, U.S. Pat. No. 5,221,752, EP 0468339, JP 04211648, WO 99/46272, WO 2006/058720 and WO 2006/120104.
Suitable prolyl endopeptidase inhibitors for the purpose of the present invention are, e.g. Fmoc-Ala-Pyrr-CN, Z-Phe-Pro-Benzothiazole (Probiodrug), Z-321 (Zeria Pharmaceutical Co Ltd.); ONO-1603 (Ono Pharmaceutical Co Ltd); JTP-4819 (Japan Tobacco Inc.) and S-17092 (Servier).
Other suitable compounds that can be used according to the present invention in combination with QC-inhibitors are NPY, an NPY mimetic or an NPY agonist or antagonist or a ligand of the NPY receptors.
Preferred according to the present invention are antagonists of the NPY receptors.
Suitable ligands or antagonists of the NPY receptors are 3a, 4,5,9b-tetrahydro-1 h-benz[e]indol-2-yl amine-derived compounds as disclosed in WO 00/68197.
NPY receptor antagonists which may be mentioned include those disclosed in European patent applications EP 0 614 911, EP 0 747 357, EP 0 747 356 and EP 0 747 378; international patent applications WO 94/17035, WO 97/19911, WO 97/19913, WO 96/12489, WO 97/19914, WO 96/22305, WO 96/40660, WO 96/12490, WO 97/09308, WO 97/20820, WO 97/20821, WO 97/20822, WO 97/20823, WO 97/19682, WO 97/25041, WO 97/34843, WO 97/46250, WO 98/03492, WO 98/03493, WO 98/03494 and WO 98/07420; WO 00/30674, U.S. Pat. Nos. 5,552,411, 5,663,192 and 5,567,714; 6,114,336, Japanese patent application JP 09157253; international patent applications WO 94/00486, WO 93/12139, WO 95/00161 and WO 99/15498; U.S. Pat. No. 5,328,899; German patent application DE 393 97 97; European patent applications EP 355 794 and EP 355 793; and Japanese patent applications JP 06116284 and JP 07267988. Preferred NPY antagonists include those compounds that are specifically disclosed in these patent documents. More preferred compounds include amino acid and non-peptide-based NPY antagonists. Amino acid and non-peptide-based NPY antagonists which may be mentioned include those disclosed in European patent applications EP 0 614 911, EP 0 747 357, EP 0 747 356 and EP 0 747 378; international patent applications WO 94/17035, WO 97/19911, WO 97/19913, WO 96/12489, WO 97/19914, WO 96/22305, WO 96/40660, WO 96/12490, WO 97/09308, WO 97/20820, WO 97/20821, WO 97/20822, WO 97/20823, WO 97/19682, WO 97/25041, WO 97/34843, WO 97/46250, WO 98/03492, WO 98/03493, WO 98/03494, WO 98/07420 and WO 99/15498; U.S. Pat. Nos. 5,552,411, 5,663,192 and 5,567,714; and Japanese patent application JP 09157253. Preferred amino acid and non-peptide-based NPY antagonists include those compounds that are specifically disclosed in these patent documents.
Particularly preferred compounds include amino acid-based NPY antagonists. Amino acid-based compounds, which may be mentioned include those disclosed in international patent applications WO 94/17035, WO 97/19911, WO 97/19913, WO 97/19914 or, preferably, WO 99/15498. Preferred amino acid-based NPY antagonists include those that are specifically disclosed in these patent documents, for example BIBP3226 and, especially, (R)—N2-(diphenylacetyl)-(R)—N-[1-(4-hydroxy-phenyl)ethyl]arginine amide (Example 4 of international patent application WO 99/15498).
M1 receptor agonists and compositions containing such inhibitors are described, e.g. in WO 2004/087158, WO 91/10664.
Suitable M1 receptor antagonists for the purpose of the present invention are for example CDD-0102 (Cognitive Pharmaceuticals); Cevimeline (Evoxac) (Snow Brand Milk Products Co. Ltd.); NGX-267 (TorreyPines Therapeutics); sabcomeline (GlaxoSmithKline); alvameline (H Lundbeck A/S); LY-593093 (Eli Lilly & Co.); VRTX-3 (Vertex Pharmaceuticals Inc.); WAY-132983 (Wyeth) and CI-101 7/(PD-151832) (Pfizer Inc.).
Acetylcholinesterase inhibitors and compositions containing such inhibitors are described, e.g. in WO 2006/071274, WO 2006/070394, WO 2006/040688, WO 2005/092009, WO 2005/079789, WO 2005/039580, WO 2005/027975, WO 2004/084884, WO 2004/037234, WO 2004/032929, WO 03/101458, WO 03/091220, WO 03/082820, WO 03/020289, WO 02/32412, WO 01/85145, WO 01/78728, WO 01/66096, WO 00/02549, WO 01/00215, WO 00/15205, WO 00/23057, WO 00/33840, WO 00/30446, WO 00/23057, WO 00/15205, WO 00/09483, WO 00/07600, WO 00/02549, WO 99/47131, WO 99/07359, WO 98/30243, WO 97/38993, WO 97/13754, WO 94/29255, WO 94/20476, WO 94/19356, WO 93/03034 and WO 92/19238.
Suitable acetylcholinesterase inhibitors for the purpose of the present invention are for example Donepezil (Eisai Co. Ltd.); rivastigmine (Novartis AG); (−)-phenserine (TorreyPines Therapeutics); ladostigil (Hebrew University of Jerusalem); huperzine A (Mayo Foundation); galantamine (Johnson & Johnson); Memoquin (Universita di Bologna); SP-004 (Samaritan Pharmaceuticals Inc.); BGC-20-1259 (Sankyo Co. Ltd.); physostigmine (Forest Laboratories Inc.); NP-0361 (Neuropharma SA); ZT-1 (Debiopharm); tacrine (Warner-Lambert Co.); metrifonate (Bayer Corp.) and INM-176 (WhanIn).
NMDA receptor antagonists and compositions containing such inhibitors are described, e.g. in WO 2006/094674, WO 2006/058236, WO 2006/058059, WO 2006/010965, WO 2005/000216, WO 2005/102390, WO 2005/079779, WO 2005/079756, WO 2005/072705, WO 2005/070429, WO 2005/055996, WO 2005/035522, WO 2005/009421, WO 2005/000216, WO 2004/092189, WO 2004/039371, WO 2004/028522, WO 2004/009062, WO 03/010159, WO 02/072542, WO 02/34718, WO 01/98262, WO 01/94321, WO 01/92204, WO 01/81295, WO 01/32640, WO 01/10833, WO 01/10831, WO 00/56711, WO 00/29023, WO 00/00197, WO 99/53922, WO 99/48891, WO 99/45963, WO 99/01416, WO 99/07413, WO 99/01416, WO 98/50075, WO 98/50044, WO 98/10757, WO 98/05337, WO 97/32873, WO 97/23216, WO 97/23215, WO 97/23214, WO 96/14318, WO 96/08485, WO 95/31986, WO 95/26352, WO 95/26350, WO 95/26349, WO 95/26342, WO 95/12594, WO 95/02602, WO 95/02601, WO 94/20109, WO 94/13641, WO 94/09016 and WO 93/25534.
Suitable NMDA receptor antagonists for the purpose of the present invention are for example Memantine (Merz & Co. GmbH); topiramate (Johnson & Johnson); AVP-923 (Neurodex) (Center for Neurologic Study); EN-3231 (Endo Pharmaceuticals Holdings Inc.); neramexane (MRZ-2/579) (Merz and Forest); CNS-5161 (CeNeS Pharmaceuticals Inc.); dexanabinol (HU-211; Sinnabidol; PA-50211) (Pharmos); EpiCept NP-1 (Dalhousie University); indantadol (V-3381; CNP-3381) (Vernalis); perzinfotel (EAA-090, WAY-126090, EAA-129) (Wyeth); RGH-896 (Gedeon Richter Ltd.); traxoprodil (CP-101606), besonprodil (PD-196860, CI-1041) (Pfizer Inc.); CGX-1007 (Cognetix Inc.); delucemine (NPS-1506) (NPS Pharmaceuticals Inc.); EVT-101 (Roche Holding AG); acamprosate (Synchroneuron LLC.); CR-3991, CR-2249, CR-3394 (Rottapharm SpA.); AV-101 (4-Cl-kynurenine (4-Cl-KYN)), 7-chloro-kynurenic acid (7-Cl-KYNA) (VistaGen); NPS-1407 (NPS Pharmaceuticals Inc.); YT-1006 (Yaupon Therapeutics Inc.); ED-1812 (Sosei R&D Ltd.); himantane (hydrochloride N-2-(adamantly)-hexamethylen-imine) (RAMS); Lancicemine (AR-R-15896) (AstraZeneca); EVT-102, Ro-25-6981 and Ro-63-1908 (Hoffmann-La Roche AG/Evotec).
Furthermore, the present invention relates to combination therapies useful for the treatment of atherosclerosis, restenosis, pancreatitis or arthritis, administering a QC inhibitor in combination with another therapeutic agent selected from the group consisting of inhibitors of the angiotensin converting enzyme (ACE); angiotensin II receptor blockers; diuretics; calcium channel blockers (CCB); beta-blockers; platelet aggregation inhibitors; cholesterol absorption modulators; HMG-Co-A reductase inhibitors; high density lipoprotein (HDL) increasing compounds; renin inhibitors; IL-6 inhibitors; antiinflammatory corticosteroids; antiproliferative agents; nitric oxide donors; inhibitors of extracellular matrix synthesis; growth factor or cytokine signal transduction inhibitors; MCP-1 antagonists and tyrosine kinase inhibitors providing beneficial or synergistic therapeutic effects over each monotherapy component alone.
Angiotensin II receptor blockers are understood to be those active agents that bind to the AT1-receptor subtype of angiotensin II receptor but do not result in activation of the receptor. As a consequence of the blockade of the AT1 receptor, these antagonists can, e.g. be employed as antihypertensive agents.
Suitable angiotensin II receptor blockers which may be employed in the combination of the present invention include AT1 receptor antagonists having differing structural features, preferred are those with non-peptidic structures. For example, mention may be made of the compounds that are selected from the group consisting of valsartan (EP 443983), losartan (EP 253310), candesartan (EP 459136), eprosartan (EP 403159), irbesartan (EP 454511), olmesartan (EP 503785), tasosartan (EP 539086), telmisartan (EP 522314), the compound with the designation E-41 77 of the formula




the compound with the designation SC-52458 of the following formula





and the compound with the designation the compound ZD-8731 of the formula





or, in each case, a pharmaceutically acceptable salt thereof.

Preferred AT1-receptor antagonists are those agents that have been approved and reached the market, most preferred is valsartan, or a pharmaceutically acceptable salt thereof.
The interruption of the enzymatic degradation of angiotensin to angiotensin II with ACE inhibitors is a successful variant for the regulation of blood pressure and thus also makes available a therapeutic method for the treatment of hypertension.
A suitable ACE inhibitor to be employed in the combination of the present invention is, e.g. a compound selected from the group consisting alacepril, benazepril, benazeprilat; captopril, ceronapril, cilazapril, delapril, enalapril, enaprilat, fosinopril, imidapril, lisinopril, moveltopril, perindopril, quinapril, ramipril, spirapril, temocapril and trandolapril, or in each case, a pharmaceutically acceptable salt thereof.
Preferred ACE inhibitors are those agents that have been marketed, most preferred are benazepril and enalapril.
A diuretic is, for example, a thiazide derivative selected from the group consisting of chlorothiazide, hydrochlorothiazide, methylclothiazide, and chlorothalidon. The most preferred diuretic is hydrochlorothiazide. A diuretic furthermore comprises a potassium sparing diuretic such as amiloride or triameterine, or a pharmaceutically acceptable salt thereof.
The class of CCBs essentially comprises dihydropyridines (DHPs) and non-DHPs, such as diltiazem-type and verapamil-type CCBs.
A CCB useful in said combination is preferably a DHP representative selected from the group consisting of amlodipine, felodipine, ryosidine, isradipine, lacidipine, nicardipine, nifedipine, niguldipine, niludipine, nimodipine, nisoldipine, nitrendipine and nivaldipine, and is preferably a non-DHP representative selected from the group consisting of flunarizine, prenylamine, diltiazem, fendiline, gallopamil, mibefradil, anipamil, tiapamil and verapamil, and in each case, a pharmaceutically acceptable salt thereof. All these CCBs are therapeutically used, e.g. as anti-hypertensive, anti-angina pectoris or anti-arrhythmic drugs.
Preferred CCBs comprise amlodipine, diltiazem, isradipine, nicardipine, nifedipine, nimodipine, nisoldipine, nitrendipine and verapamil or, e.g. dependent on the specific CCB, a pharmaceutically acceptable salt thereof. Especially preferred as DHP is amlodipine or a pharmaceutically acceptable salt thereof, especially the besylate. An especially preferred representative of non-DHPs is verapamil or a pharmaceutically acceptable salt, especially the hydrochloride, thereof.
Beta-blockers suitable for use in the present invention include beta-adrenergic blocking agents (beta-blockers), which compete with epinephrine for beta-adrenergic receptors and interfere with the action of epinephrine. Preferably, the beta-blockers are selective for the beta-adrenergic receptor as compared to the alpha-adrenergic receptors, and so do not have a significant alpha-blocking effect. Suitable beta-blockers include compounds selected from acebutolol, atenolol, betaxolol, bisoprolol, carteolol, carvedilol, esmolol, labetalol, metoprolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol and timolol. Where the beta-blocker is an acid or base or otherwise capable of forming pharmaceutically acceptable salts or prodrugs, these forms are considered to be encompassed herein, and it is understood that the compounds may be administered in free form or in the form of a pharmaceutically acceptable salt or a prodrug, such as a physiologically hydrolyzable and acceptable ester. For example, metoprolol is suitably administered as its tartrate salt, propranolol is suitably administered as the hydrochloride salt, and so forth.
Platelet aggregation inhibitors include PLAVIX® (clopidogrel bisulfate), PLETAL® (cilostazol) and aspirin.
Cholesterol absorption modulators include ZETIA® (ezetimibe) and KT6-971 (Kotobuki Pharmaceutical Co. Japan).
HMG-Co-A reductase inhibitors (also called beta-hydroxy-beta-methylglutaryl-co-enzyme-A reductase inhibitors or statins) are understood to be those active agents which may be used to lower lipid levels including cholesterol in blood.
The class of HMG-Co-A reductase inhibitors comprises compounds having differing structural features. For example, mention may be made of the compounds, which are selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin, or in each case, a pharmaceutically acceptable salt thereof.
Preferred HMG-Co-A reductase inhibitors are those agents, which have been marketed, most preferred is atorvastatin, pitavastatin or simvastatin, or a pharmaceutically acceptable salt thereof.
HDL-increasing compounds include, but are not limited to, cholesterol ester transfer protein (CETP) inhibitors. Examples of CETP inhibitors include JTT7O5 disclosed in Example 26 of U.S. Pat. No. 6,426,365 issued Jul. 30, 2002, and pharmaceutically acceptable salts thereof.
Inhibition of interleukin 6 mediated inflammation may be achieved indirectly through regulation of endogenous cholesterol synthesis and isoprenoid depletion or by direct inhibition of the signal transduction pathway utilizing interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, interleukin-6 antisense oligonucleotide (ASON), gp130 protein inhibitor/antibody, tyrosine kinase inhibitors/antibodies, serine/threonine kinase inhibitors/antibodies, mitogen-activated protein (MAP) kinase inhibitors/antibodies, phosphatidylinositol 3-kinase (PI3K) inhibitors/antibodies, Nuclear factor kappaB (NF-κB) inhibitors/antibodies, IκB kinase (IKK) inhibitors/antibodies, activator protein-1 (AP-1) inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, PPAR gamma and/or PPAR beta/delta activators/ligands or a functional fragment thereof.
A suitable antiinflammatory corticosteroid is dexamethasone.
Suitable antiproliferative agents are cladribine, rapamycin, vincristine and taxol.
A suitable inhibitor of extracellular matrix synthesis is halofuginone.
A suitable growth factor or cytokine signal transduction inhibitor is, e.g. the ras inhibitor R115777.
A suitable tyrosine kinase inhibitor is tyrphostin.
Suitable renin inhibitors are described, e.g. in WO 2006/116435. A preferred renin inhibitor is aliskiren, preferably in the form of the hemi-fumarate salt thereof.
MCP-1 antagonists may, e.g. be selected from anti-MCP-1 antibodies, preferably monoclonal or humanized monoclonal antibodies, MCP-1 expression inhibitors, CCR2-antagonists, TNF-alpha inhibitors, VCAM-1 gene expression inhibitors and anti-C5a monoclonal antibodies.
MCP-1 antagonists and compositions containing such inhibitors are described, e.g. in WO 02/070509, WO 02/081463, WO 02/060900, US 2006/670364, US 2006/677365, WO 2006/097624, US 2006/316449, WO 2004/056727, WO 03/053368, WO 00/198289, WO 00/157226, WO 00/046195, WO 00/046196, WO 00/046199, WO 00/046198, WO 00/046197, WO 99/046991, WO 99/007351, WO 98/006703, WO 97/012615, WO 2005/105133, WO 03/037376, WO 2006/125202, WO 2006/085961, WO 2004/024921, WO 2006/074265.
Suitable MCP-1 antagonists are, for instance, C-243 (Telik Inc.); NOX-E36 (Noxxon Pharma AG); AP-761 (Actimis Pharmaceuticals Inc.); ABN-912, NIBR-177 (Novartis AG); CC-11006 (Celgene Corp.); SSR-150106 (Sanofi-Aventis); MLN-1202 (Millenium Pharmaceuticals Inc.); AGI-1067, AGIX-4207, AGI-1096 (AtherioGenics Inc.); PRS-211095, PRS-211092 (Pharmos Corp.); anti-C5a monoclonal antibodies, e.g. neutrazumab (G2 Therapies Ltd.); AZD-6942 (AstraZeneca plc.); 2-mercaptoimidazoles (Johnson & Johnson); TEI-E00526, TEI-6122 (Deltagen); RS-504393 (Roche Holding AG); SB-282241, SB-380732, ADR-7 (GlaxoSmithKline); anti-MCP-1 monoclonal antibodies (Johnson & Johnson).
Combinations of QC-inhibitors with MCP-1 antagonists may be useful for the treatment of inflammatory diseases in general, including neurodegenerative diseases.
Combinations of QC-inhibitors with MCP-1 antagonists are preferred for the treatment of Alzheimer's disease.
Most preferably the QC inhibitor is combined with one or more compounds selected from the following group:
PF-4360365, m266, bapineuzumab, R-1450, Posiphen, (+)-phenserine, MK-0752, LY-450139, E-2012, (R)-flurbiprofen, AZD-103, AAB-001 (Bapineuzumab), Tramiprosate, EGb-761, TAK-070, Doxofylline, theophylline, cilomilast, tofimilast, roflumilast, tetomilast, tipelukast, ibudilast, HT-0712, MEM-1414, oglemilast, Linezolid, budipine, isocarboxazid, phenelzine, tranylcypromine, indantadol, moclobemide, rasagiline, ladostigil, safinamide, ABT-239, ABT-834, GSK-189254A, Ciproxifan, JNJ-17216498, Fmoc-Ala-Pyrr-CN, Z-Phe-Pro-Benzothiazole, Z-321, ONO-1603, JTP-4819, S-17092, BIBP3226; (R)—N2-(diphenylacetyl)-(R)—N-[1-(4-hydroxyphenyl)ethyl]arginine amide, Cevimeline, sabcomeline, (PD-151832), Donepezil, rivastigmine, (−)-phenserine, ladostigil, galantamine, tacrine, metrifonate, Memantine, topiramate, AVP-923, EN-3231, neramexane, valsartan, benazepril, enalapril, hydrochlorothiazide, amlodipine, diltiazem, isradipine, nicardipine, nifedipine, nimodipine, nisoldipine, nitrendipine, verapamil, amlodipine, acebutolol, atenolol, betaxolol, bisoprolol, carteolol, carvedilol, esmolol, labetalol, metoprolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, timolol, PLAVIX® (clopidogrel bisulfate), PLETAL® (cilostazol), aspirin, ZETIA® (ezetimibe) and KT6-971, statins, atorvastatin, pitavastatin or simvastatin; dexamethasone, cladribine, rapamycin, vincristine, taxol, aliskiren, C-243, ABN-912, SSR-150106, MLN-1202 and betaferon.
In particular, the following combinations are considered:

    
    
        a QC inhibitor, in particular QCI, in combination with Atorvastatin for the treatment and/or prevention of atherosclerosis
        a QC inhibitor, in particular QCI, in combination with immunosuppressive agents, preferably rapamycin for the prevention and/or treatment of restenosis
        a QC inhibitor, in particular QCI, in combination with immunosuppressive agents, preferably paclitaxel for the prevention and/or treatment of restenosis
        a QC inhibitor, in particular QCI, in combination with AChE inhibitors, preferably Donepezil, for the prevention and/or treatment of Alzheimer's disease
        a QC inhibitor, in particular QCI, in combination with interferones, preferably Aronex, for the prevention and/or treatment of multiple sclerosis
        a QC inhibitor, in particular QCI, in combination with interferones, preferably betaferon, for the prevention and/or treatment of multiple sclerosis
        a QC inhibitor, in particular QCI, in combination with interferones, preferably Rebif, for the prevention and/or treatment of multiple sclerosis
        a QC inhibitor, in particular QCI, in combination with Copaxone, for the prevention and/or treatment of multiple sclerosis
        a QC inhibitor, in particular QCI, in combination with dexamethasone, for the prevention and/or treatment of restenosis
        a QC inhibitor, in particular QCI, in combination with dexamethasone, for the prevention and/or treatment of atherosclerosis
        a QC inhibitor, in particular QCI, in combination with dexamethasone, for the prevention and/or treatment of rheumatoid arthritis
        a QC inhibitor, in particular QCI, in combination with HMG-Co-A-reductase inhibitors, for the prevention and/or treatment of restenosis, wherein the HMG-Co-A-reductase inhibitor is selected from atorvastatin, cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin
        a QC inhibitor, in particular QCI, in combination with HMG-Co-A reductase inhibitors, for the prevention and/or treatment of atherosclerosis wherein the HMG-Co-A-reductase inhibitor is selected from atorvastatin, cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin
        a QC inhibitor, in particular QCI, in combination with HMG-Co-A reductase inhibitors, for the prevention and/or treatment of rheumatoid arthritis wherein the HMG-Co-A-reductase inhibitor is selected from atorvastatin, cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin
    
    


Such a combination therapy is in particular useful for AD, FAD, FDD and neurodegeneration in Down syndrome as well as atherosclerosis, rheumatoid arthritis, restenosis and pancreatitis.
Such combination therapies might result in a better therapeutic effect (less proliferation as well as less inflammation, a stimulus for proliferation) than would occur with either agent alone.
With regard to the specific combination of inhibitors of QC and further compounds it is referred in particular to WO 2004/098625 in this regard, which is incorporated herein by reference.
In a further embodiment the present invention provides a method for preventing or treating a disease or condition, selected from a group consisting of inflammatory diseases selected from

    a. neurodegenerative diseases, e.g. mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, Familial Danish Dementia, multiple sclerosis,
    b. chronic and acute inflammations, e.g. rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis,
    c. fibrosis, e.g. lung fibrosis, liver fibrosis, renal fibrosis,
    d. cancer, e.g. cancer/hemangioendothelioma proliferation, gastric carcinomas,
    e. metabolic diseases, e.g. hypertension,
    f. and other inflammatory diseases, e.g. neuropathic pain, graft rejection/graft failure/graft vasculopathy, HIV infections/AIDS, gestosis, tuberous sclerosis.


Additionally, the present invention includes the use of the compounds of this invention and their corresponding pharmaceutically acceptable acid salt forms for the preparation of a medicament for the prevention or treatment of any of the above diseases or conditions.
Most preferably, the present QC inhibitors are used for the treatment of the above-mentioned neurodegenerative diseases. Even preferred is the use of the QC inhibitors of the present invention for the treatment of a disease selected from restenosis, pancreatitis, rheumatoid arthritis and atherosclerosis, most preferably restenosis or pancreatitis.
The compound may be administered to a patient by any conventional route of administration, including, but not limited to, intravenous, oral, subcutaneous, intramuscular, intradermal, parenteral and combinations thereof.
In a further preferred form of implementation, the invention relates to pharmaceutical compositions, that is to say, medicaments, that contain at least one compound of the invention or salts thereof, optionally in combination with one or more pharmaceutically acceptable carriers and/or solvents.
The pharmaceutical compositions may, for example, be in the form of parenteral or enteral formulations and contain appropriate carriers, or they may be in the form of oral formulations that may contain appropriate carriers suitable for oral administration. Preferably, they are in the form of oral formulations.
The inhibitors of QC activity administered according to the invention may be employed in pharmaceutically administrable formulations or formulation complexes as inhibitors or in combination with inhibitors, substrates, pseudosubstrates, inhibitors of QC expression, binding proteins or antibodies of those enzyme proteins that reduce the QC protein concentration in mammals. The compounds of the invention make it possible to adjust treatment individually to patients and diseases, it being possible, in particular, to avoid individual intolerances, allergies and side-effects.
The compounds also exhibit differing degrees of activity as a function of time. The physician providing treatment is thereby given the opportunity to respond differently to the individual situation of patients: he is able to adjust precisely, on the one hand, the speed of the onset of action and, on the other hand, the duration of action and especially the intensity of action.
The compounds may be advantageously administered, for example, in the form of pharmaceutical preparations that contain the active ingredient in combination with customary additives like diluents, excipients and/or carriers known from the prior art. For example, they can be administered parenterally (for example i.v. in physiological saline solution) or enterally (for example orally, formulated with customary carriers).
Depending on their endogenous stability and their bioavailability, one or more doses of the compounds can be given per day in order to achieve the desired reduction of MCP activity. For example, such a dosage range in humans may be in the range of from about 0.01 mg to 250.0 mg per day, preferably in the range of about 0.01 to 100 mg of compound per kilogram of body weight per day.
The compounds used according to the invention can accordingly be converted in a manner known per se into conventional formulations, such as, for example, tablets, (bitable) capsules, dragées, pills, suppositories, granules, aerosols, syrups, drops, liquid, solid and cream-like emulsions and suspensions and/or also as suppositories or as nasal sprays solutions, using inert, non-toxic, pharmaceutically suitable carriers and additives or solvents. In each of those formulations, the therapeutically effective compounds are preferably present in a concentration of approximately from 0.1 to 80% by weight, more preferably from 1 to 50% by weight, of the total mixture, that is to say, in amounts sufficient for the mentioned dosage latitude to be obtained.
The formulations may be advantageously prepared, for example, by extending the active ingredient with solvents and/or carriers, optionally with the use of emulsifiers and/or dispersants, it being possible, for example, in the case where water is used as diluent, for organic solvents to be optionally used as auxiliary solvents.
Examples of excipients useful in connection with the present invention include: water, non-toxic organic solvents, such as paraffins (for example natural oil fractions), vegetable oils (for example rapeseed oil, groundnut oil, sesame oil), alcohols (for example ethyl alcohol, glycerol), glycols (for example propylene glycol, polyethylene glycol); solid carriers, such as, for example, natural powdered minerals (for example highly dispersed silica, silicates), sugars (for example raw sugar, lactose and dextrose); emulsifiers, such as non-ionic and anionic emulsifiers (for example polyoxyethylene fatty acid esters, polyoxyethylene fatty alcohol ethers, alkylsulphonates and arylsulphonates), dispersants (for example lignin, sulphite liquors, methylcellulose, starch and polyvinylpyrrolidone) and lubricants (for example magnesium stearate, talcum, stearic acid and sodium lauryl sulphate) and optionally flavourings.
Administration may be carried out in the usual manner, preferably enterally or parenterally, especially orally. In the case of enteral administration, tablets may contain in addition to the mentioned carriers further additives such as sodium citrate, calcium carbonate and calcium phosphate, together with various additives, such as starch, preferably potato starch, gelatin and the like. Furthermore, lubricants, such as magnesium stearate, sodium lauryl sulphate and talcum, can be used concomitantly for tabletting. In the case of aqueous suspensions and/or elixirs intended for oral administration, various taste correctives or colourings can be added to the active ingredients in addition to the above-mentioned excipients.
In the case of parenteral administration, solutions of the active ingredients using suitable liquid carriers can be employed. In general, it has been found advantageous to administer, in the case of intravenous administration, amounts of approximately from 0.01 to 2.0 mg/kg, preferably approximately from 0.01 to 1.0 mg/kg, of body weight per day to obtain effective results and, in the case of enteral administration, the dosage is approximately from 0.01 to 2 mg/kg, preferably approximately from 0.01 to 1 mg/kg, of body weight per day.
It may nevertheless be necessary in some cases to deviate from the stated amounts, depending upon the body weight of the experimental animal or the patient or upon the type of administration route, but also on the basis of the species of animal and its individual response to the medicament or the interval at which administration is carried out. Accordingly, it may be sufficient in some cases to use less than the above-mentioned minimum amount, while, in other cases, the mentioned upper limit will have to be exceeded. In cases where relatively large amounts are being administered, it may be advisable to divide those amounts into several single doses over the day. For administration in human medicine, the same dosage latitude is provided. The above remarks apply analogously in that case.
The above disclosure describes the present invention in general. A more complete understanding can be obtained by reference to the following figures and examples. These examples are described solely for purposes of illustration and are not intended to limit the scope of the invention. Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitation.
Reference Example 1
Preparation of Human QC
Host Strains and Media
Pichia pastoris strain X33 (AOX1, AOX2), used for the expression of human QC was grown, transformed and analyzed according to the manufacturer's instructions (Invitrogen). The media required for P. pastoris, i.e. buffered glycerol (BMGY) complex or methanol (BMMY) complex medium, and the fermentation basal salts medium were prepared according to the manufacturer's recommendations.
Molecular Cloning of Plasmid Vectors Encoding the Human QC
All cloning procedures were done applying standard molecular biology techniques. For expression in yeast, the vector pPICZαB (Invitrogen) was used. The pQE-31 vector (Qiagen) was used to express the human QC in E. coli. The cDNA of the mature QC starting with codon 38 was fused in frame with the plasmid encoded 6× histidine tag. After amplification utilizing the primers pQCyc-1 and pQCyc-2 (WO 2004/098625) and subcloning, the fragment was inserted into the expression vector employing the restriction sites of SphI and HindIII.
Transformation of P. pastoris and Mini-Scale Expression
Plasmid DNA was amplified in E. coli JM109 and purified according to the recommendations of the manufacturer (Qiagen). In the expression plasmid used, pPICZαB, three restriction sites are provided for linearization. Since SacI and BstXI cut within the QC cDNA, PmeI was chosen for linearization. 20-30 μg plasmid DNA was linearized with PmeI, precipitated by ethanol, and dissolved in sterile, deionized water. 10 μg of the DNA was then applied for transformation of competent P. pastoris cells by electroporation according to the manufacturer's instructions (BioRad). Selection was done using plates containing 150 μg/ml Zeocin. One transformation using the linearized plasmid yielded several hundred transformants.
In order to test the recombinant yeast clones for QC expression, recombinants were grown for 24 h in 10 ml conical tubes containing 2 ml BMGY. Afterwards, the yeast was centrifuged and resuspended in 2 ml BMMY containing 0.5% methanol. This concentration was maintained by addition of methanol every 24 h up to 72 h. Subsequently, QC activity in the supernatant was determined. The presence of the fusion protein was confirmed by western blot analysis using an antibody directed against the 6× histidine tag (Qiagen). Clones that displayed the highest QC activity were chosen for further experiments and fermentation.
Large-Scale Expression in a Fermenter
Expression of the QC was performed in a 5 l reactor (Biostat B, B. Braun biotech), essentially as described in the “Pichia fermentation process guidelines” (Invitrogen). Briefly, the cells were grown in the fermentation basal salts medium supplemented with trace salts, and with glycerol as the sole carbon source (pH 5.5). During an initial batch phase for about 24 h and a subsequent fed-batch phase for about 5 h, cell mass was accumulated. Once a cell wet weight of 200 g/l was achieved, induction of QC expression was performed using methanol applying a three-step feeding profile for an entire fermentation time of approximately 60 h. Subsequently, cells were removed from the QC-containing supernatant by centrifugation at 6000×g, 4° C. for 15 min. The pH was adjusted to 6.8 by addition of NaOH, and the resultant turbid solution was centrifuged again at 37000×g, 4° C. for 40 min. In cases of continued turbidity, an additional filtration step was applied using a cellulose membrane (pore width 0.45 μm).
Purification of 6× Histidine Tagged QC Expressed in P. pastoris 
The His-tagged QC was first purified by immobilized metal affinity chromatography (IMAC). In a typical purification, 1000 ml of culture supernatant were applied to a Ni2+-loaded Chelating Sepharose FF column (1.6×20 cm, Pharmacia), that was equilibrated with 50 mM phosphate buffer, pH 6.8, containing 750 mM NaCl, at a flow rate of 5 ml/min. After washing with 10 column volumes of equilibration buffer and 5 column volumes of equilibration buffer containing 5 mM histidine, the bound protein was eluted by a shift to 50 mM phosphate buffer, pH 6.8, containing 150 mM NaCl and 100 mM histidine. The resulting eluate was dialyzed against 20 mM Bis-Tris/HCl, pH 6.8, at 4° C. overnight. Subsequently, the QC was further purified by anion exchange chromatography an a Mono Q6 column (BioRad), equilibrated with dialysis buffer. The QC-containing fraction was loaded onto the column using a flow rate of 4 ml/min. The column was then washed with equilibration buffer containing 100 mM NaCl. The elution was performed by two gradients resulting in equilibration buffer containing 240 mM and 360 mM NaCl in 30 or 5 column volumes, respectively. Fractions of 6 ml were collected and the purity was analyzed by SDS-PAGE. Fractions containing homogenous QC were pooled and concentrated by ultrafiltration. For long-term storage (−200° C.), glycerol was added to a final concentration of 50%. Protein was quantified according to the methods of Bradford or Gill and von Hippel (Bradford, M. M. 1976 Anal Biochem 72, 248-254; Gill, S. C. and von Hippel, P. H. 1989 Anal Biochem 182, 319-326.).
Expression and Purification of QC in E. coli 
The construct encoding the QC was transformed into M15 cells (Qiagen) and grown an selective LB agar plates at 37° C. Protein expression was carried out in LB medium containing 1% glucose and 1% ethanol at room temperature. When the culture reached an OD600 of approximately 0.8, expression was induced with 0.1 mM IPTG overnight. After one cycle of freezing and thawing, cells were lysed at 4° C. by addition of 2.5 mg/ml lysozyme in 50 mM phosphate buffer, pH 8.0, containing 300 mM NaCl and 2 mM histidine for approximately 30 min. The solution was clarified by centrifugation at 37000×g, 4° C. for 30 min, followed by a filtration applying a glass frit (DNA separation) and two additional filtration steps applying cellulose filters for crude and fine precipitates. The supernatant (approx. 500 ml) was applied onto a Ni2+-affinity column (1.6×20 cm) at a flow rate of 1 ml/min. Elution of QC was carried out with 50 mM phosphate buffer containing 150 mM NaCl and 100 mM histidine. The QC-containing fraction was concentrated by ultrafiltration.
Reference Example 2
MALDI-TOF Mass Spectrometry
Matrix-assisted laser desorption/ionization mass spectrometry was carried out using the Voyager De-Pro (Applied Biosystems, Darmstadt) with a linear time of flight analyzer. The instrument was equipped with a 337 nm nitrogen laser, a potential acceleration source and a 1.4 m flight tube. Detector operation was in the positive-ion mode. Samples (5 μl) were mixed with equal volumes of the matrix solution. For matrix solution we used sinapinic acid, prepared by solving 20 mg sinapinic acid (Sigma-Aldrich) in 1 ml acetonitrile/0.1% TFA in water (1/1, v/v). A small volume (≈1 μl) of the matrix-analyte-mixture was transferred to a probe tip.
For long-term testing of Glu1-cyclization, Aβ-derived peptides were incubated in 100 μl 0.1 M sodium acetate buffer, pH 5.2 or 0.1 M Bis-Tris buffer, pH 6.5 at 30° C. Peptides were applied in 0.5 mM [β3-11a] or 0.15 mM [Aβ3-21a] concentrations, and 0.2 U QC was added all 24 hours. In case of Aβ3-21a, the assays contained 1% DMSO. At different times, samples were removed from the assay tube, peptides extracted using ZipTips (Millipore) according to the manufacturer's recommendations, mixed with matrix solution (1:1 v/v) and subsequently the mass spectra recorded. Negative controls contained either no QC or heat deactivated enzyme. For the inhibitor studies the sample composition was the same as described above, with exception of the inhibitory compound added (5 mM benzimidazole or 2 mM 1,10-phenanthroline).
Example 1
Preparation and Expression of human MCP-1 in Mammalian Cell Culture
Cell Lines and Media
Human neuroblastoma cell line SH-SY5Y, human embryonic kidney cell line HEK293 and human monocyte cell line THP-1 were cultured in appropriate cell culture media (DMEM, 10% FBS for SH-SY5Y and HEK293), (RPMI1640, 10% FBS for THP-1), in a humidified atmosphere of 5% CO2 (HEK293, THP-1) or 10% CO2 (SH-SY5Y) at 37° C.
Isolation of Human MCP-1
Full-length cDNA of human MCP-1 was isolated from SH-SY5Y cells using RT-PCR. Total RNA of SH-SY5Y cells was reversely transcribed by SuperScript II (Invitrogen) and subsequently, human MCP-1 was amplified on a 1:12.5 dilution of generated cDNA product in a 25 μl reaction with Pfu-DNA-Polymerase (Promega) using primers hMCP-1-1 (sense) and hMCP-1-2 (antisense) (Table 1). The resulting PCR-product was cloned into vector pcDNA 3.1 using the HindIII and NotI restriction sites and the sequence confirmed by DNA-sequencing.
Site-Directed Mutagenesis of Human MCP-1
Deletions of the first (ΔQ1) and first and second (ΔQ1P2) amino acids of the mature human MCP-1 were generated by site-directed mutagenesis using primer ΔQ1-1 and ΔQ1-2 for ΔQ1 (Table 1) and primers ΔQ1P2-1 and ΔQ1P2-2 for ΔQ1P2 (Table 1). Parental DNA was digested with Dpn I. The pcDNA 3.1 plasmids with the deletions ΔQ1 and ΔQ1P2 of the mature human MCP-1 were transformed into E. coli JM109. Ampicillin-resistant clones were confirmed by sequencing and subsequently isolated for cell culture purposes using the EndoFree Maxi Kit (Qiagen).
Expression of N-Terminal Variants of Human MCP-1 in HEK293 Cells
For expression of N-terminal variants of human MCP-1, HEK293 cells were cultured in collagen I coated 6-well dishes and grown until 80% confluency, transfected using Lipofectamin2000 (Invitrogen) according to manufacturer's manual and incubated in the transfection solution for 5 hours. Afterwards, cells were allowed to recover in normal growth media over night. The next day, cells were incubated another 24 h in growth media. For analysis of efficacy of QC-inhibition, cells were incubated for 24 h in absence or presence of the specific inhibitor. After 24 h, the media containing the human MCP-1 variants were collected and investigated in a migration assay for chemotactic potency. Furthermore, an aliquot of cell culture supernatant was stored at −80° C. for quantification of human MCP-1 concentration using a human MCP-1-ELISA (Pierce).
TransWell Chemotaxis Assay
The chemotaxis assay was performed using 24 well TransWell plates with a pore size of 5 μm (Corning). Media containing the human MCP-1 variants expressed in HEK293 were used as chemoattractant. To this avail, 600 μl of the culture media of N-terminal human MCP-1 variants was applied undiluted or in dilutions 1:3, 1:10 and 1:30 in RPMI1640 to the lower chamber of the TransWell plate. Furthermore, undiluted media of HEK293 cells transfected with vector control were applied as negative control to the lower chamber. THP-1 cells were harvested and resuspended in RPMI1640 in a concentration of 1*106 cells/100 μl and applied in 100 μl aliquots to the upper chamber. Cells were allowed to migrate towards the chemoattractant for 2 h at 37° C. Subsequently, cells from the upper chamber were discarded and the lower chamber was mixed with 50 μl 70 mM EDTA in PBS and incubated for 15 min at 37° C. to release cells attached to the membrane. Afterwards, cells migrated to the lower chamber were counted using a cell counter system (Schärfe System). The chemotactic index was calculated by dividing cells migrated to the stimulus from cells migrated to the negative control.
Example 2
Investigations on the Proteolytic Degradation of Human MCP-1(1-76) 
Methods
N-Terminal Degradation by Recombinant Human DP4
Full length recombinant human MCP-1(1-76) (SEQ ID NO: 1) encoded by the nucleic acid sequence as shown in SEQ ID NO: 2, obtained in Example 1 above, starting with an N-terminal glutamine (Peprotech) was dissolved in 25 mM Tris/HCl pH 7.6 in a concentration of 10 μg/ml. The MCP-1 solution was either pre-incubated with recombinant human QC (0.0006 mg/ml) (obtained according to Reference Example 1 above, SEQ ID No: 3 for nucleic acid sequence and SEQ ID No: 4 for amino acid sequence) for 3 h at 30° C. and subsequently incubated with recombinant human DP4 (0.0012 mg/ml) at 30° C. (see FIG. 1) or incubated with DP4 without prior QC application. Resulting DP4 cleavage products were analyzed after 0 min, 15 min, 30 min, 1 h, 4 h and 24 h using Maldi-TOF mass spectrometry.
N-Terminal Degradation by Human Rheumatoid Synovial Fibroblast MMP-1
Human recombinant MCP-1 carrying an N-terminal glutaminyl instead of a pyroglutamyl residue (Peprotech) was dissolved in 25 mM Tris/HCl, pH 7.6, in a concentration of 10 μg/ml. The MMP-1 proenzyme from human rheumatoid synovial fibroblasts (Calbiochem) was activated using 25 mM p-aminophenylmercuric acetate (APMA), dissolved in 0.1 N NaOH at 37° C. for 3 h in a APMA:enzyme-mixture of 10:1. MCP-1 was either pre-incubated with recombinant human QC (0.0006 mg/ml) for 3 h at 30° C. and subsequently incubated with MMP-1 at 30° C. or incubated with MMP-1 without prior QC application. Resulting MMP-1 cleavage products were analyzed after 0 min, 15 min, 30 min, 1 h, 2 h, 4 h and 24 h using Maldi-TOF mass spectrometry.
N-Terminal Degradation by Human Rheumatoid Synovial Fibroblast MMP-1 and Recombinant Human DP4
Human recombinant MCP-1 starting with a N-terminal glutamine (Peprotech) was dissolved in 25 mM Tris/HCl, pH 7.6, in a concentration of 10 μg/ml. MMP-1 proenzyme from human rheumatoid synovial fibroblasts (Calbiochem) was activated using 25 mM p-aminophenylmercuric acetate (APMA) dissolved in 0.1 N NaOH. The APMA:enzyme-mixture of 10:1 was incubated at 37° C. for 3 h. MCP-1 solution was either pre-incubated with recombinant human QC (0.0006 mg/ml) for 3 h at 30° C. and subsequently incubated with MMP-1 and DP4 at 30° C. or incubated with MMP-1 and DP4 without QC application. Resulting MMP-1 cleavage products were analyzed after 0 min, 15 min, 30 min, 1 h, 2 h, 4 h and 24 h using Maldi-TOF mass spectrometry.
Example 3
Effect of QC Specific Inhibitor 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride (in the Following Also Designated as QCI) on Cuff-Induced Accelerated Atherosclerosis in ApoE3*Leiden Mice
Timeline
30 male ApoE3*Leiden mice (age 12 weeks) were fed a mildly hypercholesterolemic diet for 3 weeks prior to surgical cuff placement.
After 3 weeks, the mice underwent surgical non-constricting cuff placement (day 0) and were divided into 2 groups, matched for plasma cholesterol levels. The mice either received control (acidified) drinking water or drinking water containing the QC specific inhibitor 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride in a concentration of 2.4-mg/ml. 7 days after start of treatment, the inhibitor concentration was reduced to 1.2 mg/ml. 5 Mice of each group were sacrificed after 2 days for analysis of monocyte adhesion and infiltration, and 10 mice were sacrificed after 2 weeks for histomorphometric analysis to quantify the inhibition of accelerated atherosclerotic lesions and neointima formation.
Surgical Procedure of Cuff Placement
At the time of surgery, mice were anaesthetized with an intraperitoneal injection of 5 mg/kg Dormicum, 0.5 mg/kg Domitor and 0.05 mg/kg Fentanyl. This cocktail gives complete narcosis for at least one hour and can be quickly antagonized with Antisedan 2.5 mg/kg and Anexate 0.5 mg/kg.
A longitudinal 1 cm incision is made in the internal side of the leg and the femoral artery is dissected for 3 mm length from the femoral nerve and femoral vein. The femoral artery is looped with a ligature and a non-constrictive fine bore polyethylene tubing (0.4 mm inner diameter, 0.8 mm outer diameter, length 2 mm) is longitudinally opened and sleeved loosely around the femoral artery. The cuff is closed up with two ligature knots. The skin is closed with a continued suture.
After surgery, the animals were antagonized and placed in a clean cage on top of a heating pad for a few hours.
Sacrifice of the Animals
For histological analysis, animals were sacrificed either 2 days or 14 days after cuff placement. After anaesthesia, the thorax was opened and a mild pressure-perfusion (100 mmHg) with 4% formaldehyde was performed for 3 minutes by cardiac puncture. After perfusion, a longitudinal 2 cm incision was made in the internal side of the leg and the cuffed femoral artery was harvested as a whole and fixed overnight in 4% formaldehyde and processed to paraffin.
Analysis of Monocyte Adhesion and MCP-1 Expression
Adhesion of leukocytes in general and monocytes/macrophages in particular to the activated endothelium of the cuffed vessel wall was analyzed by microscopic analysis of cross sections harvested 2 days after cuff placement. The number of adhering and/or infiltrating leukocytes in general, identified as adhering cells at the luminal side of the vessel segment, and monocytes/macrophages in particular was counted and illustrated as cells per cross-section or as defined areas per cross section. Monocytes were identified by specific immunohistochemical staining by the polyclonal rabbit AIA31240 antibody, recognizing monocytes and macrophages. In addition on these sections a specific immunohistochemical staining for MCP-1 was performed.
Analysis of Vascular Remodeling and Accelerated Athero-Sclerosis
Vessel wall remodeling, accelerated atherosclerosis and neoinitima formation were analyzed morphometrically in all mice sacrificed after 14 days. A full comparison between the two groups was performed for all relevant vessel wall parameters (neointima formation, vascular circumference (i.e. outward remodelling), media thickness, lumen stenosis). Accelerated atherosclerosis was analyzed by immunohistochemical staining for macrophages and foam cells in the lesion area by AIA31240 antibody. Furthermore, these sections were also stained for MCP-1.
Example 4
Proteolytic Degradation of Human MCP-1(1-76) by Dipeptidyl-Peptidase 4 (DP4), Aminopeptidase P, and by Proteases Present in Human Serum
N-Terminal Degradation by Recombinant Human Aminopeptidase P
Human recombinant MCP-1 carrying an N-terminal glutaminyl instead of a pyroglutamyl residue (Peprotech) was dissolved in 25 mM Tris/HCl, pH 7.6 in a concentration of 10 μg/ml. MCP-1 was incubated with 30 μg/ml Aminopeptidase P (R&D Systems) at 30° C. Gln1-MCP-1 was either used without pGlu-modification or was pre-incubated with recombinant human QC (6 μg/ml) for 3 h at 30° C. in order to generate pGlu. Resulting Aminopeptidase P cleavage products were analyzed using Maldi-TOF mass spectrometry after 0 min, 15 min, 30 min, 1 h, 2 h, 4 h and 24 h.
N-Terminal Degradation of MCP-1 by Recombinant Human DP4 in Absence and Presence of a QC-Specific Inhibitor
Recombinant human MCP-1(1-76) (SEQ ID NO: 1) encoded by the nucleic acid sequence as shown in SEQ ID NO: 2, obtained in Example 1 above, starting with an N-terminal glutamine (Peprotech) was dissolved in 25 mM Tris/HCl pH 7.6 in a concentration of 10 μg/ml. The MCP-1 solution was either pre-incubated with recombinant human QC (0.0006 mg/ml) (obtained according to Reference Example 1 above) for 3 h at 30° C. and subsequently incubated with recombinant human DP4 (0.0012 mg/ml) at 30° C. (see FIG. 1) or incubated with DP4 without prior QC application. In addition, the incubation of Gln1-MCP-1 with recombinant human QC was carried out in presence of 10 μM of 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride. Resulting DP4 cleavage products were analyzed using Maldi-TOF mass spectrometry after 0 min, 15 min, 30 min, 1 h, 2 h and 4 h.
N-Terminal Degradation of Human MCP-1 in Human Serum
Human recombinant MCP-1 carrying an N-terminal glutaminyl instead of a pyroglutamyl residue (Peprotech) was dissolved in 25 mM Tris/HCl, pH 7.6, in a concentration of 100 μg/ml. MCP-1 was either pre-incubated with recombinant human QC (0.006 mg/ml) for 3 h at 30° C. and subsequently incubated with human serum at 30° C. or incubated with human serum without addition of QC. The cleavage products were analyzed using Maldi-TOF mass spectrometry after 0 min, 10 min, 30 min, 1 h, 2 h, 3 h 5 h and 7 h for Gln1-MCP-1 and 0 min, 30 min, 1 h, 2 h, 3 h 5 h, 7 h and 24 h for pGlu1-MCP-1.
Example 5
Degradation of Human MCP-2, MCP-3 and MCP-4
N-Terminal Degradation of Human MCP-2 by DP4
Human recombinant MCP-2 carrying an N-terminal glutaminyl instead of a pyroglutamyl residue (Peprotech) was dissolved in 25 mM Tris/HCl, pH 7.6, in a concentration of 10 μg/ml. MCP-2 was either pre-incubated with recombinant human QC (0.0006 mg/ml) for 3 h at 30° C. and subsequently incubated with recombinant human DP4 (0.0012 mg/ml) at 30° C. or incubated with recombinant human DP4 (0.0012 mg/ml) without pre-incubation with QC. Resulting DP4 cleavage products were analyzed using Maldi-TOF mass spectrometry after 0 min, 15 min, 30 min, 1 h, 2 h, 4 h and 24.
N-Terminal Degradation of Human MCP-3 by DP4
Human recombinant MCP-3 carrying an N-terminal glutaminyl instead of a pyroglutamyl residue (Peprotech) was dissolved in 25 mM Tris/HCl, pH 7.6, in a concentration of 10 μg/ml. MCP-3 was either pre-incubated with recombinant human QC (0.0006 mg/ml) for 3 h at 30° C. and subsequently incubated with recombinant human DP4 (0.00012 mg/ml) at 30° C. or incubated with recombinant human DP4 (0.00012 mg/ml) without prior QC application. Resulting DP4 cleavage products were analyzed using Maldi-TOF mass spectrometry after 0 min, 15 min, 30 min, 1 h, 2 h, 4 h and 24 h.
N-Terminal Degradation of Human MCP-4 by DP4
Human recombinant MCP-4 carrying an N-terminal glutaminyl instead of a pyroglutamyl residue (Peprotech) was dissolved in 25 mM Tris/HCl, pH 7.6, in a concentration of 10 μg/ml. MCP-4 was either pre-incubated with recombinant human QC (0.0006 mg/ml) for 3 h at 30° C. and subsequently incubated with recombinant human DP4 (0.00006 mg/ml) at 30° C. or incubated with recombinant human DP4 (0.00006 mg/ml) without prior QC application. Resulting DP4 cleavage products were analyzed using Maldi-TOF mass spectrometry after 0 min, 15 min, 30 min, 1 h, 2 h, 4 h and 24 h.
Example 6
Chemotactic Potency of Different N-Terminal Variants of Human MCP-1, MCP-2, MCP-3, MCP-4
Chemotactic Potency of N-Terminal Variants of Human MCP-1
MCP-1 starting with glutamine 1 (Gln1-MCP-1) (Peprotech) was incubated with (i) recombinant human QC to generate pGlu1-MCP-1, (ii) human recombinant DP4 to generate Asp3-MCP-1, (iii) human synovial fibroblast MMP-1 to generate Ile5-MCP-1 and human recombinant Aminopeptidase P to generate Pro2-MCP-1. Concentrations of 1, 5, 10, 50, 100, 500 and 1000 ng/ml of the generated MCP-1 variants were tested using the THP-1 chemotaxis assay (n=3).
Chemotactic Potency of Human MCP-1 in Absence or Presence of a QC-Inhibitor
MCP-1 with N-terminal glutamine (Gln1-MCP-1) (Peprotech) was incubated with recombinant human QC and DP4 (Gln1-MCP-1+QC+DP4), human recombinant DP4 alone (Gln1-MCP+DP4) and with recombinant human QC in combination with 10 μM of QC-inhibitor 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride and DP4 (Gln1-MCP-1+QC+QCI+DP4). Concentrations of 1, 5, 10, 50, 100, 500 and 1000 ng/ml of generated MCP-1 variants were tested using chemotaxis assay (n=3).
Comparison of the Chemotactic Potency of Variants of Human MCP-1, MCP-2, MCP-3 and MCP-4 Possessing an N-Terminal Glutaminyl or Pyroglutamyl Residue.
Human MCP-1, MCP-2, MCP-3 and MCP-4 with an N-terminal glutamine (Peprotech) or pyroglutamyl-residue (incubation of Gln1-MCPs with human recombinant QC at a dilution of 1:100 for 2 h at 30° C.) were tested for chemotactic potency. Concentrations of 1, 5, 10, 50, 100, 500 and 1000 ng/ml of a particular MCP were tested using chemotaxis assay (n=3).
Comparison of the Chemotactic Potency of Variants of Human MCP-1, MCP-2, MCP-3 and MCP-4 Possessing an N-Terminal Glutaminyl Residue with the Respective DP4 Cleavage Product
The human MCP-1, MCP-2, MCP-3 and MCP-4 starting with an N-terminal glutamine (Peprotech) was directly applied to the chemotaxis assay and compared to chemotactic potency of the DP4 cleavage products of MCP-1, MCP-2, MCP-3 and MCP-4. For the generation of the DP4 cleavage product, the respective MCPs were incubated with human recombinant DP4 at a 1:100 dilution for 2 h at 30° C. prior to assay. Concentrations of 1, 5, 10, 50, 100, 500 and 1000 ng/ml of a particular MCP were tested using chemotaxis assay (n=3).
Example 7
Application of a QC-Inhibitor to a Model of LPS-Induced Sepsis in Rats
Preparation
The QC-inhibitor 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride was formulated using 0.9% (w/v) saline at the highest concentration required. Lower doses were obtained by serial dilution using 0.9% (w/v) saline. In addition, a stock solution (1 mg/mL) of LPS was prepared using 0.9% (w/v) saline and diluted using 0.9% (w/v) saline to provide the required concentration for dosing.
Concentrations
Dose levels were expressed in terms of the amount of inhibitor administered without regard to purity or active content.
Species
Male Han Wistar rats were obtained from Charles River (UK) Ltd., Margate, Kent.
Acclimatisation and Health Procedures
On arrival, all animals were examined for ill-health. Animals were acclimatised for a period of at least 5 days prior to dosing. During this time animals were identified by their cage labels. A veterinary examination was performed before the start of any experimental procedures to ensure their suitability for the study.
Experimental Design
The study was performed over two days (five animals from each treatment group on each day).
Food and water was available ad libitum, except when the animals are removed from the home cage for the study procedures. Each animal received two single intravenous administrations of vehicle or QC-inhibitor 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea in a low, intermediate and high dose (Table 2) at 3.5 hours and 0.5 hours before LPS administration, using a constant dose volume of 2 mL/kg as a slow bolus.
Thirty minutes following the last administration of vehicle or test article each animal received an intraperitoneal injection of LPS or saline, using a constant dose volume of 5 mL/kg. Individual dose volumes were based on the individual body weights obtained on the day of dosing. The treatment groups employed for the study are depicted in Table 2.
Sampling and TNFα Determination
A terminal blood sample was collected at 2 hours post-LPS. Blood samples were centrifuged at 2300×g for 10 minutes at 4° C. and subsequently analyzed for TNFα. Samples were analysed using a quantitative sandwich enzyme immunoassay.
Example 8
Evaluation of a QC-Inhibitor in a Mouse Model of Thioglycollate-Induced Peritonitis
Animals
For each experiment C57/Bl6J wild type mice were purchased from Charles River Laboratories Inc. For each experiment the mice were age- and sex-matched.
Induction of Thioglycollate-Induced Peritonitis
For induction of peritonitis mice were injected intraperitoneally (i.p.) with 25 ml/kg body weight of sterile 8% (w/v) thioglycollate (Sigma-Aldrich; time: t=0). At different time points before and after thioglycollate application, mice were injected i.p. with various concentrations of QC-inhibitor. For lavage of the peritoneum, the animals were anesthesized using 2% isofluran. Peritoneal exudates were collected at time points (4, 24 hours) after thioglycollate injection by washing the peritoneum with 8 ml of sterile phosphate-buffered saline (PBS). Subsequently, the lavage fluids were centrifuged to pellet the cells and stained for FACS analysis.
Analysis of Cellular Composition of Collected Exudates Using FACS-Analysis
Samples were stained for BD Trucount tubes (BD Trucount tubes; catalog no. 340334; BD Biosciences) according to the manufacturer's instructions. Cells were blocked with CD16/32 (Caltag) and stained with the following antibodies for 15 min: CD3-FITC (Caltag)/CD13-PE (BD)/F4/80-APC (Caltag); Moma2-FITC (Acris) and IgG1-PE (BD)/IgG2a-APC (Caltag) as isotype controls. After staining, cells were lysed with BD FACSLyse (BD) for 15 min in the dark at room temperature. Flow cytometric analysis of 5000 beads per sample as reference standard was performed on a BD FACSCalibur (BD Biosciences).
Results
Preparation and Expression of Human MCP-1 in Mammalian Cell Culture
Amplification of human MCP-1 from human neuroblastoma cell line SH-SY5Y RNA resulted in a PCR-product of 300 bp. Sequencing of the isolated cDNA revealed a silent single nucleotide polymorphism of codon 105 coding for cysteine 35.
Expression of human MCP-1 variants in HEK293 leads to elevated levels within cell culture supernatant as monitored by human MCP-1 ELISA. Thereby, the level between the expressions of MCP-1 (WT) and MCP-1 (ΔQ1) (FIG. 5C), and MCP-1 (WT) in absence or presence of 10 μM 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride (FIG. 7A) are not significantly changed. However, the expression of MCP-1 (ΔQ1P2) is reduced by 28% compared to MCP-1 (WT). The supernatant was collected and applied in TransWell migration assays (see FIGS. 4 and 5 C and D in this regard).
TransWell Chemotaxis Assay
Purified human MCP-1 displays a bell-shaped chemotactic dose response curve, when attracting, e.g. monocytes, showing an optimum at approx. 1-50 ng/ml. Therefore, the generated cell culture supernatants containing MCP 1 variants were sequentially diluted in order to achieve the optimal working concentration of MCP-1 for chemotaxis assay attracting THP-1 monocytes.
After expression of MCP-1 (WT) and MCP-1 (ΔQ1), the concentrations of MCP-1 variants did not significantly differ (FIG. 5C). Application of MCP-1 (WT) to the chemotaxis assay led to a chemotactic response of THP-1 cells (FIG. 5D), implied by the elevated chemotactic index. However, MCP-1 (ΔQ1) failed to induce chemotaxis of THP-1 (FIG. 5D) suggested by a chemotactic index of approx. 1. These results support previous results, that N-truncated MCP-1 is inactive. This finding is further substantiated by the inability of MCP-1 (ΔQ1P2) to induce chemotaxis of THP-1 cells (FIG. 6B). Expression of MCP-1 (WT) in HEK293 cells has no influence on MCP-1 concentration in absence or presence of chemotactic cytokines (chemokines). However, the application of chemokines leads to significantly lower chemotaxis of THP 1 cells at dilutions 1:3 and 1:10 (FIG. 7B). This suggests a prevention of N-terminal pGlu-formation of MCP-1 (WT) by QC-specific inhibitor 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride and, therefore, an inactivation of MCP-1 (WT), either by N-terminal proteolytic degradation or by the sole prevention of pGlu formation.
Investigations on the Proteolytic Degradation of Human MCP-1(1-76)
Within the circulation, MCP-1 is protected by a N-terminal pGlu-residue, which confers resistance against N-terminal cleavage by aminopeptidases, e.g. DP4. As a result of QC inhibitor administration, the unprotected N-terminus is readily cleaved by DP4. The N-terminal truncation, in turn, leads to inactivation of human MCP-1 (FIGS. 5 and 6). MMP-1 inactivates mature MCP-1 by cleavage of the 4 N-terminal amino acids (pE/Q-P-D-A). The reaction is independent from the presence of a N-terminal pGlu residue. This process reflects the situation of MCP-1 inactivation within the circulation. The resulting cleavage product MCP 1(5-76) has been shown to be present within plasma and resembles a naturally occurring CCR2 receptor antagonist. The present experiments point to the finding that MMP-1 cleavage is slightly faster in case of a N-terminal glutamine residue (FIG. 2A: 2 h, 4 h vs. 2B: 2 h, 4 h). Furthermore, incubation of human MCP-1 carrying an N-terminal Gln residue (FIG. 3A) with human DP4 and human MMP-1 shows an accelerated degradation in comparison to pGlu-MCP-1 (FIG. 3B).
Taken together, the results imply that the N-terminal pGlu formation represents a mechanism of protection, conferring resistance against N-terminal degradation by post-proline cleaving enzymes, e.g. DP4, aminopeptidases and, as implied by the results with MMP-1, to a certain extent also endoproteases. Prevention of N-terminal pGlu formation by QC inhibitor application leads to a faster inactivation of human MCP-1.
Analysis of Vascular Remodeling and Accelerated Atherosclerosis in ApoE3*Leiden Mice
Treatment of cuff-induced accelerated atherosclerosis in ApoE3*Leiden mice had no effect on the total area within the outer diameter of the vessel segment (FIG. 8A) and no statistically significant effect on the remaining lumen (FIG. 8 B), although a slight increase in the remaining lumen can be observed. However, 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride shows a profound reduction of 40% on the percentage of lumen stenosis (FIG. 9A) and 45% reduction of the area of neointima formation (FIG. 9B). Both values are statistically significant. Furthermore, the inhibitor also reduced the area of the media (FIG. 10 A) and the intima/media ratio (FIG. 10B), although the reduction in intima/media ration lacks statistically significance (P<0.102).
The analysis of the cellular composition in the specific vessel wall layers shows no differences in relative contribution of smooth muscle cells and macrophages/foam cells to the composition of both the media and the adventitia after 2 days and 14 days (FIG. 15). Although one could expect a more specific effect on monocyte/macrophage content in the vessel wall due to the effect of 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride on MCP-1, and therefore on monocyte attraction, it should be noted that MCP-1 also has a direct effect on smooth muscle cell proliferation as recently has been discovered and published by Schepers, A. 2006 Arterioscler Thromb Vasc Biol. 26, 2063-2069.
Analysis of Monocyte Adhesion and MCP-1 Expression
Treatment of the mildly hypercholesterolemic ApoE3*Leiden mice (plasma cholesterol levels 12-15 mM) with 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride resulted in a profound reduction of total adhering cells by 45%, (p<0.05) after 2 days. Specific analysis of adhering monocytes revealed an even stronger reduction of 67% (p<0.05) to the treated cuffed vessel segments (FIG. 11).
MCP-1 expression was reduced in the vessel segments of 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride treated mice 2 days after surgery, the moment of the highest elevation of MCP-1 expression in the model used (FIG. 12, 13A, 14A). These results indicate that early after vascular injury within the lesions a reduction of MCP-1 expression can be detected in both the media and the intima (i.e inside the Lamina elastica interna) of the vessel wall segment, when 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride is administered. Analysis of the relative area of the cross sections positive for MCP-1 revealed a 52% (P=0.01) reduction of MCP 1 expression in the media and a 36% (P=0.001) reduction in the intima (FIG. 14A). Analysis of the absolute area positive for MCP-1 (expressed in μm2 positive per cross section) reveals a similar reduction of MCP-1 expression in the media (41% reduction, p=0.09) and the intima (40% reduction, p=0.05), although the reduction within the media is statistically not significant (Student's T-test) (FIG. 13A).
At the later time point of 14 days, when the neointima formation/accelerated atherosclerosis has progressed, the overall MCP-1 expression is lower than observed for the early time point and in contrast, no reduction of MCP-1 expression can be monitored, in the media or in the neointima (FIG. 13B, 14B) suggesting an effect of 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride only for the time of strong induction of MCP-1.
Taken together, these data indicate that oral dosing of 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride has a beneficial effect on post interventional vascular remodelling and accelerated atherosclerosis in the ApoE3*Leiden cuff model.
Proteolytic Degradation of Human MCP-1(1-76) by Human Aminopeptidases and Human Serum in Combination with a QC-Specific Inhibitor
For further illustration of the effect of the QC-inhibitor 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride on the generation of the N-terminal pGlu-residue and its subsequent impact on proteolytic stability, human MCP-1 carrying either N-terminal glutamine (FIG. 17 A) or pyroglutamic acid (FIG. 17 B) was incubated with DP4. N-terminal pGlu-formation was achieved by pre-incubation of the precursor with human QC, reflecting the physiological maturation process. As expected, in absence of the pre-incubation with human QC, MCP-1 is susceptible to DP4 cleavage (FIG. 17 A). In contrast, the pre-incubation with human QC leads to the formation of the N-terminal pGlu-residue and, therefore, to its protection against DP4 cleavage (FIG. 17 B). In addition, the pre-incubation of human MCP-1 with human QC in presence of the QC-inhibitor 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride results in the inhibition of QC and, therefore, to a prevention of pGlu-MCP-1 formation. The prevention of pGlu-MCP-1 formation by 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride renders the MCP-1 peptide again susceptible to DP4 cleavage (FIG. 17 C). Thus, the inhibition of QC leads to the de-stabilization of the N-Terminus of MCP-1 in vitro and in vivo.
In analogy to the N-terminal truncation of human MCP-1 by DP4, the incubation of Gln1-MCP-1 with recombinant human aminopeptidase P leads to the cleavage of the unprotected N-Terminus. Thereby, aminopeptidase P cleaves between the N-terminal amino acids Gln1 and Pro2 and liberates the N-terminal glutaminyl residue (FIG. 16 A). However, pre-incubation of Gln1-MCP-1 with human QC causes the formation of the N-terminal pGlu-residue and, therefore, the protection against aminopeptidase P cleavage (FIG. 16 B). Thus, the formation of the N-terminal pGlu-residue is also a protection mechanism against aminopeptidase P cleavage and against the cleavage of presumably all other proline-specific aminopeptidases.
For further investigations on the proteolytic stability of human MCP-1, the data obtained by incubation of MCP-1 with the purified proteases, were substantiated by the incubation of human MCP-1 with human serum. The incubation of human Gln1-MCP-1 with human serum shows the N-terminal truncation of the substrate and the liberation of the first 2 amino acids (Gln1Pro2). In addition, QC activity in plasma competes with the N-terminal proteolysis and stabilizes MCP-1, ending at a final ratio of approx. 60% truncated Asp3-MCP-1 and 40% full-length pGlu1-MCP-1 (FIG. 18 A). Furthermore, the pre-incubation of human MCP-1 with human QC leads to the formation of the N-terminal pGlu-residue and, thus, to the stabilization of human MCP-1. At least in the chosen time-frame and dilution of the serum, no degradation of pGlu1-MCP-1 was observed (FIG. 18 B). In addition, the incubation of MCP-1 in serum in presence of 9.6 μM of the DP4-inhibitor Isoleucyl-Thiyzolidide also prevents the N-terminal degradation, proving, that MCP-1 is degraded by DP4 or a DP4-like activity in human serum (FIG. 18 C).
Proteolytic Degradation of Human MCP-2, MCP-3 and MCP-4
In analogy to the N-terminal degradation of human MCP-1, the susceptibility of other human MCPs, namely MCP-2, MCP-3 and MCP-4, against N-terminal truncation by DP4 was investigated. As observed for MCP-1 before, the N-terminal pGlu-residue protects MCP-2 (FIG. 19 B), MCP-3 (FIG. 20 B) and MCP-4 (FIG. 21 B) against proteolytic degradation by DP4. However, the uncyclized variants, starting with an N-terminal glutamine are readily truncated by DP4 as shown for Gln1-MCP-2 (FIG. 19 A), Gln1-MCP-3 (FIG. 20 A) and Gln1-MCP-4 (FIG. 21 A). Therefore, the N-terminal pGlu-residue stabilizes all MCPs against truncation by aminopeptidases, such as DP4. Thus, the presented concept, to reduce QC activity in vivo in order to provoke accelerated turnover and diminished chemotaxis and receptor activation, applies for all members of the MCP-family.
Chemotactic Potency of Different N-Terminal Variants of Human MCP-1, MCP-2, MCP-3, MCP-4
In order to investigate the influence of different N-terminal variants of MCP-1 on the ability to attract human THP-1 monocytes, Gln1-MCP-1, pGlu1-MCP-1, the aminopeptidase P cleavage product Pro2-MCP-1, the DP4 cleavage product Asp3-MCP-1 and the MMP-1 cleavage product Ile5-MCP-1 were tested in a chemotaxis assay in vitro. The full-length MCP-1 possessing an N-terminal glutaminyl or pyroglutamyl-residue were found to be equally potent in attracting THP-1 monocytes with a maximum response between 50 ng/ml and 100 ng/ml. In contrast, the truncation of MCP-1 by aminopeptidase P (Pro2-MCP-1) and DP4 (Asp3-MCP-1) leads to a loss of potency of the respective variant. The dose-response-curve shifts to higher concentrations needed to elicit the maximum response, which corresponds to an inactivation of MCP-1 by N-terminal truncation. The MMP-1 cleavage product (Ile5-MCP-1) has an equal maximum as Glu1-MCP-1 and pGlu1-MCP-1 between 50 ng/ml and 100 ng/ml, however, the amount of cells migrating to this variant, ie. the chemotactic potency, is much lower, compared to full-length MCP-1 (FIG. 22).
To further investigate the role of QC in stabilizing MCP-1 and its impact on the migration of THP-1 monocytes, Gln1-MCP-1 was incubated with human DP4. In parallel samples, MCP-1 was pre-incubated with human QC prior to DP4 application. As expected, the obtained dose-response curves imply a proteolytic stability of pGlu1-MCP-1 reflected by a maximum response at 50-100 ng/ml. In contrast, in absence of QC, Gln1-MCP-1 is truncated by DP4, which leads to a shift of the dose-response curve to higher MCP-1 concentrations (500-1000 ng/ml) needed to elicit the maximum response. In addition, the pre-incubation of Gln1-MCP-1 with QC and the QC-inhibitor 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride prevents pGlu-formation and, thus, renders the peptide vulnerable to DP4 cleavage, as observed by the shift of the dose-response curve to higher MCP-1 concentrations compared to pGlu1-MCP-1 (FIG. 23). Therefore, the inhibition of QC leads to the N-terminal destabilization of MCP-1 through degradation by DP4 and, thus, to its inactivation with respect to the monocyte chemotactic activity.
In addition, the ability of MCP-2, MCP-3 and MCP-4 possessing an N-terminal glutamine or pyroglutamate to attract human THP-1 monocytes was investigated. In analogy to MCP-1, the pGlu-formation at the N-terminus of MCP-2 and MCP-3 has no influence on the potency, compared to the respective glutamine-precursors. However, for MCP-4 the pGlu-formation slightly increases the potency of the peptide (FIG. 24). However, since the glutaminyl-precursors are cleaved by DP4 (FIGS. 19, 20 21), also the potencies of the N-truncated DP4 cleavage products of MCP-2, MCP-3 and MCP-4 were investigated using the chemotaxis assay. For all three variants, the truncation by 2 amino acids leads to a partial inactivation of the chemokines (FIG. 25). Therefore, the pGlu-formation at the N-Terminus of all known MCPs not only protects against N-terminal truncation, but also protects against the loss of chemotactic potency. The presented approach to alleviate the activity of MCP-1 by suppression of N-terminal maturation therefore applies for all members of the MCP family in human beings.
Application of a QC-Inhibitor to a Model of LPS-Induced Sepsis in Rats
In order to investigate the general anti-inflammatory properties of 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride, the inhibitor was applied to a model of LPS-induced sepsis in rats. As a marker for the initiated inflammatory response, the levels of the cytokine TNFα were determined depending on QC-inhibitor treatment. As depicted in FIG. 26, the application of 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride leads to a dose-dependent reduction in TNFα levels ranging from the low dose (5 mg/kg) to the intermediate dose (20 mg/kg). In addition, also the highest dose (80 mg/kg) reduces the TNFα-level in plasma, however, a slight increase was observed compared to the intermediate dose. Therefore, QC-inhibitor application is able to significantly reduce the inflammatory responses shown here exemplarily for TNFα. The experiment shows, that, although the effect of QC-inhibitors is highly specific for the de-stabilization of the N-Terminus of MCPs, the inactivation of this chemokines has an impact also on other inflammatory parameters such as TNFα. Therefore, suppression of other pro-inflammatory cytokines is a further result of the presented concept of destabilizing MCPs. The approach is therefore suitable to develop medications for different inflammatory disorders with varying degree of MCP action.
Application of a QC-Inhibitor to a Model of thioglycollate-Induced peritonitis in Mice
To further investigate the effect of QC-inhibitor administration on the migration of immune cells in vivo, 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea hydrochloride was applied to a model of thioglycollate-induced peritonitis in mice. The cellular composition of the peritoneal lavage fluid was determined with special emphasis on infiltrating monocytes 4 h and 24 hours after thioglycollate-challenge. As shown in FIG. 27, the QC-inhibitor 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxy phenyl)thiourea hydrochloride reduced the number of infiltrating monocytes to the peritoneum dose-dependently after 4 h. In addition, the presence of Moma2-positive monocytes/macrophages was assessed 24 h after thioglycollate application. As depicted in FIG. 28, the QC-inhibitor 1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxy-phenyl)thiourea hydrochloride also significantly reduced the number of Moma2-positive cells. Therefore, the inhibition of QC destabilizes the N-Terminus of MCPs in vivo.
The experiment proves the applicability of MCP destabilization by QC inhibition to observe a therapeutic effect. The recruitment of monocytes, which is a general feature of several inflammatory disorders, for instance, but not limited to atherosclerosis and restenosis, is suppressed. The experiment therefore provides a method for characterizing QC inhibitors for their applicability in different inflammatory disorders.







TABLE 1







Utilized primers














SEQ






ID


Primer
Sequence (5′→3′)
Application
NO














hMCP-1-1
ATAT AAGCTT ATGAAAGTCTCTGCCGCCCTTC
Isolation
5





of human




MCP-1


 


hMCP-1-2
ATAT GCGGCCGC TCAAGTCTTCGGAGTTTGGG
Isolation
6




of human




MCP-1


 


ΔQ1-1
CATTCCCCAAGGGCTCGCTCCAGATGCAATCAATGCC
Site-
7




directed




mutagenesis




ΔQ1


 


ΔQ1-2
GGCATTGATTGCATCTGGAGCGAGCCCTTGGGGAATG
Site-
8




directed




mutagenesis




ΔQ1


 


ΔQ1P2-1
CATTCCCCAAGGGCTCGCTGATGCAATCAATGCCCCAG
Site-
9




directed




mutagenesis




ΔQ1P2


 


ΔQ1P2-2
CTGGGGCATTGATTGCATCAGCGAGCCCTTGGGGAATG
Site-
10




directed




mutagenesis




ΔQ1P2
















TABLE 2







Dosing of a QC-inhibitor in LPS-induced sepsis in rats
















Dose
Formulation
Intra-
Dose
Formulation
Number



Intravenous
level
concentration
Peritoneal
level
concentration
of


Group
Treatment 1
(mg/kg)
(mg/mL)
Treatment 2
(μg/kg)
(μg/mL)
animals





1
Vehicle
—
—
Saline
—
—
10


2
Vehicle
—
—
LPS
100
20
10


3
QCI
5
2.5
LPS
100
20
10


4
QCI
20
10
LPS
100
20
10


5
QCI
80
40
LPS
100
20
10









Synthesis of the QC Inhibitors













































Analytical Conditions

ESI-Mass spectra were obtained with a SCIEX API 365 spectrometer (Perkin Elmer). The 1H-NMR (500 MHz) data was recorded on a BRUKER AC 500, using DMSO-D6 as solvent. Chemical shifts are expressed as parts per million downfield from tetramethylsilane. Splitting patterns have been designated as follows: s (singulet), d (doublet), dd (doublet of doublet), t (triplet), m (multiplet), and br (broad signal).
Detailed Synthesis Description
Examples 1-12 and 14-53
1H-imidazole-1-propanamine was reacted with the corresponding isothiocyanate in ethanol under reflux for 8 h. After that the solvent was removed and the remaining oil was dissolved in methylene chloride. The organic layer was washed twice with a saturated solution of NaHCO3 followed by NaHSO4 and brine, dried then evaporated. The remaining solid was re-crystallized from ethyl acetate, yielding the example thiourea in yields of 80-98%.
Example 13
1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea
4.0 mmol of 3,4-dimethoxyphenyl isothiocyanate and 4.0 mmol of 3-(1H-imidazol-1-yl)alkyl-1-amine were dissolved in 10 mL of absolute ethanol. After stirring for 2 h under reflux, the solvent was evaporated and the resulting solid was recrystallized from ethanol.
Yield: 0.66 g (51.3%); mp: 160.0-161.0° C.
1H NMR δ 1.8-2.0 (m, 2H), 3.4-3.5 (m, 2H), 3.75 (s, 6H), 3.9-4.0 (m, 2H), 6.7-6.8 (m, 1H), 6.9 (br m, 2H), 6.95 (s, 1H), 7.15 (s, 1H), 7.55 (br s, 1H), 7.6 (s, 1H), 9.3 (s, 1H); MS m/z 321.2 (M+H), 253.3 (M-C3H3N2.)
Examples 96-102
1H-imidazole-1-propanamine was reacted with the corresponding isocyanate in ethanol under reflux for 8 h. After that the solvent was removed and the remaining oil was dissolved in methylene chloride. The organic layer was washed twice with a saturated solution of NaHCO3 followed by NaHSO4 and brine, dried then evaporated. The remaining solid was re-crystallized from ethyl acetate, yielding the example urea in yields of 85-90%.
Examples 136, 137
The 1H-imidazole-1-alkylamines were prepared according to the literature from □-brom-alkyl-phtalimides and imidazolium salt and. subsequent hydrazinolysis. The resulting products were transformed into the thioureas according to example 1-53 giving a 88% (example 136) and 95% (example 137) yield.
Examples 54-95
All examples were made from the corresponding thioureas by reacting with Water-soluble-carbodiimide (WSCD) and 1H-imidazole-1-propanamine in dry dimethyl formamide for 2 h at r.t. giving the trisubstituted guanidines with yields from 40-87%.
Examples 103-105
Imidazole was reacted with the corresponding brommethylphenylcyanide in DMF, utilizing 1 equivalent of NaH for 3 h under rt., giving the 1H-imidazole-1-methylphenylcyanides. The solvent was removed and the resulting oil was re-dissolved in dioxane. The cyanides were converted in the corresponding amines using 1 equivalent of LiAlH4. After adding a saturated solution of KHSO4, dioxane was evaporated and the aqueous layer was extracted by means of CHCl3. The organic layer was concentrated in vacuo and the amine was converted in the corresponding thioureas according to example 1-53 giving a 78% (example 103) and 65% (example 104) and 81% (example 105) yield.
Examples 106-109
Starting from the corresponding methansulfonate-2-methylpropyl-phthalimides the amines were synthesized as described for the amines in example 136-137. The resulting products were transformed into the thioureas according to example 1-53 giving example 106-109 in total yields of 25-30%.
Examples 110-112
1H-imidazole-1-propanamine was reacted with the corresponding 2-chlorobenzo[d]thiazole in toluol for 24 h at a temperature of 130° C. After removing the solvent and recrystallization from methanol example 110-112 was yielded in an amount of 55-65%.
Examples 113-118, 120-124 and 126-132
1H-imidazole-1-propanamine was reacted with the corresponding 2-phenyl acetic acid in dry dioxane by adding one equivalent of CAIBE and N-methylmorpholine at a temperature of 0° C. After 2 h the mixture was allowed to warm to r.t. and the mixture was stirred for 12 h. After removing the solvent the resulting oil was redissolved in methylene chloride and the organic layer was washed by means of an aqueous solution of NaHCO3 and water, dried and the solvent was evaporated. The remaining oil was dissolved in dioxane adding Laweson's Reagent. After stirring for 12 h a saturated solution of NaHCO3 was added. Dioxane was evaporated and the aqueous layer was extracted by means of ethyl acetate. The organic layer was separated, dried and the solvent was evaporated. The remaining solid was crystallized from acetyl acetate/ether, giving 113-118, 120-124 and 126-132 with total yields of 62-85%.
Example 119
1 N-(3-(1H-imidazol-1-yl)propyl)-2-(3,4-dimethoxyphenyl)ethanethioamide
A mixture of 4.0 mmol triethylamine and 4.0 mmol of 3-(1H-imidazol-1-yl)alkyl-1-amine 20 mL of dioxane was added drop wise to an ice cooled, stirred solution of 4.0 mmol of 2-(3,4-dimethoxyphenyl)acetyl chloride in 30 mL of dioxane. The mixture was allowed to warm to r.t., and then stirred for 1 h. After removing the solvent by reduced pressure, the residue was redissolved in 50 mL of dichloromethane. The organic layer was washed by means of 30 mL of saturated aqueous solution of NaHCO3, and water. The organic solution was dried, filtered, and the solvent was removed under reduced pressure. After redissolving in 50 mL of dry dioxane 2.2 mmol of Lawesson's reagent was added, and the mixture was heated to 90° C. and stirred for 8 h. The solvent was removed by reduced pressure, and the residue was redissolved in 50 mL of dichloromethane. The organic layer was washed three times by means of a saturated aqueous solution of NaHCO3, followed three times by water, dried, filtered, and then the organic solvent was removed. The compound was purified by chromatography using a centrifugal-force-chromatography device, (Harrison Research Ltd.) utilizing silica plates of a layer thickness of 2 mm, and a CHCl3/MeOH gradient as eluting system.
Yield: 0.14 g (10.6%); melting point: 148.0-150.0° C.
1H NMR δ 2.0-2.15 (br m, 2H), 3.4-3.5 (m, 2H), 3.7 (s, 6H) 6.75-6.8 (m, 2H), 4.1-4.2 (m, 2H), 6.8-6.9 (m, 2H), 6.95-7.0 (m, 1H), 7.4 (s, 1H), 7.75-7.85 (br m, 1H), 8.6 (s, 1H) 10.2 (s, 1H); MS m/z 320.2 (M+H), 252.2 (M-C3H3N2.)
Example 125
N-(3-(1H-imidazol-1-yl)propyl)-1-(3,4-dimethoxyphenyl)cyclopropanecarbothioamide
11.06 mmol of 3,4-dimethoxyphenyl acetonitrile, 34.8 mmol of 2-Bromo-1-chloroethanole an 1.16 mmol of triethylbenzylammonium Hydrochloride were dissolved in 10 mL of an aqueous solution of KOH (60%). The mixture was transferred into an ultrasonic bath and vigorously stirred for 3 h at room temperature. The resulting suspension was diluted with 40 mL of water and extracted three times by means of 20 mL of dichloromethane. The combined organic layers where washed by means of an aqueous solution of hydrochloric acid (1N), dried over Na2SO4 and the solvent was removed under reduced pressure. The remaining oil was purified by flash-chromatography using silica gel and ethyl acetate/heptane as eluting system, resulting in 0.81 g (34.4%) of 1-(3,4-dimethoxyphenyl)cyclopropanecarbonitrile
3.9 mmol of 1-(3,4-dimethoxyphenyl)cyclopropanecarbonitrile and 11.2 mmol of KOH were suspended in 80 mL of ethylene glycol. The mixture was stirred for 12 h under reflux. Then 80 mL of water were added and the aqueous layer was extracted two times with ether. After pH adjustment to a value of pH=4-5 using HCl (1N) the aqueous layer was extracted three times by means of ether, then the combined organic layers were dried over Na2SO4 and the solvent was removed, resulting in 0.81 g (93.5%) of 1-(3,4-dimethoxyphenyl)cyclopropanecarboxylic acid.
3.44 mmol of 1-(3,4-dimethoxyphenyl)cyclopropanecarboxylic acid, 3.5 mmol of N-Methyl morpholine, and 3.5 mmol of isobutyl chloroformiat were dissolved in dry tetrahydrofurane and stirred for 15 min at −15° C. Then 3.5 mmol of 3-(1H-imidazol-1-yl)alkyl-1-amine was added and the mixture was allowed to warm to 0° C. and was stirred for 12 h. The solvent was removed under reduced pressure and the remaining oil was redissolved in chloroform. Then the organic layer was washed two times by means of a saturated aqueous solution of NaHCO3, then dried over Na2SO4 and the solvent was removed. Purification was performed by means of centrifugal forced chromatography using a Chromatotron® device (Harrison Research Ltd.) utilizing silica plates of a layer thickness of 2 mm, and a CHCl3/MeOH gradient as eluting system resulting in 0.671 g (59.3%) of N-(3-(1H-imidazol-1-yl)propyl)-1-(3,4-dimethoxyphenyl)cyclopropane-carboxamide.
After redissolving in 30 mL of dry dioxane 1.43 mmol of Lawesson's reagent were added, and the mixture was heated to 90° C. and stirred for 8 h. The solvent was removed by reduced pressure, and the residue was remains were dissolved in 50 mL of dichloromethane. The organic layer was washed three times by means of a saturated aqueous solution of NaHCO3, followed three times by water, dried, filtered, and then the organic solvent was removed. The compound was purified by chromatography using a centrifugal-force-chromatography device, (Harrison Research Ltd.) utilizing silica plates of a layer thickness of 2 mm, and a CHCl3/MeOH gradient as eluting system.
Yield: 0.33 g (46.2%); melting point: 127.0-127.5° C.
1H NMR δ 1.1-1.2 (t, 2H), 1.55-1.6 (t, 2H), 2.0-2.1 (m, 2H), 3.5-3.6 (m, 2H), 3.7-3.8 (s, 6H), 4.1-4.2 (t, 2H) 6.8-6.9 (m, 3H), 7.65 (s, 1H), 7.75 (s, 1H), 8.8 (m, 1H), 9.05 (s, 1H; MS m/z 346.0 (M+H), 278.2 (M-C3H3N2.), 177.1 (M-C6H8N3S.)
Examples 133-135
A mixture of 1 equivalent triethylamine and 3,4-dimethoxyaniline in dioxane was added to an stirred solution of the corresponding ω-bromoalkyl acidic chloride at a temperature of 0° C. The solution was allowed to warm to r.t. and stirred for 2 h. The solvent was evaporated, and the remaining oil was redissolved in dichloromethane. The organic layer was washed by means of water, dried, filtered, and the solvent was removed under reduced pressure.
Imidazole and sodium hydride were suspended in and the mixture was stirred under inert conditions at r.t. for 3 h. ω-Bromo-N-(3,4-dimethoxy-phenyl)alkylamide was added and the mixture was heated to 100° C. and stirred for 8 h. After that, the solvent was evaporated, hot toluene were added and the solution was filtered. Then the solvent was removed under reduced pressure. The transformation into the thioamides was performed as described for example 113-132 by means of Laweson's reagent, giving 133-135 in total yields of 13-20%.
The analytical data for further examples, which were synthesized according to the general synthesis schemes described above, are as follows:
Example 1
1-(3-(1H-imidazol-1-yl)propyl)-3-methylthiourea
melting point: 122-122.5° C.
1H NMR δ 1.85-1.95 (m, 2H), 2.8 (s, 3H), 3.2-3.5 (br d, 2H), 3.8-3.9 (m, 2H), 6.85 (d, 1H), 7.15 (d, 1H), 7.3-7.5 (br d, 2H), 7.65 (s, 1H); MS m/z 199.1 (M+H), 221.3 (M+Na), 131.0 (M-C3H3N2.)
Example 2
1-(3-(1H-imidazol-1-yl)propyl)-3-tert-butylthiourea
melting point: 147.0-147.5° C.
1H NMR δ 1.3-1.4 (s, 9H), 1.85-1.95 (m, 2H), 3.5 (t, 2H), 3.8 (t, 2H), 6.85 (d, 1H), 7.15 (d, 1H), 7.3-7.5 (br d, 2H), 7.65 (s, 1H); MS m/z 241.1 (M+H), 173.1 (M-C3H3N2.)
Example 3
1-(3-(1H-imidazol-1-yl)propyl)-3-benzylthiourea
melting point: 127.0-128.0° C.
1H NMR δ 1.85-1.95 (m, 2H), 3.2-3.5 (br d, 2H), 3.8-3.9 (m, 2H), 4.6 (s, 2H), 6.8 (d, 1H), 7.15 (d, 1H), 7.19-7.35 (m, 5H), 7.5-7.6 (br d, 2H), 7.85 (s, 1H); MS m/z 275.3 (M+H), 207.1 (M-C3H3N2.)
Example 5
1-(3-(1H-imidazol-1-yl)propyl)-3-phenylthiourea
melting point: 166.5-167.0° C.
1H NMR δ 1.95-2.05 (m, 2H), 3.3-3.5 (br d, 2H), 3.9-4.0 (m, 2H), 6.85 (d, 1H), 7.05 (m, 1H) 7.15 (d, 1H), 7.25 (m, 2H), 7.35 (m, 2H), 7.6 (s, 1H), 7.8 (br s, 1H), 9.5 (br s, 1H); MS m/z 261.1 (M+H), 193.2 (M-C3H3N2.)
Example 6
1-(3-(1H-imidazol-1-yl)propyl)-3-(4-fluorophenyl)thiourea
melting point: 147.0-148.0° C.
1H NMR δ 1.95-2.05 (m, 2H), 3.3-3.5 (br d, 2H), 3.9-4.05 (m, 2H), 6.85 (d, 1H), 7.05-7.15 (m, 3H), 7.3-7.4 (m, 2H), 7.6 (s, 1H), 7.7-7.8 (br s, 1H), 9.4 (br s, 1H); MS m/z 279.3 (M+H), 211.2 (M-C3H3N2.)
Example 7
1-(3-(1H-imidazol-1-yl)propyl)-3-(4-ethylphenyl)thiourea
melting point: 100.0-100.5° C.
1H NMR δ 1.15-1.2 (t, 3H), 1.9-2.0 (m, 2H), 2.5-2.6 (m, 2H), 3.3-3.5 (br d, 2H), 3.9-4.05 (m, 2H), 6.85 (d, 1H), 7.1-7.2 (m, 3H), 7.25-7.3 (m, 2H), 7.6 (s, 1H), 7.7-7.8 (br s, 1H), 9.4 (br s, 1H); MS m/z 289.3 (M+H), 221.1 (M-C3H3N2.)
Example 8
1-(3-(1H-imidazol-1-yl)propyl)-3-(4-(trifluoromethyl)phenyl)thiourea
melting point: 154.5-155.0° C.
1H NMR δ 1.9-2.1 (br m, 2H), 3.4-3.6 (br d, 2H), 3.95-4.1 (br m, 2H), 6.85 (d, 1H), 7.2 (d, 1H), 7.6-7.8 (m, 5H), 8.2 (br s, 1H), 9.9 (br s, 1H); MS m/z 329.3 (M+H), 261.2 (M-C3H3N2.)
Example 10
1-(3-(1H-imidazol-1-yl)propyl)-3-(4-acetylphenyl)thiourea
melting point: 170.0-171.0° C.
1H NMR δ 1.9-2.1 (br m, 2H), 2.4-2.5 (s, 3H), 3.2-3.5 (br m, 2H), 3.9-4.1 (m, 2H), 6.85 (d, 1H), 7.15 (d, 1H), 7.5-7.65 (br m, 3H), 7.8-7.9 (m, 2H), 8.1 (m, 2H), 9.8 (br s, 1H)
MS m/z 303.2 (M+H), 235.1 (M-C3H3N2.)
Example 11
1-(3-(1H-imidazol-1-yl)propyl)-3-(4-methoxyphenyl)thiourea
melting point: 125.0-125.5° C.
1H NMR δ 1.8-2.0 (br m, 2H), 3.2-3.5 (br m, 2H), 3.7 (s, 3H), 3.9-4.0 (m, 2H), 6.7-6.9 (m, 3H), 7.1-7.2 (m, 3H), 7.5 (s, 1H), 7.6 (s, 1H), 9.2 (s, 1H); MS m/z 291.1 (M+H), 223.2 (M-C3H3N2.)
Example 14
1-(3-(1H-imidazol-1-yl)propyl)-3-(2,4-dimethoxyphenyl)thiourea
melting point: 120.0-120.5° C.
1H NMR δ 1.8-2.0 (br m, 2H), 3.4-3.5 (br m, 2H), 3.75 (s, 6H), 3.9-4.0 (m, 2H), 6.5 (d, 1H), 6.6 (s, 1H), 6.9 (s, 1H) 7.15 (s, 1H), 7.3 (d, 1H), 7.5 (br s, 1H), 7.6 (s, 1H), 9.75 (s, 1H); MS m/z 321.2 (M+H), 253.3 (M-C3H3N2.)
Example 15
1-(3-(1H-imidazol-1-yl)propyl)-3-(3,5-dimethoxyphenyl)thiourea
melting point: 142.0-143.0° C.
1H NMR δ 1.8-2.0 (br m, 2H), 3.4-3.5 (br m, 2H), 3.6 (s, 6H), 3.95-4.0 (m, 2H), 6.25 (m, 1H), 6.6 (m, 2H), 6.9 (s, 1H), 7.2 (s, 1H), 7.6 (s, 1H), 7.8 (s, 1H), 9.5 (s, 1H); MS m/z 321.2 (M+H), 253.3 (M-C3H3N2.)
Example 23
1-(3-(1H-imidazol-1-yl)propyl)-3-(2,3-dihydrobenzo[b][1,4]dioxin-7-yl)-thiourea
melting point: 103.0-103.5° C.
1H NMR δ 1.9-2.0 (br m, 2H), 3.3-3.5 (br d, 2H), 3.9-4.0 (m, 2H), 4.2-4.3 (m, 4H), 6.7 (m, 1H), 6.8-6.8 (m, 1H), 6.9 (m, 2H), 7.2 (s, 1H), 7.6 (m, 2H), 9.3 (s, 1H); MS m/z 319.3 (M+H), 251.3 (M-C3H3N2.)
Example 24
1-(3-(1H-imidazol-1-yl)propyl)-3-(benzo[d][1,3]dioxol-6-yl)thiourea
melting point: 115.0-115.6° C.
1H NMR δ 1.9-2.1 (br m, 2H), 3.4-3.5 (br d, 2H), 4.05-4.15 (m, 2H), 6.0 (s, 2H), 6.7 (m, 1H), 6.8-6.85 (m, 1H), 6.95 (d, 1H), 7.25 (s, 1H), 7.45 (s, 1H), 7.7 (br s, 1H), 8.5 (br s, 1H), 9.4 (br s, 1H); MS m/z 305.2 (M+H), 237.2 (M-C3H3N2.)
Example 25
1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4,5-trimethoxyphenyl)thiourea
melting point: 124.5-125.5° C.
1H NMR δ 1.8-2.0 (m, 2H), 3.4-3.5 (br m, 2H), 3.6 (s, 3H) 3.7 (s, 6H), 3.9-4.0 (m, 2H), 6.65 (m, 2H), 6.85 (s, 1H), 7.2 (s, 1H), 7.6 (s, 1H), 7.7 (br s, 1H), 9.4 (s, 1H); MS m/z 351.3 (M+H), 283.2 (M-C3H3N2.)
Example 26
1-(3-(1H-imidazol-1-yl)propyl)-3-(3-methoxyphenyl)thiourea
melting point: 89.5-90.0° C.
1H NMR δ 1.9-2.1 (br m, 2H), 3.4-3.5 (br m, 2H), 3.7 (s, 3H), 3.9-4.0 (m, 2H), 6.6-6.7 (m, 1H), 6.8-6.9 (m, 2H), 7.1 (m, 2H), 7.15-7.25 (br m, 1H), 7.6 (s, 1H), 7.8 (br s, 1H), 9.5 (s, 1H); MS m/z 291.1 (M+H), 223.2 (M-C3H3N2.)
Example 27
1-(3-(1H-imidazol-1-yl)propyl)-3-(4-ethoxyphenyl)thiourea
melting point: 126.0-126.5° C.
1H NMR δ 1.5 (br m, 3H), 1.9-2.0 (br m, 2H), 3.4-3.5 (br m, 2H), 3.9-4.0 (br m, 4H), 6.8-6.9 (m, 2H), 6.95 (s, 1H), 7.15-7.2 (m, 2H), 7.25 (s, 1H), 7.55-7.6 (br s, 1H), 7.8 (s, 1H), 9.3 (s, 1H); MS m/z 305.2 (M+H), 237.2 (M-C3H3N2.)
Example 33
1-(3-(1H-imidazol-1-yl)propyl)-3-(4-(methylthio)phenyl)thiourea
melting point: 140.0-140.5° C.
1H NMR δ 1.8-2.05 (br m, 2H), 2.5 (s, 3H), 3.3-3.5 (br m, 2H), 3.9-4.1 (m, 2H), 6.9 (m, 1H), 7.1-7.3 (br m, 5H), 7.6 (s, 1H), 7.75 (br s, 1H), 9.4 (s, 1H); MS m/z 307.2 (M+H), 239.2 (M-C3H3N2.)
Example 42
1-(3-(1H-imidazol-1-yl)propyl)-3-(4-nitrophenyl)thiourea
melting point: 165.0. 166.0° C.
1H NMR δ 1.9-2.05 (m, 2H), 3.3-3.5 (br d, 2H), 3.95-4.05 (m, 2H), 6.85 (d, 1H), 7.15 (d, 1H), 7.6 (d, 1H), 7.7 (m, 2H) 8.1 (m, 2H), 8.3 (br s, 1H), 10.1 (br s, 1H); MS m/z 306.2 (M+H), 237.9 (M-C3H3N2.)
Example 50
1-(3-(1H-imidazol-1-yl)propyl)-3-(4-(dimethylamino)phenyl)thiourea
melting point: 146.5-147.0° C.
1H NMR δ 1.9-2.0 (m, 2H), 2.9 (s, 6H), 3.4 (m, 2H), 3.9-4.0 (m, 2H), 6.7 (m, 2H), 6.9 (s, 1H), 7.05-7.1 (m, 2H), 7.15 (s, 1H), 7.4 (br s, 1H), 7.6 (s, 1H), 9.2 (s, 1H); MS m/z 304.2 (M+H), 236.0 (M-C3H3N2.)
Example 102
1-(3-(1H-imidazol-1-yl)propyl)-3-(3,4-dimethoxyphenyl)urea
melting point: 114.5-115.0° C.
1H NMR δ 1.7-1.9 (m, 2H), 2.9-3.1 (m, 2H), 3.7 (2s, 6H), 3.9-4.0 (m, 2H), 6.1 (t, 1H), 6.7 (s, 2H), 6.8 (s, 1H), 7.15 (d, 2H), 7.6 (s, 1H), 8.2 (s, 1H); MS m/z 321.2 (M+H), 253.3 (M-C3H3N2.)
Example 106
1-((S)-3-(1H-imidazol-1-yl)-2-methylpropyl)-3-(3,4-dimethoxyphenyl)-thiourea
melting point: 150.5-151.5° C.
1H NMR δ 0.9 (d, 3H), 2.3-2.4 (m, 2H), 2.5 (s, 1H), 3.7 (d, 6H), 4.0-4.1 (br m, 1H), 4.15-4.25 (br m, 1H), 6.75-6.8 (m, 1H), 6.85 (m, 1H), 6.9-7.0 (m, 1H), 7.65 (s, 1H), 7.75 (s, 2H), 9.1 (s, 1H), 9.5 (s, 1H); MS m/z 335.6 (M+H), 267.1 (M-C3H3N2.)
Example 107
1-((R)-3-(1H-imidazol-1-yl)-2-methylpropyl)-3-(3,4-dimethoxyphenyl)-thiourea
melting point: 155.0-157.5° C.
1H NMR δ 0.9 (d, 3H), 2.3-2.4 (m, 2H), 2.5 (s, 1H), 3.7 (d, 6H), 4.0-4.1 (br m, 1H), 4.15-4.25 (br m, 1H), 6.75-6.8 (m, 1H), 6.85 (m, 1H), 6.9-7.0 (m, 1H), 7.65 (s, 1H), 7.75 (s, 2H), 9.1 (s, 1H), 9.5 (s, 1H); MS m/z 335.4 (M+H), 267.2 (M-C3H3N2.)
Example 109
1-((1-((1H-imidazol-1-yl)methyl)cyclopropyl)methyl)-3-(3,4-dimethoxy-phenyl)thiourea
melting point: 166.5-168.5° C.
1H NMR δ 0.7-0.8 (br m, 2H), 1.85-1.9 (m, 1H), 2.15-2.2 (m, 1H), 2.2-2.3 (m, 1H), 3.4-3.5 (m, 1H), 3.7 (d, 6H), 4.2 (s, 1H), 4.95 (s, 1H), 6.75-6.8 (br m, 1H), 6.85-6.9 (br m, 1H), 7.0 (s, 1H), 7.5 (m, 1H), 7.6 (m, 1H), 7.7 (s, 0.5H), 7.8 (s, 0.5H), 8.85 (s, 0.5H), 9.1 (s, 0.5H), 9.35 (s, 0.5H), 9.45 (s, 0.5H); MS m/z 347.2 (M+H), 279.2 (M-C3H3N2.), 137.5 (M-C9H13N4S.)
Example 110
N-(3-(1H-imidazol-1-yl)propyl)benzo[d]thiazol-2-amine
1H NMR δ 1.95-2.15 (m, 2H), 3.25-3.35 (m, 2H), 4.0-4.1 (t, 2H), 6.9 (s, 1H), 6.95-7.05 (t, 1H), 7.15-7.2 (m, 2H), 7.35-7.4 (d, 1H), 7.60-7.70 (m, 2H), 8.0-8.1 (br s, 1H); MS m/z 259.4 (M+H), 191.3 (M-C3H3N2.)
Example 111
N-(3-(1H-imidazol-1-yl)propyl)-6-chlorobenzo[d]thiazol-2-amine
1H NMR δ 1.95-2.15 (m, 2H), 3.25-3.35 (m, 2H), 4.0-4.1 (t, 2H), 6.9 (s, 1H), 7.1-7.2 (d, 2H), 7.3-7.4 (d, 1H), 7.65 (s, 1H), 7.8 (s, 1H), 8.2 (s, 1H); MS m/z 293.3 (M+H), 225.3 (M-C3H3N2.)
Example 112
N-(3-(1H-imidazol-1-yl)propyl)-6-methoxybenzo[d]thiazol-2-amine
1H NMR δ 1.9-2.05 (m, 2H), 3.2-3.3 (m, 2H), 3.7 (s, 3H), 4.0-4.1 (t, 2H), 6.7-6.8 (d, 1H), 6.9 (s, 1H), 7.15-7.2 (s, 1H), 7.2-7.3 (m, 2H), 7.65 (s, 1H), 7.8 (s, 1H); MS m/z 289.1 (M+H), 221.4 (M-C3H3N2.)
Example 115
(R)—N-(3-(1H-imidazol-1-yl)propyl)-2-phenylpropanethioamide
melting point: 82.0-82.5° C.
1H NMR δ 1.4-1.55 (d, 3H), 1.9-2.0 (m, 2H), 3.4-3.5 (m, 2H), 3.85-3.95 (m, 2H), 4.0-4.1 (q, 1H), 6.8-6.9 (s, 1H), 7.1 (s, 1H), 7.15-7.2 (m, 1H), 7.2-7.3 (m, 2H), 7.35-7.4 (m, 2H), 7.55 (s, 1H), 10.1 (s, 1H); MS m/z 274.4 (M+H), 206.3 (M-C3H3N2.)
Example 116
(S)—N-(3-(1H-imidazol-1-yl)propyl)-2-phenylpropanethioamide
melting point: 82.5-83.5° C.
1H NMR δ 1.4-1.55 (d, 3H), 1.9-2.0 (m, 2H), 3.4-3.5 (m, 2H), 3.85-3.95 (m, 2H), 4.0-4.1 (q, 1H), 6.8-6.9 (s, 1H), 7.1 (s, 1H), 7.15-7.2 (m, 1H), 7.2-7.3 (m, 2H), 7.35-7.4 (m, 2H), 7.55 (s, 1H), 10.1 (s, 1H); MS m/z 274.4 (M+H), 206.3 (M-C3H3N2.)
Example 121
N-(3-(1H-imidazol-1-yl)propyl)-1-(4-chlorophenyl)cyclobutanecarbo-thioamide
melting point: 137.5-139.0° C.
1H NMR δ 1.55-1.75 (br m, 2H), 1.85-1.95 (br m, 2H), 2.4-2.5 (br m, 2H), 2.7-2.85 (br m, 2H), 3.3-3.5 (br m, 2H), 3.8 (m, 2H), 6.9 (s, 1H), 7.0 (s, 1H), 7.3 (m, 2H), 7.45 (s, 1H) 7.5 (m, 2H), 9.6 (t, 1H); MS m/z 334.3 (M+H), 266.1 (M-C3H3N2.)
Example 122
N-(3-(1H-imidazol-1-yl)propyl)-1-(4-chlorophenyl)cyclopentanecarbo-thioamide
melting point: 140.0-141.0° C.
1H NMR δ 1.5-1.65 (br m, 4H), 1.8-1.9 (m, 2H), 2.0-2.1 (m, 2H), 2.6 (m, 2H), 3.4-3.5 (m, 2H), 3.7-3.8 (m, 2H), 6.85 (s, 1H), 7.0 (s, 1H), 7.35 (m, 2H), 7.4 (m, 2H), 7.5 (s, 1H), 9.4 (t, 1H); MS m/z 348.2 (M+H), 280.2 (M-C3H3N2.)
Example 123
N-(3-(1H-imidazol-1-yl)propyl)-1-(4-methoxyphenyl)cyclohexanecarbo-thioamide
melting point: 162.5-164.0° C.
1H NMR δ 1.2-1.3 (m, 1H), 1.35-1.5 (br m, 5H), 1.85-2.0 (br m, 4H), 2.4-2.6 (br m, 2H), 3.4-3.5 (m, 2H), 3.7 (s, 3H), 3.8 (m, 2H), 6.8 (m, 3H), 7.0 (s, 1H), 7.3 (m, 2H), 7.5 (s, 1H), 9.2 (t, 1H); MS m/z 358.3 (M+H), 290.3 (M-C3H3N2.)
Example 124
N-(3-(1H-imidazol-1-yl)propyl)-1-(4-methoxyphenyl)cyclopropanecarbothioamide
melting point: 129.0-129.5° C.
1H NMR δ 1.0-1.1 (m, 2H), 1.5-1.6 (m, 2H), 1.9-2.0 (br m, 2H), 3.4-3.5 (m, 2H), 3.7 (s, 3H), 3.9 (m, 2H), 6.9 (m, 3H), 7.1 (s, 1H), 7.2-7.3 (m, 2H), 7.6 (s, 1H), 8.9 (br s, 1H); MS m/z 316.0 (M+H), 248.4 (M-C3H3N2.)
Example 134
5-(1H-imidazol-1-yl)-N-(3,4-dimethoxyphenyl)pentanethioamide
melting point: 128.0-128.5° C.
1H NMR δ 1.65-1.70 (m, 2H), 1.75-1.80 (m, 2H), 2.7-2.75 (m, 2H), 3.7 (s, 3H), 3.75 (s, 3H), 4.0-4.05 (t, 2H), 6.9-7.0 (m, 2H), 7.2 (s, 1H), 7.3 (d, 1H), 7.5 (s, 1H), 7.75 (s, 1H) 11.0 (s, 1H); MS m/z 320.2 (M+H), 252.2 (M-C3H3N2.)
Example 136
1-(2-(1H-imidazol-1-yl)ethyl)-3-(3,4-dimethoxyphenyl)thiourea
melting point: 157.5-159.0° C.
1H NMR δ 3.7 (2 s, 6H), 3.8 (m, 2H), 4.2 (m, 2H), 6.7 (m, 1H), 6.85 (m, 1H), 6.9 (m, 2H), 7.15 (s, 1H), 7.5 (br s, 1H), 7.6 (s, 1H), 9.5 (s, 1H); MS m/z 307.2 (M+H), 239.1 (M-C3H3N2.)

## Claims

1. A method of treating an inflammatory disease or condition, comprising:
administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of a glutaminyl cyclase (QC) inhibitor;
wherein the QC inhibitor has a Ki for QC inhibition of 1 μM or less.

2. The method of treating according to claim 1, wherein the disease is mild cognitive impairment (MCI).

3. The method of treating according to claim 2, wherein said pharmaceutical composition comprises a further agent, selected from the group consisting of nootropic agents, neuroprotectants, antiparkinsonian drugs, amyloid protein deposition inhibitors, beta amyloid synthesis inhibitors, antidepressants, anxiolytic drugs, antipsychotic drugs and anti-multiple sclerosis drugs.

4. The method of treating according to claim 1, wherein the disease is a chronic or acute inflammation, selected from rheumatoid arthritis, atherosclerosis, restenosis and pancreatitis.

5. The method of treating according to claim 4, wherein the disease is selected from restenosis and pancreatitis.

6. The method of treating according to claim 4, wherein the disease is restenosis.

7. The method of treating according to claim 4, wherein the disease is selected from rheumatoid arthritis and atherosclerosis.

8. The method of treating according to claim 4, wherein said pharmaceutical composition comprises a further agent, selected from the group consisting of inhibitors of the angiotensin converting enzyme (ACE); angiotensin II receptor blockers; diuretics; calcium channel blockers (CCB); beta-blockers; platelet aggregation inhibitors; cholesterol absorption modulators; HMG-Co-A reductase inhibitors; high density lipoprotein (HDL) increasing compounds; renin inhibitors; IL-6 inhibitors; antiinflammatory corticosteroids; antiproliferative agents; nitric oxide donors; inhibitors of extracellular matrix synthesis; growth factor or cytokine signal transduction inhibitors; MCP-1 antagonists and tyrosine kinase inhibitors.

9. The method of treating according to claim 1, wherein the disease and/or condition afflicts a human being.

10. The method of treating according to claim 1, wherein said QC inhibitor is a compound of formula I including pharmaceutically acceptable salts, solvates and stereoisomers thereof:



wherein,
A is either
(i) selected from an alkyl chain, alkenyl chain or alkynyl chain; or
(ii) a group selected from






wherein,
R6, R7, R8, R9 and R10 are independently H or an alkyl chain, alkenyl chain, alkynyl chain, cycloalkyl, a carbocycle, aryl, heteroaryl, or a heterocycle;
n and n1 are independently 1-5;
m is 1-5;
o is 0-4; and


B is a group selected from








wherein,
D and E independently represent an alkyl chain, alkenyl chain, alkynyl chain, a cycloalkyl, carbocycle, aryl, -alkylaryl, heteroaryl, -alkylheteroaryl, acyl or a heterocycle;
Z is CH or N;
X represents CR20R21, O, S, NR19, with the proviso for formulas (VIII) and (IX) that, if Z=CH, X is O or S;
R19 is selected from the group consisting of H, alkyl, cycloalkyl, aryl, heteroaryl, -oxyalkyl, -oxyaryl, carbonyl, amido, hydroxy, NO2, NH2, CN;
R20 and R21 are independently selected from H, alkyl, cycloalkyl, heterocycle, aryl, heteroaryl, -oxyalkyl, -oxyaryl, carbonyl, amido, NO2, NH2, CN, CF3;

X1, X2 and X3 are independently O or S provided that X2 and X3 are not both O;
Y is O or S, with the proviso that Y may not by O, when the carbocycle formed by R17 and R18 has 3 members in the ring;
R11, R12, R13 and R14 can be independently selected from H, an alkyl chain, an alkenyl chain, an alkynyl chain, cycloalkyl, carbocycle, aryl, heteroaryl, a heterocycle, halo, alkoxy-, -thioalkyl, carboxyl, carboxylic acid ester, carbonyl, carbamide, carbimide, thiocarbamide, thiocarbonyl, NH2, or NO2;
R15 and R16 are independently of each other H or a branched alkyl chain, an unbranched alkyl chain, a branched alkenyl chain or an unbranched alkenyl chain;
R17 and R18 are independently selected from H, an alkyl chain, alkenyl chain, alkynyl chain, carbocycle, aryl, heteroaryl, or heteroalkyl, or can be connected to form a carbocycle with up to 6 ring atoms; and
n3 is 0 or 1.

11. The method of treating according to claim 1, wherein said QC inhibitor or a pharmaceutically acceptable salt, solvate or stereoisomer thereof is selected from:
(i) a compound of formula 1*,




(ii) a compound of formula 1a,




wherein R is selected from Methyl; tert-Butyl; Benzyl; Phenyl; 4-(fluoro)-phenyl; 4-(chloro)-phenyl; 4-(ethyl)-phenyl; 4-(trifluoromethyl)-phenyl; 4-(methoxy-carbonyl)-Phenyl; 4-(acetyl)-phenyl; 4-(methoxy)-phenyl; bicyclo[2.2.1]hept-5-en-2-yl; 3,4-(dimethoxy)-phenyl; 2,4-(dimethoxy)-phenyl; 3,5-(dimethoxy)-phenyl; 2-(methoxy-carbonyl)-Phenyl; 4-(oxazol-5-yl)-phenyl; 4-(pyrazol-1-yl)-phenyl; 4-(isopropyl)-phenyl; 4-(piperidine-1-sulfonyl)-Phenyl; 4-(morpholin-4-yl)-phenyl; 4-(cyano)-phenyl; 2,3-dihydro-benzo[1,4]benzo[1,3]dioxol-5-yl; 3,4,5(trimethoxy)-phenyl; 3-(methoxy)-phenyl; 4-(ethoxy)-phenyl; 4-(benzyloxy)-phenyl; 4-(methoxy)-benzyl; 3,4-(dimethoxy)-benzyl; 2-(methoxy-carbonyl)-thiophene-3-yl; 3-(ethoxy-carbonyl)-4,5,6,7-tetrahydrobenzo[b]thio-phene2-yl; 2-(methoxy-carbonyl)-4-(methyl)-thiophene-3-yl; Benzo[c][1,2,5]thiazol-4-yl; Benzo[c][1,2,5]thiazol-5-yl; 5-(methyl)-3-(phenyl)-isooxazol-4-yl; 3,5-(dimethyl)-isooxazol-4-yl; 4-(iodo)-phenyl; 4-(bromo)-phenyl; 4-(methyl)-phenyl; Naphthalen-1-yl; 4-(nitro)-phenyl; Butyl; Cyclooctyl; Furan-2-ylmethyl; Tetrahydrofuran-2-ylmethyl; Benzo[1,3]dioxol-5-ylmethyl; 2-(morpholin-4-yl)-ethyl; 4-(methylsulfanyl)-phenyl; 4-(dimethylamino)-phenyl; 4-(trifluoromethoxy)-phenyl; Benzoyl; or Pyridin-4-yl;
(iii) a compound of formula 1b,





wherein
R1 is Cyano and R2 is Methyl;
R1 is Cyano and R2 is 3,4-(dimethoxy)-phenyl;
R1 is Cyano and R2 is 2,4-(dimethoxy)-phenyl;
R1 is Cyano and R2 is 3,5-(dimethoxy)-phenyl;
R1 is Cyano and R2 is 2,3-dihydrobenzo[b][1,4]dioxin-7-yl;
R1 is Cyano and R2 is Benzo[d][1,3]dioxol-6-yl;
R1 is Cyano and R2 is 3,4,5-(trimethoxy)-phenyl;
R1 is Cyano and R2 is 3-(methoxy)-phenyl;
R1 is Cyano and R2 is 4-(ethoxy)-phenyl;
R1 is Cyano and R2 is 4-(benzyloxy)-phenyl;
R1 is Cyano and R2 is Phenyl;
R1 is Cyano and R2 is 4-(methoxy)-phenyl;
R1 is Cyano and R2 is 4-(acetyl)-phenyl;
R1 is Cyano and R2 is 4-(nitro)-phenyl;
R1 is Cyano and R2 is Benzyl;
R1 is Cyano and R2 is Naphthalen-1-yl;
R1 is Cyano and R2 is 4-(fluoro)-phenyl;
R1 is Cyano and R2 is 4-(iodo)-phenyl;
R1 is Cyano and R2 is 4-(bromo)-phenyl;
R1 is Cyano and R2 is Cyclooctyl;
R1 is Cyano and R2 is tert-butyl;
R1 is Cyano and R2 is 4-(methyl)-phenyl;
R1 is Cyano and R2 is 4-(methylthio)-phenyl;
R1 is Cyano and R2 is 4-(ethyl)-phenyl;
R1 is Cyano and R2 is 4-(dimethylamino)-phenyl;
R1 is Cyano and R2 is Butyl;
R1 is Cyano and R2 is Trityl;
R1 is Cyano and R2 is (Benzo[d][1,3]dioxol-6yl)methyl;
R1 is Cyano and R2 is (tetrahydrofuran-2-yl)methyl;
R1 is Cyano and R2 is 4-(trifluoromethyl)-phenyl;
R1 is Cyano and R2 is (furan-2-yl)methyl;
R1 is Cyano and R2 is 2-(morpholin-4-yl)-ethyl;
R1 is Cyano and R2 is 4-(oxazol-5-yl)-phenyl;
R1 is Cyano and R2 is Pyridin-3-yl;
R1 is Cyano and R2 is 4-(cyano)-phenyl;
R1 is Cyano and R2 is 4-(trifluoromethoxy)-phenyl;
R1 is Cyano and R2 is 4-(piperidinosulfonyl)-phenyl;
R1 is Cyano and R2 is 4-(1H-pyrazol-1-yl)phenyl;
R1 is H and R2 is 3,4-(dimethoxy)-phenyl;
R1 is Methyl and R2 is 3,4-(dimethoxy)-phenyl;
R1 is Cyano and R2 is 2,3,4-(trimethoxy)-phenyl; or
R1 is Cyano and R2 is Cycloheptyl;


(iv) a compound of formula 1c,





wherein R3 is selected from Ethyl; 6-fluoro-4H-benzo[d][1,3]dioxin-8-yll; 3-(cylopentyloxy)-4-(methoxy)-phenyll; 4-(heptyloxy)-phenyll; 3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yll; 4-(butoxy)-phenyll; or 3,4-(dimethoxy)-phenyll;

(v) a compound of formula 1d,





wherein the substitution position on the benzyl ring is selected from 2, 3, or 4;

(vi) a compound of formula 1e,





wherein
R4 is H and R5 is Methyl;
R4 is Methyl and R5 is H;
R4 is Methyl and R5 is Methyl; or
R4 is —CH2—CH2— and R5 is —CH2—CH2—;


(vii) a compound of formula 1f,





wherein R6 is selected from H, Chloro, or Methoxy;

(viii) a compound of formula 1g,





wherein
R7 is Phenyl, R8 is H, and R9 is H;
R7 is Thiophen-2-yl, R8 is H, and R9 is H;
R7 is Phenyl, R8 is Methyl, and R9 is H;
R7 is Phenyl, R8 is H, and R9 is Methyl;
R7 is Phenyl, R8 is H, and R9 is Ethyl;
R7 is Phenyl, R8 is H, and R9 is Phenyl;
R7 is 3,4-(dimethoxy)-Phenyl, R8 is H, and R9 is H;
R7 is 3,4-(dimethoxy)-Phenyl, R8 is Methyl, and R9 is Methyl;
R7 is 4-(chloro)-phenyl, R8 is —CH2—CH2—CH2—, and R9 is —CH2—CH2—CH2—;
R7 is 4-(chloro)-phenyl, R8 is —CH2—C2H4—CH2—, and R9 is —CH2—C2H4—CH2—;
R7 is 4-(methoxy)-phenyl, R8 is —CH2—C3H6—CH2—, and R9 is —CH2—C3H6—CH2—;
R7 is 4-(methoxy)-phenyl, R8 is —CH2—CH2—, and R9 is —CH2—CH2—;
R7 is 3,4-(dimethoxy)-Phenyl, R8 is —CH2—CH2—, and R9 is —CH2—CH2—;
R7 is 3,4,5-(trimethoxy)-Phenyl, R8 is —CH2—CH2—, and R9 is —CH2—CH2—;
R7 is 2,3,4-(trimethoxy)-Phenyl, R8 is —CH2—CH2—, and R9 is —CH2—CH2—;
R7 is 2-(methoxy)-phenyl, R8 is —CH2—CH2—, and R9 is —CH2—CH2—;
R7 is 3-(methoxy)-phenyl, R8 is —CH2—CH2—, and R9 is —CH2—CH2—;
R7 is 2,3-(dimethoxy)-Phenyl, R8 is —CH2—CH2—, and R9 is —CH2—CH2—;
R7 is 3,5-(dimethoxy)-Phenyl, R8 is —CH2—CH2—, and R9 is —CH2—CH2—; or
R7 is 2,5-(dimethoxy)-Phenyl, R8 is —CH2—CH2—, and R9 is —CH2—CH2—;


(ix) a compound of formula 1h,





wherein n is selected from 3, 4, or 5;

(x) a compound of formula 1i,





wherein m is selected from 2 or 4; or

(xi) a compound selected from

12. The method of treating according to claim 11, wherein said QC inhibitor is 1-(3-(1H-imidazole-1-yl)propyl)-3-(3,4-dimethoxy-phenyl)thiourea hydrochloride.

13. The method of treating according to claim 1, wherein administering said pharmaceutical composition comprises parenteral, enteral or oral administration.

14. The method of treating according to claim 12, wherein the disease is restenosis.

15. The method of treating according to claim 12, for the treatment of an inflammatory disease or condition.

16. The method of treating according to claim 1, wherein the QC inhibitor has a Ki for QC inhibition of 0.1 μM or less.